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Cardiovascular diseases (CVD) are one of the leading causes of mortality and 
morbidity in the Western world. According to figures from the Netherlands 
Heart Foundation (NHF), approximately 40,000 people died from cardiac or 
vascular diseases in The Netherlands in 2010 1. Although, the advances in 
research have already contributed to a decreased number of cardiovascular 
deaths in developed countries, still millions of people suffer from these 
diseases worldwide. Next to the successful intervention in developed 
countries, the incidence of CVD is believed to increase in developing countries 
over the next years, but also in the USA the prevalence of CVD is expected to 
increase 2. Despite extensive research and the implementation of novel 
interventions not all patients at risk of a cardiovascular event can be detected 
timely or treated successfully. The knowledge on the consequences of risk 
factors, including obesity 3, hypertension 4, diabetes 5, smoking 6, and 
hyperlipidemia 7, but also on disease detection and prediction need to be 
expanded even further, to obtain be able to truly develop personalized 
medicine strategies and resolve cardiovascular diseases on a global scale. 
Atherosclerosis 
Atherosclerosis is the key underlying cause of CVD, responsible for a significant 
number of cardiac and vascular events, such as stroke, myocardial infarction, 
and peripheral artery disease. Atherosclerosis is considered to be a chronic 
inflammatory disease of the medium and large arteries 8. The disease is 
characterized by two main hallmarks: (I) lipid/lipoprotein metabolism and (II) 
inflammation. It is the interplay between these two processes that defines the 
principle pathogenesis and distinguishes atherosclerosis from other chronic 
inflammatory diseases 9. Lipid and cholesterol accumulation in the 
subendothelial layer occurs at sites with disturbed flow, such as curvatures and 
bifurcations of the arteries 10,11. The endothelial layer will hence become 
activated which is even further stimulated by accumulation of low density 
lipoprotein (LDL) cholesterol particles and the subsequent oxidation of these 
LDL particles 12. This activated endothelium will produce inflammatory 
cytokines, but also increase the expression of adhesion receptors such as 
vascular cell adhesion molecule (VCAM) 1 and intercellular cell adhesion 
molecule (ICAM) 1 on the luminal membranes 13-15. The upregulation of 
adhesion molecules will result in an increased attraction and adhesion of 
leukocytes to this activated endothelium 16. Interestingly, the locations of the 
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vasculature which have higher incidence of plaque development, already have 
increased leukocyte counts and signs of low-grade inflammation before 
development of atherosclerosis 17 (figure 1). 
Initially, the main leukocyte population attracted to the early 
atherosclerotic lesion will be monocytes. Monocytes will roll along the vessel 
wall and adhere at sites with increased adhesion receptors (or integrins). 
Eventually, the monocytes will attach to the endothelial layer of the vessel and 
can transmigrate into the subendothelial layer 16,18. The inflammatory milieu of 
the intima will trigger the monocytes to differentiate into macrophages. The 
latter cell type is considered to be a tissue-resident, mature form of 
monocytes. Oxidized cholesterol present in the early lesion will be scavenged 
by these macrophages via class B scavenger receptors and CD36. However, as 
these cells are unable to metabolize these oxLDL molecules efficiently and 
cholesterol efflux is also inhibited, intra-cellular cholesterol will accumulate, 
giving rise to the formation of macrophage foam cells. These cells have a 
foamy appearance due to the presence of large amounts of cholesterol filled 
endosomes and cytoplasmic lipids 19-22. The macrophages and foam cells 
present in the initial atherosclerotic lesions, together with other attracted 
leukocytes, such as T-lymphocytes, will produce pro-inflammatory cytokines 
and thereby stimulate further expansion of the lesion by attraction of 
additional leukocytes to the progressing atherosclerotic plaque.  
 Over time, advanced atherosclerotic lesions can develop, most often 
asymptomatic, and thus without any clinical symptoms for many years 23,24. 
However, some lesions can progress into more unstable lesions by thinning of 
the fibrous cap covering the a-cellular and necrotic material present in the core 
of the lesion. Thinning of the cap is caused by e.g. matrix metallo-proteases 
(MMP), secreted by macrophages/foam cells in the lesion. Matrix metallo-
proteases have also been shown to be involved in proteolytic cleavage of some 
cytokines thereby stimulating the inflammatory response 9. Eventual  rupture 
of the cap will present the debris from the core of the lesion to the blood 
stream and trigger coagulation, giving rise to the formation of thrombi. These 
thrombi will in the end cause local or peripheral clinical symptoms and even 
death due to the occlusion of arteries and subsequent inhibition of blood flow 
24. 
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Lipid/lipoprotein Metabolism in Atherosclerosis 
Cholesterol synthesis and transportation 
Lipids and cholesterols are essential to most organisms as many processes 
depend on these compounds for normal function. Cholesterol is one of the 
main components of cell membranes and functions as precursor for steroid 
hormones 25 and vitamin D 26, while lipids in general are an important energy 
source for the body. As lipids and cholesterol are poorly soluble in aqueous 
solutions, they need to be encapsulated in order to be transported in the 
blood. Several different subsets of lipoproteins can be distinguished involved in 
cholesterol transport. The most important lipoprotein fractions are very low 
density lipoprotein (VLDL), low density lipoprotein (LDL), and high density 
lipoprotein (HDL). Generally, LDL is thought to be the ‘bad’ cholesterol 27,28 and 
HDL the ‘good’ cholesterol 29,30.  
The liver plays a central role in the turnover of lipids and is responsible 
for the conversion of free fatty acids and chylomicrons into ApoB100-bound 
VLDL particles which are secreted into the circulation. Upon lipolysis, governed 
by lipoprotein lipases, VLDL is converted into LDL which is subsequently 
sequestered by the liver, but can also be used as metabolites in other 
pathways throughout the body. HDL particles are bound to ApoA-I which is 
important in the sequestration of cholesterol from cells via dedicated 
receptors . ATP-binding cassette transporter (ABCA) 1 is one of these receptors 
and is present on macrophages, supporting (limited) efflux of cholesterol to 
HDL particles 31,32.   
Lipoproteins in Atherosclerosis 
Hypercholesterolemia is, already for many years now, considered one of the 
most important risk factors for the development of atherosclerosis 33. 
Disturbances in the lipid/lipoprotein metabolism can affect the levels of 
various lipoprotein subsets, as these processes are responsible for the 
transport of lipoproteins throughout the circulation 34. At sites with turbulent 
flow and thus decreased shear stress, LDL cholesterol can accumulate in the 
intima, where it is prone to oxidation by local radicals, resulting in the 
development of oxLDL. As mentioned, this will initiate atherogenesis by 
endothelial cell activation due to disturbed blood flow 35,36. The humoral 
response to the oxLDL accumulation in the intima will further aggravate this 
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immunological initiation of atherosclerosis 37. The presence of lipoprotein, and 
more in particular oxLDL, is one of the central hallmarks of atherosclerosis. 
Exposure of (free) lipids and cholesterol, as well as necrotic material entrapped 
in the lesion to the blood flow upon plaque rupture may give rise to the clinical 
manifestations of cardiovascular disease 24. 
 Next to free cholesterol, also cellular cholesterol contributes to 
atherogenesis. Oxidized LDL phagocytized by macrophages, stimulates the 
inflammatory response in the vessel wall by the release of pro-inflammatory 
cytokines from macrophage foam cells and the induction of necrosis of these 
cells. Intracellular cholesterol can be present either cytoplasmic or lysosomal. 
Further, cholesterol crystals can be observed in cells which have accumulated 
excessive amounts of lipids and cholesterol.  
 
Figure 1 - Schematic overview of early atherosclerosis development 
Atherosclerotic plaque development is initiated by low density lipoprotein (LDL) cholesterol 
accumulation in the subendothelial layer of the vessel wall. Free radicals present in the tissue 
will lead to the formation of oxidized LDL (oxLDL), resulting in activation of endothelial cells. 
Upon activation endothelial cells will release chemo-attractant cytokines (chemokines) and 
upregulate the expression of integrins, facilitating the adhesion, rolling, and transmigration of 
circulating monocytes. In the subendothelial tissue monocytes will differentiate into 
macrophages which will subsequently scavenge the cholesterol and stimulate the pro-
inflammatory immune response.  
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Inflammation in Atherosclerosis 
Inflammation is, next to the lipid metabolism, a second essential process in the 
pathogenesis of atherosclerosis 9. The inflammatory response consists of a 
cellular and humoral component and includes many immune cells, but also 
interactions with local endothelial cells and smooth muscle cells. As described 
earlier, circulating monocytes and plaque macrophages are critical actors in 
initial lesion development, but also in lesion progression, and eventual 
destabilization of the atherosclerotic plaque 19. 
Monocyte subsets in human 
Human monocytes can be divided in two subsets based on expression of the 
membrane markers CD14 and CD16 38. In humans, CD14 is a co-receptor for 
binding of lipopolysaccharide (LPS) in combination with toll-like receptor (TLR) 
4 and LPS-binding protein (LBP) 39,40, while CD16 is a Fc receptor (FcϒRIII) which 
bind the constant Fc region of antibodies 41. The two monocyte subsets that 
are currently being described in literature are CD14high/CD16- and 
CD14low/CD16++. The most abundant monocyte population in the circulation is 
the ‘classical’ CD14high/CD16- monocytes, comprising over 90% of circulating 
monocytes 42. The classical monocytes are also often defined as inflammatory 
monocytes 43. The second population comprises the ‘non-classical’ 
CD14low/CD16++ monocytes, which are also referred to as patrolling monocytes. 
There are however also indications of a third monocyte population which has 
intermediate expression for both CD14 and CD16 (CD14+/CD16+) 44. 
 The classical and non-classical monocyte populations show differential 
expression of chemokine receptors involved in chemotaxis towards 
inflammatory stimuli 45. In relation to atherosclerosis and other inflammatory 
diseases such as rheumatoid arthritis, both subsets of circulating monocytes 
are thought to be important, however recruitment of these cells towards the 
site of inflammation is regulated by different chemokine receptors 42,46. The 
CC-motif chemokine receptor 2 (CCR2) is expressed in high levels by ‘classical’ 
CD14high/CD16- monocytes, and the responsiveness towards monocyte chemo-
attractant protein (MCP) 1 is considered to be a characteristic of this subset 47. 
The CX3C-motif chemokine receptor 1 (CX3CR1), or fractalkine receptor, is 
expressed by both monocyte subsets 48, however the expression is 
approximately two-fold higher in ‘non-classical’ monocytes 49. This receptor is 
involved not only in chemotactic responses, but also has a role in cell survival 
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50,51. Other important chemokine receptors expressed by monocytes are CCR1 
and CCR5 and to a lesser extent CXCR2, which also are important for the 
patrolling properties of monocytes together with CCR2 and CX3CR1 47-49. As 
monocyte migration into the atherosclerotic lesion is mainly studied in mice 
there is only limited information on the role of these human subsets and their 
migratory behavior in atherosclerosis. 
 
Table 1 - Monocyte subsets in human and mouse (Adapted from: Hristov et al 52) 
 
Monocyte subsets in mice 
In mice different circulating monocyte populations can be distinguished within 
the (CD11b+ / Ly6G-) monocytes population. In contrast to the human situation 
where monocyte subsets are defined based on CD14 and CD16 expression, in 
mice the subsets are identified based on Ly6C (or Gr1; binds both Ly6C and 
Ly6G) expression in combination with the general marker for myeloid cells 
(CD11b) and exclusion of granulocyte (Ly6G). Classical or inflammatory 
monocytes express high levels of Ly6C (or Gr1; Ly6Chigh monocytes), while 
patrolling or ‘non-classical’ monocytes express low levels of Ly6C (Ly6Clow 
monocytes) 48,53,54. As in human monocytes, the classical (Ly6Chigh) murine 
monocytes express high levels of CCR2, while patrolling (Ly6Clow) monocytes do 
not express CCR2, but do express CX3CR1 and CCR5 42,55.  
Studies in mice have shown that the different monocyte populations 
reflect different stages of development 56-58. The bone marrow produces 
Ly6Chigh monocytes, which can differentiate into Ly6Clow monocytes in the 
periphery in the absence of inflammatory stimuli 55,59. However, this 
progressive differentiation from Ly6Chigh in the bone marrow to Ly6Clow in the 
periphery is still debated in literature 60,61. Despite the similarities in chemokine 
receptor patterns for CCR2 and CX3CR1 (table 1), it is still questionable to what 
extent monocyte subsets in mouse and man can be compared directly, as in 
Monocyte subset Alternative name Major markers 
Human   
CD14highCD16- Classical/Inflammatory CD14, CCR2, CD16, CD62L, SR-A, VEGFR1 
CD14lowCD16++ Non-classical/patrolling CD16, HLA-DR, CD11c, CX3CR1, CCR5 
CD14+CD16+ Intermediate CD14, CD16, CCR2, Tie2, CD105, MHCII, HLA-DR 
Mouse   
Ly6Chigh (Gr1+) Classical Ly6C/Gr1, CCR2, CD62L 
Ly6C-/low (Gr1-) Patrolling CX3CR1, CCR5, LFA1, CD11c 
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C57Bl/6 mice both subpopulations are roughly present in equal numbers 62. 
Nevertheless, it has been shown that circulating monocytes are essential for 
atherogenesis, as inhibition or depletion of (subsets of) monocytes results in 
reduced plaque development 57,58 (figure 2). 
Monocyte/Macrophage Axis in Atherosclerosis 
Monocytes are the first leukocytes to enter the sub-endothelial space in 
response to lipoprotein accumulation in the early stages of atherogenesis. 
However, also during plaque progression and eventual plaque destabilization 
resulting in clinical manifestation of the disease, monocytes (and 
macrophages) are pivotal 63,64. It has been shown that monocytes respond to 
tissue-derived signals by migrating into lymphoid and non-lymphoid tissues 
65,66. Triggers for these tissue-derived signals can be tissue damage or infection. 
In atherosclerosis, it is however more complex as not only inflammatory 
signals, caused by modified cholesterol in the intima, but also disturbed 
laminar flow were seen to contribute to the recruitment of monocytes 22,42. 
This also explains why atherosclerotic lesions are almost exclusively detected 
in curvatures and bifurcations of arteries 11. Adhesion molecules on endothelial 
cells facilitate the adhesion of circulating monocytes to the arterial wall, and 
subsequently aid in the transmigration into the intima 13-15. This process is 
supported by chemokines secreted by activated endothelial cells and 
inflammatory cells in the lesion.  
 For human disease the chronology of leukocyte plaque invasion is not 
completely understood, as tracking and fate-mapping studies are almost 
impossible in the human situation. In mice however, many studies have been 
performed in which monocytes have been tracked or depleted to get more 
insight in the processes involved in atherosclerosis development and the role 
of monocytes herein. Ly6Chigh monocytes have been show to expand under 
hypercholesterolemic conditions and promote the inflammatory processes 
during atherogenesis 67. The role of Ly6Clow monocytes is more debatable in 
the development of atherosclerosis, as these monocytes are often considered 
to be anti-inflammatory and are traditionally thought to give rise to anti-
inflammatory M2 macrophages and dendritic cells. This dogma is being 
challenged nowadays with our growing understanding of monocyte 
development.  
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Figure 2 - Monocyte subsets in atherogenesis  
Two important monocyte populations are described in mouse and humans related to 
atherosclerosis. On the one hand, the inflammatory Ly6Chigh (mouse) or CD14high/CD16- (human) 
monocytes which mainly migrate towards inflammatory sides such as the atherosclerotic lesion 
via CCR2 and predominantly give rise to (tissue-resident) macrophages. On the other hand, the 
patrolling Ly6C-/low (mouse) or CD14+/CD16+ (human) monocytes which mainly migrate via 
CX3CR1 and give rise to both myeloid dendritic cells and macrophages. 
 
Macrophages in Atherosclerosis 
Macrophages are more comparable between mouse and man, as the subsets 
present in man are also observed in mice. Monocytes that infiltrate the tissue 
or inflammatory site (e.g. atherosclerotic lesion) differentiate into M0 
macrophages. These macrophages are considered to be non-polarized and do 
not have specific pro- or anti-inflammatory properties. Polarization of these 
macrophages towards a pro- or anti-inflammatory phenotype is dependent on 
the local milieu 68-70. 
 
A9R6637.tmp   17 15-9-2013   19:30:44
Chapter 01 
________________________________________________________________ 
18 
Macrophages, as part of the innate immune system, are responsible 
for the scavenging of foreign materials. In the atherosclerotic lesion these cells 
will ingest the oxidized LDL from the intima. However, this process results in 
cell activation and thereby propagating the already ongoing immune response. 
Cytokines and proteases secreted by macrophages have an important role in 
plaque development and destabilization of the fibrous cap covering the 
atheroma 9,71,72.  
Local stimuli such as cytokines and cell-cell interactions can stimulate 
these tissue-resident macrophages to polarize into either classically activated, 
pro-inflammatory (M1) macrophages or alternatively activated, anti-
inflammatory (M2) macrophages 68,69. Classically activated macrophages are 
considered to be the immune effector cells which are involved in the 
engulfment and digestion of microbes and other foreign particles. These cells 
are also important mediators of the inflammatory response and next to this 
have high proteolytic capacity. M1 macrophages are activated by 
lipopolysaccharide (LPS) and interferon (IFN) ϒ and produce high levels of 
interleukin (IL) 12, while no or low levels of IL10 are produced. Other cytokines 
produced by M1 macrophages are IL1β, IL6, and tumor necrosis factor (TNF) α 
70. Alternatively activated macrophages (M2) macrophages can be divided in 
M2a and M2c macrophages based on their membrane marker expression and 
cytokine production. In contrast to ‘inflammatory’ M1 macrophages, M2 
macrophages are considered to be anti-inflammatory or wound-healing cells 
70,73. Polarization towards M2a or M2c phenotype can be induced by 
stimulation with IL4, or with IL10 and transforming growth factor (TGF) β, 
respectively 73. These M2 macrophages mainly produce IL10, stimulating anti-
inflammatory pathways in e.g. T-lymphocytes 9,70,73. 
In atherosclerosis the role of the different macrophage subsets has not 
yet been elucidated completely. Nevertheless, studies indicate that a 
heterogeneous set of macrophage subsets is present in the lesion 68,69. Besides 
the well-known pro-inflammatory M1, and anti-inflammatory M2a and M2c 
macrophages, also oxLDL polarized macrophages (Mox) 74 and CXCL4 polarized 
macrophages (M4) 75 can be found in atherosclerotic plaques 70,76. Due to the 
complexity of determining distinct macrophage subsets in the lesion in 
combination with potential phenotype switching of lesional macrophages 77,78 
the exact role of the different subsets in atherosclerosis development remains 
uncertain.  
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Hematopoietic Compartments 
The development of atherosclerotic lesions is considered to be a local 
pathology, however plaque rupture can result in systemic effects and even 
death due to e.g. myocardial infarction or stroke. As the cells present in the 
lesion are attracted from the periphery via the circulation and also cytokines 
and chemokines are released into the circulation, there is also an important 
systemic contribution. Recently, several studies have shown that there is 
indeed an important role for the bone marrow and the spleen, which are both 
involved in myelopoiesis, and thus in the production of monocytes 59,79-81. 
 In mice it has been shown that atherosclerosis in combination with 
cardiovascular risk factors such as hyperlipidemia, result in systemic changes 
and adaptations of the hematopoietic process. Mainly, myeloid hematopoiesis 
(myelopoiesis) is affected, and leads to dynamic changes in bone marrow and 
spleen 59,80. Increased numbers of monocytes (monocytosis) and also 
granulocytes can be detected upon cholesterol rich diet feeding in both mouse 
and man 82,83. However, it is still disputable to what extent these changes are 
caused by hyperlipidemia, inflammation, or the combination of both factors. 
Despite the fact that still many questions need to be investigated, it is clear 
that hematopoiesis plays an important role in not only replenishing the pool of 
peripheral leukocytes and tissue-resident inflammatory cells, but also in 
boosting and regulating various inflammatory diseases. 
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Figure 3 - Myelopoiesis in pro-atherogenic mouse models 
Inflammatory stimuli in combination with hypercholesterolemia trigger the release of myeloid 
progenitor cells as well as mature monocytes from the bone marrow into the circulation. 
Myeloid progenitor cells will preferentially migrate towards the spleen, giving rise to 
extramedullar hematopoiesis. In combination with accumulation of bone marrow-derived 
monocytes in the spleen, a splenic reservoir will be formed consisting of (mainly Ly6Chigh) 
monocytes. Upon additional stimulus, these cells are quickly mobilized from the spleen and 
migrate towards e.g. atherosclerotic lesions to form plaque macrophages and dendritic cells. 
 
 
In normal myelopoiesis we can distinguish several intermediate 
myeloid precursor subsets developing from multipotent hematopoietic stem 
cells in the bone marrow. Common myeloid progenitors (CMP) develop via 
granulocyte/macrophage progenitors (GMP) and eventually mature 
granulocytes and monocytes. This development is controlled by cytokines, 
such as granulocyte/macrophage colony stimulating factor (GM-CSF), 
granulocyte colony stimulating factor (G-CSF), and macrophage colony 
stimulating factor (M-CSF) 84-87. During development of monocytes, and their 
differentiation into macrophages, different transcription factors are expressed. 
Initially, PU.1 and Kruppel-like factor (Klf) 4 are activated, while later in the 
differentiation process Early growth response protein (Egr) 1 and interferon 
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regulating factor (IRF) 8 are more important 88,89. The expression of these 
transcription factors is specific to cells of the myeloid lineage and more 
specifically monocytes and macrophages 79. IRF8 deficiency can also influence 
atherosclerosis development in mouse models indicating the importance of 
regulating and maintaining normal myelopoiesis 90. 
 Besides the bone marrow, the spleen is also an important 
compartment in atherosclerosis-associated myelopoiesis. According to studies 
performed in pro-atherogenic apolipoprotein E deficient (ApoE-/-) mice, Ly6Chigh 
monocytes migrate from the bone marrow into the circulation 59,80,83. 
Subsequently, these cells will migrate into the spleen and differentiate towards 
Ly6Clow monocytes 91. The spleen thus serves as a reservoir for rapid 
mobilization of monocytes upon inflammatory stimuli. In a pro-inflammatory 
system, such as observed in atherosclerosis, not only mature cells are released 
from the bone marrow, but also progenitors will be mobilized. These 
hematopoietic progenitors will home to the spleen and locally start producing 
mature myeloid cells. This extra-medullar hematopoiesis is one of the 
mechanisms responsible for the monocytosis observed in 
hypercholesterolemic, but also hyperglycemic, pro-atherogenic mice 92,93. 
Overall, hematopoiesis contributes to atherosclerosis through enhanced 
production of myeloid cells and more specifically monocytes (figure 3). 
From Cells to Biomarkers 
Early detection and the selection of the optimal procedure for treatment are 
important aspects of cardiovascular biomarker research. Traditionally, 
different types of biomarkers can be distinguished and can be divided in 
diagnostic, prognostic, and predictive biomarkers. Diagnostic biomarkers are 
used to identify the presence of disease in a patient. These markers can be 
used in a clinical setting e.g. to distinguish between chest pain caused by 
myocardial infarction and chest pain due to non-cardiac related causes. 
Prognostic and predictive biomarkers give information on future risk of 
developing a specific event or disease. Prognostic biomarkers give information 
in untreated individuals, while predictive biomarkers can give more insight in 
the effectiveness of a treatment for individual patients. Both prognostic and 
predictive biomarkers can give indications for adapting the treatment. 
 Risk prediction for cardiovascular disease can be based on circulating, 
imaging, and genetic biomarkers 94. Traditionally, risk prediction is mainly 
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based on risk factors as hyperlipidemia, hypertension, diabetes mellitus, and 
smoking. These markers have been developed into predictive models such as 
the Framingham risk score 95. Research has shown that these models for 
assessing CVD risk at population level are limited in predicting the risk for 
individual patients, due to changes in biomarkers upon treatment 96 and lack of 
significant differences at the level of individual patients 97,98.  
 In recent years, many novel biomarkers have been presented which 
are developed in new (high-throughput) platforms 99. Based on the more 
traditional lipid and lipoprotein profiling additional biomarkers have been 
proposed. The ratio between apolipoprotein (Apo) B and ApoA-I, which are 
part of LDL and HDL, respectively, is a strong predictive marker of 
cardiovascular events 100,101. Another well-known biomarker for cardiovascular 
disease is C-reactive protein (CRP), which is a marker for systemic 
inflammation and is used in the clinic for many years102. The downside of CRP, 
and many more biomarkers in general, is the fact that different cohort studies 
result in different risk predictions 103-105. Further, CRP is not specific for CVD as 
it is a more general marker for inflammation. Finally, biomarkers proposed so 
far have limited in their predictive value for an individual patient and often the 
biomarkers are inadequate with regard to specificity and sensitivity upon 
validation. Nevertheless, current and future biomarkers will contribute to 
personalized medicine extensively by improving diagnosis and prognosis for 
individual patients. By optimizing these strategies treatment and life style 
changes can be even more specified to the needs of a specific person, 
minimizing the risk for future cardiovascular morbidity and mortality. 
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Table 2 - Non-comprehensive list of CVD biomarkers 
 
 
Whole cells and also circulating monocytes are already being used as 
biomarker for disease. Both secreted and membrane-bound markers are 
related to different pathological conditions. Peripheral blood mononuclear 
cells (PBMCs) from patients with systemic sclerosis secrete more CD163, which 
might give information on prognosis 116. In Alzheimer’s disease LPS induced IL-6 
release by PBMCs functions as prognostic marker for disease severity and 
cognitive outcome 117. Besides these secreted proteins also membrane markers 
can be used as biomarker. Monocyte HLA-DR expression has a strong 
relationship with disease severity and prognosis in acute liver failure 118, while 
Sialic acid-binding Ig-like lectin 1 (Siglec-1) and Fcϒreceptor I (CD64) expression 
function as biomarker in systemic lupus erythromatosus 119,120. For 
cardiovascular disease only one biomarker is described that is possibly derived 
from (plaque) monocytes, however the exact cell type responsible for the 
secretion of junction plakoglobin has not been determined yet 121. As 
monocytes play a critical role in the development of atherosclerosis, in depth 
research towards biomarker discovery based on these cells will be necessary, 
to be able to more efficiently diagnose and treat patients at risk for CVD. 
 
Biomarker  Pathology Ref 
CRP C reactive protein Acute inflammation 102,104 
ApoB/ApoA-I Apolipoprotein B/A-I Predictive marker CV events 100,101 
BNP B-type natriuretic peptide Prognostic marker heart failure 106,107 
sCD40L Soluble CD40 ligand Plaque instability 108 
CCL18 CC-motif chemokine ligand 18 Unstable angina pectoris 109 
hsTNT High sensitive troponin T Myocardial injury 107,110,111 
sPLA2 Secreted phospholipases A2 Prognostic marker CV events 112 
MPO Myeloperoxidase Risk for future CV events 113,114 
GDF15 Growth differentiation factor 15 Heart failure 107,115 
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Focus & Outline of the Thesis 
Despite the fact that in some developed countries the morbidity and mortality 
of cardiovascular diseases is diminishing, there is still need for more research 
as the incidence of disease is increasing in developing countries, and current 
diagnostic tools as well as therapies appear to be insufficient. Furthermore, 
there is a need for earlier, predictive and less invasive methods to detect the 
risk for atherosclerosis associated disorders. It is believed that circulating cells 
are the new target to determine the state of disease and risk for future events 
in patients suspected to have progressed cardiovascular diseases. This thesis 
focuses on the role of circulating monocytes in relation to atherosclerotic 
plaque development on the one hand, and the possibility of using these cells as 
biomarker source for plaque phenotype, and possibly even the risk for a future 
cardiovascular event on the other hand. 
 
Circulating monocytes in mouse models of atherosclerosis 
In Chapter 2, the effect of depleting monocytes and macrophages from the 
circulation, but also the atherosclerotic lesion will be investigated, using a pro-
atherogenic mouse model. As the monocyte/macrophage axis plays a central 
role in atherosclerosis, depleting these subsets should have profound impact 
on local lesion associated processes, but also shed new light on the systemic 
importance of circulating cells in atherosclerosis. 
Subsequently, the role of monocyte chemotaxis towards the 
atherosclerotic lesion will be analyzed in Chapter 3. We aim to gain insight into 
the processes regulating mobilization of monocytes from the periphery upon 
chemokine release. This chapter addresses the role GRK2 plays in chemotaxis 
and the effects of hematopoietic and macrophage specific deficiency on 
atherosclerotic lesion development in LDL receptor knock-out mice. 
 As atherosclerosis development is also critically dependent on lipids, 
and more in particular cholesterol, Chapter 4, will address the role of 
hypercholesterolemia on circulating monocytes. The processes underlying 
foam cell formation in the lesion are already well described, however little is 
known on the peripheral processes and responses of leukocytes, and in 
particular monocytes, upon increased cholesterol levels. Through diet-induced 
hypercholesterolemia, we are able to unravel the systemic adaptations, as well 
as functional changes in circulating monocytes. 
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Circulating monocytes as biomarker in human atherosclerotic disease 
The second part of this thesis focuses on the role of monocytes (and 
macrophages) in human cardiovascular disease.  
 First, in Chapter 5, the effects of cell activation, as observed in 
atherosclerosis, will be investigated on a protein level. Whole cell phage 
display is used to identify novel markers on human monocytes, which are 
specific for unstable angina pectoris and also advanced atherosclerotic lesions.  
 Subsequently, in Chapter 6, monocytes from stable and unstable 
angina pectoris patients will be studied on a mRNA level to determine whether 
there are baseline differences in monocyte activation or regulation due to the 
presence of unstable atherosclerotic plaques. Micro-array analysis, combined 
with computational analyses and flow cytometry are used to determine the 
profile of these monocyte pools, to verify whether monocytes from different 
patient groups do indeed have a different profile. We also include preliminary 
data on the differences in activation potential between monocytes from 
patients with an event during follow-up compared to controls. 
 Finally, a summary, general discussion of the results of this thesis, and 
future perspectives will be presented in Chapter 7.   
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Abstract 
Although macrophage apoptosis is deemed a critical process in plaque 
progression, macrophage ablation studies have so far yielded contradictory 
results on the actual impact of macrophage death on atherosclerosis. This may 
be partly due to ectopic effects of the ablation strategy on circulating 
monocytes as well as on other leukocyte subsets. To distinguish plaque 
macrophage cell death associated effects from that on peripheral monocytic 
cells, we here studied the impact of systemic versus plaque-targeted ablation 
of monocytic cells on plaque development. ApoE-/- mice, bearing a 
Macrophage FAS Induced Apoptosis (MaFIA) suicide gene under control of the 
CD115 promotor were used to develop advanced atherosclerotic lesions by 
perivascular collar placement in response to Western type diet feeding. 
Rapalog dimerizer was administered either systemically via intravenous tail 
vein injections, or locally via catheterized osmotic minipumps connected to the 
peri-adventitial site of the carotid arteries. Systemic treatment did not result in 
any changes regarding plaque development, despite efficient depletion of 
intimal macrophages. However, while effecting a complete ablation of 
circulating monocytes and neutrophils at 1 week after administration, systemic 
ablation led to a profoundly dysbalanced myelopoiesis, with major expansion 
of mature and immature myeloid cells in the circulation after 2 weeks. In 
contrast, focal ablation of CD115+ macrophages led to increased macrophage 
apoptosis and necrotic core size and to plaque expansion without any systemic 
effects. Taken together, extramedullar myelopoiesis and increased 
mobilization of inflammatory spleen monocytes to the circulation, upon 
systemic induction of monocyte/macrophage apoptosis causes vulnerability of 
atherosclerotic lesions. Local induction of macrophage apoptosis induced 
lesion expansion but allowed macrophage turnover without lesion 
vulnerability.  
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Introduction 
Macrophage accumulation in the atherosclerotic lesion is generally considered 
essential for plaque progression and destabilization 1. Furthermore, 
macrophages exert a range of functions to control and clear infections 2, 
regulate and modulate wound healing 3, and engulf (non-)foreign particles 4. In 
early atherosclerosis these myeloid cells are involved in the clearance of 
oxidized low density lipoproteins (oxLDL) from the vessel wall, whereas in later 
stages macrophages also mediate the clearance of apoptotic cell material from 
the lesion 1,4. Hence, macrophage cell death will at later stages be associated 
with impaired efferocytosis, and deposition of macrophage contained lipid 
debris in the plaque, both processes deemed deleterious for plaque stability 5. 
Moreover, macrophage derived matrix metallo-proteases (MMP) contribute to 
the degradation of the plaque-stabilizing collagen filaments and thereby 
undermine the integrity of the atherosclerotic lesion 6,7. 
 Although plaque macrophage build up may partly result from clonal 
expansion of resident vascular macrophages as well, the bulk was seen to 
originate from extravasated monocytes that had been attracted to the plaque  
1,8. The recruitment of monocytes is a continuous process throughout all stages 
of the atherosclerotic lesion development 9. Thus, by fostering macrophage 
accumulation, monocytes will contribute to the progression of lesions and 
more specifically to the perpetuation of the ongoing inflammatory state and 
the vulnerability of the advanced atherosclerotic lesion as well 10,11. In support 
of this notion, human leukocytosis was demonstrated to be an independent 
risk factor and predictor of clinical cardiovascular events in atherosclerosis 12-15. 
 This recognition has inspired to a wealth of studies on the interaction 
between of the myeloid lineage and hyperlipidemia and atherosclerosis. Our 
insights into the role of monocytes and macrophages in atherosclerosis have 
been greatly aided by both pharmacological and genetic 
monocyte/macrophage specific ablation studies. Clodronate liposomes have 
been used widely to study the effects of macrophage ablation in 
atherosclerosis 16, but also other pathologies 17,18. Calin et al reported that 
initially macrophage depletion in atherogenesis is beneficial, however 
increased lipid and collagen content ultimately results in plaque expansion. 
Furthermore, studies have applied diphtheria toxin dependent ablation models 
under control of CD11b 19. Induction of macrophage apoptosis via a CD11b-
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diphteria toxin model showed that depletion of monocytes/macrophages is 
influencing early lesions more pronouncedly than established lesion 19. CD11b-
hDTR and clodronate liposomes dependent myeloid cell depletion appear to 
indicate similar effects of monocyte/macrophage ablation on atherosclerosis 
development. 
 The key role of monocytes and macrophages in atherosclerosis 
development 1, but also other inflammatory diseases such as rheumatoid 
arthritis 20, has already been demonstrated. However, the aforementioned 
models for macrophage depletion are often lack specificity, and directly or 
indirectly impacted leukocyte subsets other than macrophages, thwarting data 
interpretation and resulting in unwanted side effects 19,21-23. CD11b is 
expressed by not only monocytes/macrophages, but also by neutrophils and 
dendritic cells, in contrast, CD115 is more constricted to the 
monocyte/macrophage axis, and thus CD115 will give a more specific insight in 
the role of this axis in atherosclerosis development. 
In this study we employed a loss-of-function approach using a MaFIA 
transgenic mouse model that carries an inducible FAS construct under control 
of the CD115 (also known as macrophage-colony stimulating factor receptor 
[M-CSFr]or colony stimulating factor 1 receptor [CSF-1R]) promotor 24. In 
mouse and man, the monocytic lineage depends entirely on M-CSF for their 
ontogenesis 25-27., and they produce and express high levels of this cytokine as 
well as of the cognate receptor CD115. Together with other cytokines such as 
granulocyte/macrophage colony stimulating factor (GM-CSF) and interferon 
gamma (IFN-γ) 28, M-CSF is essential for myeloid lineage commitment in the 
bone marrow29. The key role of the M-CSF receptor in the myelopoiesis leads 
to the concept of ablating macrophages based on this receptor to study the 
role of macrophages in atherosclerosis and myelopoiesis 30. This model allows 
us to deplete CD115+ monocytes and macrophages in a time-controlled 
manner, by administering a dimerizer. Lymphocytes, and also granulocytes and 
dendritic cells, are considered to be M-CSF receptor low or negative and 
predominantly develop in an M-CSF independent manner 31. 
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We provide evidence that depletion of M-CSF receptor (CD115) 
positive myeloid cells in a FAS-dependent manner, only contributes to 
atherosclerotic lesion formation in mice on a pro-atherogenic Apo lipoprotein 
E deficient (ApoE-/-) background when depleted locally in the atherosclerotic 
lesion. Systemic ablation of M-CSF receptor positive monocytes and 
macrophages does not influence atherosclerosis development, however it 
does result in deregulation of erythropoiesis and myelopoiesis. 
Materials & Methods 
Animals 
C57BL/6J−Tg(Csf1r−EGFP−NGFR/FKBP1A/TNFRSF6)2Bck/J MaFIA+/+ male mice 
obtained from the Jackson Laboratories 32, were backcrossed to ApoE−/− mice 
for more than 12 generations to obtain homozygous ApoE-/- // MaFIA+/+ mice. 
The MaFIA transgene was inherited according to Mendelian laws as 
demonstrated by qPCR analysis of gDNA (PureLink Genomic DNA Purification 
Kit, Invitrogen). Primer sequences were: 5’-CCACATGAAGCAGCAGGACTT-3’ for 
the forward primer and 5’-GGTGCGCTCCTGGACGTA-3’ for the reverse primer.  
Male mice expressing the Macrophage FAS Induced Apoptosis 
transgene (MaFIA+/+; coexpressing green fluorescent protein (GFP) and the 
dimerizer inducible suicide receptor under control of the endogenous CD115 
promotor) on a pro-atherogenic Apo lipoprotein E deficient (ApoE-/-) 
background were obtained from the animal breeding facility at the Maastricht 
University. Dimerizer treated ApoE-/- mice or solvent-treated ApoE-/- // 
MaFIA+/+ mice served as controls for the in vivo studies. Mice were fed regular 
chow diet (RM3; Special Diet Services [SDS], Essex, U.K.) or Western type diet 
(WTD; 0.25% cholesterol; SDS). Drinking water supplemented with antibiotics 
(60,000 Units/L Polymixin B Sulfate [Sigma-Aldrich, St. Louis, MO, USA] and 100 
mg/L Neomycin [Sigma-Aldrich]) was introduced two weeks before the 
introduction of Western type diet. During experiments drinking water and food 
were provided ad libitum. During all experiments animals were housed in filter 
top cages. All in vivo studies were approved by the Maastricht University Ethics 
committee for animal experiments and performed according to the Dutch 
government guidelines for animal experiments.   
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Dimerizer 
Lyophilized AP20187 was dissolved in ice-cold pure (100%) ethanol to obtain a 
0.455 mM (6.25 mg/mL) stock solution, which was stored at -20° C until further 
use. For in vitro experiments the stock solution was diluted in medium to a 
final concentration of 1 – 5 μM in the culture medium with an end 
concentration of ethanol below 0.5%. For intra-venous (iv) injections, the stock 
solution was diluted 25-fold in water containing 4% ethanol, 10% 
poly(ethylene) glycol (PEG) 400, and 1.7% Tween, resulting in an end 
concentration of 0.25 mg/mL AP20187. All intra-venous injections were 
administered within 30 minutes after preparation of the injection solution. The 
applied dose was 1 mg/kg body weight (150 μL/mouse on average). ApoE-/- 
control animals received solvent containing AP20187 at the same dose as the 
MaFIA mice, ApoE-/- // MaFIA+/+ controls received solvent-only injections. For 
the in vivo experiments in which osmotic minipumps (Alzet, Cupertino, CA, 
USA) were used, stock solution was diluted as before, however the 
administered dose dimerizer was 100-fold lower (0.01 mg/kg).  
In vivo experiments 
IV injection atherosclerosis study. Ten week old ApoE-/- // MaFIA+/+ animals 
(n=14) and ApoE-/- animals (n=13) were placed on a Western type diet. Two 
weeks after introducing the WTD animals received flow restricting collars 
around the right and left carotid arteries to induce atherosclerotic plaque 
formation, as described before 33. Three weeks later, mice received an 
intravenous AP20187 tail vein injection every 72 hours for two weeks (final 
dose of 1 mg/kg body weight). Bodyweight was measured to adjust the dose 
according to the individual weight of each mouse and monitor the effect of the 
treatment. Mice were sacrificed 18 hours after the last injection with the 
dimerizer. 
 
Osmotic minipump atherosclerosis study.  Ten week old ApoE-/- // MaFIA+/+ 
animals (n = 8) and ApoE-/- animals (n = 8) were placed on a Western type diet. 
Two weeks after introducing WTD, semi-constrictive collars were placed 
bilaterally, at the common carotid arteries, to induce atherosclerotic plaque 
formation; simultaneously an osmotic minipump containing AP20187 with 
catheters attached to the perivascular site of the carotid artery was placed. 
Mice were sacrificed two weeks after implantation of the osmotic minipumps. 
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Upon sacrifice the integrity and localization of the catheters was verified and 
animals with (suspected) malfunctions in the catheters or minipumps were 
excluded from the study.  
 
Dynamics study. Ten week old ApoE-/- // MaFIA+/+ animals (n = 16) and ApoE-/- 
animals (n = 8) were placed on a Western type diet for five weeks. 
Subsequently, MaFIA mice received an intravenous tail vein injection 
containing AP20187 (1 mg/kg body weight) every 72 hours for one or two 
weeks (n = 8 / timepoint). Control ApoE-/- mice were processed similarly. 
Bodyweight was measured to adjust the dose according to the individual 
weight of each mouse. Mice were sacrificed 18 hours after the last injection 
with the dimerizer. 
In vitro experiments 
Macrophage culture. Bone marrow cells were isolated from ApoE-/- // MaFIA+/+ 
and ApoE-/- mice (n = 4 / genotype). Bone marrow cells were isolated from one 
femur and one tibia per mouse and pooled samples were cultured in RPMI-
1640 (Invitrogen) supplemented with 10% fetal calf serum and L929 
conditioned medium (LCM) to generate bone marrow-derived macrophages 
(BMDM) as previously described 34. Medium was replaced every three days 
and differentiated BMDM were used for in vitro assays after seven days. 
 
Macrophage polarization. BMDM were incubated for 24 hours with LPS 
(100ng/mL), IFN-γ (100 U/mL), TNF-α (40 ng/mL), IL-10 (10 ng/mL), or IL-4 (20 
ng/mL). Subsequently, mRNA was isolated using the Trizol (Invitrogen) 
method. 500 ng total RNA was reverse transcribed using the iScript cDNA 
Synthesis Kit (BioRad, Veenendaal, the Netherlands). Quantitative PCR was 
performed using 10 ng cDNA, 100 nM of each primer, and SYBR Green 
(Invitrogen) in a total volume of 15 µl. Gene expression levels were corrected 
for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as housekeeping 
gene. Primer sequences are available upon request. 
 
Apoptosis assay. Peritoneal macrophages isolated from ApoE-/- // MaFIA+/+ and 
ApoE-/- mice (n = 5 / genotype) were cultured for 24 hours in RPMI-1640 
(Invitrogen, Paisley, UK) supplemented with 10% fetal calf serum (FCS). 
Subsequently, AP20187 was added to the medium to a final concentration of 
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4.55 μM and cells were incubated for 18 hours. Apoptosis was measured by 
immunohistochemically staining for cleaved caspase-3 and counterstaining 
with DAPI. Pictures were made (Leica DMIL fluorescence microscope) and 
overlays were analyzed with ImageJ Software. 
Histology 
Carotid arteries from ApoE-/- // MaFIA+/+ and ApoE-/- mice were collected, 
formalin-fixed and paraffin embedded. Subsequently, 4 μm thick sections were 
stained with haematoxylin and eosin (H&E) and lesion size and necrotic core 
area were determined in five sections per animal. Representative sections on 
separate slides were stained immunohistochemically with a macrophage-
specific antibody (MAC-3; Becton & Dickinson, NJ, USA) or with a smooth 
muscle cell-specific antibody (α-smooth muscle cell actin antibody; Sigma-
Aldrich; St. Louis, MO, USA). Apoptosis was visualized using a terminal 
deoxytransferase dUTP nick-end labeling (TUNEL) kit (Roche; Woerden, 
Netherlands). Apoptotic cell content was determined by assessment of the 
TUNEL positive area per section. Collagen was visualized by Sirius-Red staining 
of representative slides.  
Spleen and tibias were analyzed for the effects of the treatment on the 
hematopoiesis. After fixation for 24 hours in 1% paraformaldehyde spleen 
tissue was paraffin embedded and 4 μm thick sections were cut for histological 
analysis. Tibias were fixated for 24 hours and subsequently decalcified for 2 
weeks in decalcification buffer (PBS with 0.05 mM EDTA). Buffer was replaced 
every 3 days to obtain sufficient level of decalcification. Subsequently, tibias 
were paraffin embedded and 4 μm thick sections were cut for RUNX2 and 
TRAP histological analysis. All histological analyses were performed, blinded, 
by an independent operator using Quantimet (Leica) with Qwin3 quantification 
software (Leica). 
M-CSF and cholesterol levels 
Blood samples were collected in tubes containing 5 μL 0.5M EDTA and 
centrifugated for 10 minutes at 2100 rpm. Subsequently, plasma was isolated 
and used for M-CSF and total cholesterol measurement. M-CSF (ligand for 
CD115) was determined using the mouse M-CSF Quantikine ELISA kit (R&D 
Systems). Total plasma cholesterol levels were measured using a colorimetric 
assay (CHOD-PAP, Roche, Mannheim, Germany). 
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Flow cytometry 
Upon sacrifice blood, spleen, bone marrow, and peritoneal leukocytes were 
collected. In blood absolute counts were obtained using BD Trucount tubes, 
according to the protocol supplied by the manufacturer (BD Biosciences). In 
short, Fc-receptor blocking antibody was added to the Trucount tubes. 
Subsequently, 50 μL anti-coagulated whole blood was added and the tube was 
gently vortexed. After incubation for ten minutes, the antibody cocktail was 
added and incubated at room temperature in the dark for an additional 20 
minutes. Finally, hypotonic lysis buffer was added and samples were measured 
on a FACS Canto II flow cytometer (BD Biosciences). Blood parameters were 
measured using flow cytometry for the leukocyte fraction and a Coulter 
counter for determining other variables. Red blood cell and platelet numbers 
were determined as well as hemoglobin and hematocrit levels.  
Myeloid progenitors were measured in spleen and bone marrow. First, 
cells from spleen and bone marrow were stained with biotin-conjugated 
antibodies against lineage markers (CD5, CD45RA [B220], CD11b, Gr-1 
[Ly6C/G], 7-4, and Ter-119; Miltenyi Biotec). Next, lineage positive cells were 
depleted using streptavidin conjugated magnetic beads (Miltenyi Biotech) and 
LS columns (Miltenyi Biotech). Lineage negative fractions were subsequently 
stained with antibodies for Sca-1, c-Kit (CD117), CD34, CD16/32, CD115, and 
lineage markers (CD5, CD45RA [B220], CD11b, Ly6C, Ly6G, Ter-119) and 
measured on a FACS Canto II (BD Biosciences).  
Single cell suspensions were made from spleen by crushing the tissue 
over a 70 μm cell strainer (BD Biosciences, NJ, USA). To measure mature 
leukocytes, erythrocytes in spleen and bone marrow were removed by 
incubation with hypotonic lysis buffer (8.4 g NH4Cl and 0.84 g NaHCO3 per liter 
distilled water). Non-specific Fc-receptor binding was blocked by the addition 
of anti-CD16/CD32 antibody (eBioscience, San Diego, USA). Antibodies used for 
these flow cytometry experiments are shown in supplemental table 1. Samples 
and buffers were kept on ice throughout the experiment unless indicated 
otherwise. All measurements were performed on a FACS Canto II (BD 
Biosciences) and analysis of acquired data was performed using FACS Diva 
software (BD Biosciences). 
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Colony forming unit assay 
Bone marrow cells were isolated from one tibia and femur per mouse. Cells 
were counted twice using a Countess automated cell counter (Sigma-Aldrich) 
and the concentration was calculated for each sample. Per well 10,000 bone 
marrow cells were added to 2 mL methylcellulose medium with recombinant 
cytokines (MethoCult Medium, StemCell Technologies, Grenoble, France). For 
spleen 250,000 cells were added to 2 mL methylcellulose medium with 
recombinant cytokines (Stemcell Technologies). After incubation for 7 days 
(37°C; 5% CO2) the total number of colonies was quantified by an independent 
operator, and GM-CFU, E-CFU, G-CFU, and M-CFU colonies were specified 
based on morphology. 
Statistics 
Data are expressed as mean ± SEM. To compare individual groups, 2-tailed 
Students t-test was used; non-parametric data were analyzed using Mann-
Whitney U test. All statistical analyses were performed using GraphPad Prism 5 
software (GraphPad Software Inc, La Jolla, CA, USA) and p-values below 0.05 
were considered statistically significant. 
Results 
Systemic treatment ablates plaque macrophages, but only affects 
lesion composition partially 
As previously described, the MaFIA mice show weight loss due to the 
treatment with the dimerizer (data not shown)32, the weight loss is not present 
in solvent treated MaFIA mice or dimerizer treated ApoE-/- controls. Pilot 
experiments showed the ablation of both monocytes and granulocytes after 
systemic treatment for 7 days using a dose of 1 mg/kg (figure 1A+B). 
Effectiveness of the treatment on ablation of macrophages was verified in vitro 
using peritoneal macrophages isolated from ApoE-/- // MaFIA+/+ and ApoE-/- 
mice. In the MaFIA peritoneal macrophages an almost complete induction of 
dimerizer-dependent cell death (>80%) could be observed, while there was no 
apoptosis measurable in the control macrophages (figure 1C). For bone 
marrow derived macrophages in vitro no apoptosis could be induced. In depth 
analysis revealed that in vitro differentiation of BMDM resulted in 
downregulation of CD115 and thus diminished expression of the MaFIA suicide 
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gene on these cells (supplemental figure 1A+B). This process was shown to be 
dependent on the M-CSF in the culture medium, indicating a negative 
feedback of M-CSF on the expression of the M-CSF receptor (CD115).   
 
Figure 1 - In vitro and in vivo depletion of myeloid cells is functional 
In vivo and in vitro depletion of monocytes, granulocytes, and macrophages using AP20187 is 
efficient. (A, B) Monocytes (A) and granulocytes (B) can be efficiently depleted in vivo after 7 
days of treatment with 1 mg/kg intravenous injections of AP20187 (filled bar), compared to 
solvent-treated controls (open bar). (C) In vitro assays show highly efficient induction of 
apoptosis in peritoneal macrophages from ApoE-/- // MaFIA+/+ animals. Blue is DAPI (nuclei) and 
red is polycaspase (apoptosis). *** p < 0.001 
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To study the effect of ablating plaque resident macrophages on 
atherosclerosis development, we examined ApoE-/- // MaFIA+/+ (MaFIA) mice 
treated with 1 mg/kg AP20187 via intra venous injections in the tail vein. 
Treatment with AP20187 did not influence plasma cholesterol levels 
(supplemental figure 2A+B), nor in plasma M-CSF levels (supplemental figure 
2D). At baseline, we observed no differences in collar-induced plaque 
characteristics between ApoE-/- mice and (untreated) ApoE-/- // MaFIA+/+ mice 
(supplemental figure 3). After two weeks of treatment with AP20187, MaFIA 
mice did not have any changes in total plaque area (figure 2A) nor in necrotic 
core size (figure 2B) compared to AP20187 treated ApoE-/- mice. Plaque area 
did increase over the course of the two week treatment period compared to 
baseline (dashed line; figure 2A+B). Collagen was decreased significantly in 
ApoE-/- // MaFIA+/+ mice compared to ApoE-/- controls (figure 2C). As expected 
an ablation of plaque macrophages was observed in the dimerizer-treated 
ApoE-/- // MaFIA+/+ mice compared to ApoE-/- controls (figure 2D). However, the 
increased apoptosis of macrophages did not result in any effects on necrotic 
core, indicating that this reduction could possibly be caused by decreased 
monocyte migration towards the atherosclerotic lesion. Surprisingly, we also 
noted a significant reduction in smooth muscle cells (SMC) in lesions from 
ApoE-/- // MaFIA+/+ mice compared to control ApoE-/- mice (figure 2E). To verify 
whether this was related to increased apoptosis of SMCs we performed a 
TUNEL staining. An almost 4-fold increase in SMC apoptosis could be observed 
indicating that also smooth muscle cells are directly or indirectly affected by 
the systemic treatment with AP20187 in vivo (figure 2F). As there were no 
effects observed on smooth muscle cells in the control animals, it was not 
solvent-induced apoptosis of SMCs, but a specific reaction to the dimerizer 
treatment. Next, it could be noted that lesions from MaFIA mice had less 
pronounced lipid cores compared to wild type animals. However, total lipid 
core was unchanged between ApoE-/- // MaFIA+/+ and ApoE-/- mice (data not 
shown).  
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Figure 2 - Systemic treatment with AP20187 reduces plaque macrophage content 
(A – C) In vivo treatment with 1 mg/kg AP20187 via intravenous tail vein injections does not 
affect total plaque area (A) and necrotic core area (B), while collagen content decreases (C) in 
ApoE-/- // MaFIA+/+ animals. (D, E) Intimal macrophages content (D) and smooth muscle cells (E) 
are reduced in ApoE-/- // MaFIA+/+ animals upon AP20187 treatment. (F) This decreased number 
of SMCs is accompanied by an increased SMC apoptosis in ApoE-/- // MaFIA+/+ animals. (G) 
Overview of the experimental setup for the in vivo treatment with AP20187. (H) Representative 
pictures of macrophage (Mac3) and alpha smooth muscle cell actin (αSMA) staining for ApoE-/- 
and ApoE-/- // MaFIA+/+ animals. White bars are ApoE-/- controls and black bars are ApoE-/- // 
MaFIA+/+ animals. * p< 0.05 
 
Myeloid cells are depleted systemically; however recover after 
sustained treatment 
Systemic treatment (1mg/kg) resulted in decreased numbers of CD45 positive 
leukocytes in the circulation of AP20187 treated ApoE-/- // MaFIA+/+ mice 
compared to ApoE-/- mice after one week of treatment. This was mainly 
contributable to the decreased number of myeloid cells in MaFIA mice 
compared to controls. Contrary to our expectations, total leukocyte numbers 
recovered after two weeks of continuous treatment with AP20187 to levels 
equal, or even slightly increased, compared to ApoE-/- control mice. However, 
leukocyte composition was clearly affected, lymphocytes were affected only 
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partially by the AP20187 treatment; this was shown by unaltered numbers of 
CD3 positive T lymphocytes (data not shown). B lymphocytes (B220+ cells) 
were decreased in MaFIA mice after already 1 week of treatment and did not 
recover after two weeks of treatment (data not shown).  
Total myeloid cells were affected more drastically and showed an 
increase after prolonged treatment of two weeks. Monocytes (CD11b+/Ly6G-) 
and surprisingly also granulocytes (CD11b+/Ly6G+) were efficiently depleted in 
the circulation of the ApoE-/- // MaFIA+/+ compared to ApoE-/- mice after the 
first week of treatment with AP20187 (figure 3A+B). In contrast to our 
expectations, monocytes and granulocytes in MaFIA mice recovered to 
baseline values after continuous treatment for two weeks compared to short 
(one week) treatment (figure 3A+B). We also noted the expansion of a 
CD11b+/Ly6Gmid myeloid subset, not being (mature) monocytes or 
granulocytes, after one and two weeks of treatment with AP20187 (figure 3C). 
The amount of Ly6Chigh monocytes recovered faster than the Ly6C- monocytes 
(figure 3D) upon the depletion after 1 week of dimerizer treatment. This could 
be indicative of expanded production or release of Ly6Chigh monocytes from 
bone marrow and spleen in the AP20187 treated MaFIA mice. 
As the massive depletion of granulocytes was unexpected we analyzed 
the expression of both the GFP reporter and also the M-CSF receptor (CD115) 
on these cells. Monocytes were CD115high as expected, however also 
granulocytes showed low to intermediate levels of the M-CSF receptor. The 
activity of the CD115 promotor in granulocytes was confirmed by the GFP 
signal, which was comparable to the GFP level in monocytes (figure 3F). Based 
on the GFP levels we could also determine that a subset of B-cells has low 
expression of the construct, explaining the limited effects observed on 
circulating B-cells (data not shown). Treatment with AP20187 resulted in 
depletion of CD115 positive cells, however GFP expression was still measurable 
in CD115 negative cells (figure 3F), which could be indicative of post-
translational regulation of the M-CSF receptor expression.   
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Figure 3 - Sustained treatment with AP20187 results in disturbed leukocyte pattern 
(A, B) Treatment with AP20187 results in initial depletion of monocytes (A) and granulocytes (B) 
after 1 week, but apparent recovery after two weeks of treatment. (C) Leukocyte patterns are 
disturbed upon AP20187 treatment and a novel CD11b+/Ly6Gmid population increases over time. 
(D) Monocyte subset (Ly6Chigh/Ly6C-) ratio show a pattern that is similar to total monocytes and 
granulocytes, with initial depletion and subsequent recovery. (E) Representative dot plots of 
monocytes and granulocytes (top panels) and monocyte subsets (bottom panels). (F) 
Representative histograms showing CD115 (M-CSF receptor) and GFP (promotor activity) levels 
in monocytes, granulocytes, and control cells. White bars (controls, light purple bars (1 week 
treatment), and dark purple bars (2 weeks treatment). * p < 0.05, ** p < 0.01, *** p < 0.001 
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 Unexpectedly, analysis of splenic leukocytes revealed a significant and 
persistent increase in monocytes (figure 4A) and granulocytes (figure 4B) after 
1 and 2 weeks of treatment. Also CD11b+/Ly6Gmid cells were massively 
expanded in the spleen (figure 4C). Flow cytometry also revealed that the 
monocyte expansion was CD115 independent, as CD115+ monocytes were 
almost completely ablated (figure 4D), and thus all remaining monocytes were 
CD115 negative. 
 
Figure 4 - Spleen composition and function is perturbed by CD115+ cell depletion 
(A – C) Treatment of MaFIA mice with 1 mg/kg AP20187 results in increased monocytes (A), 
granulocytes (B), and CD11b+/Ly6Gmid myeloid cells (C) in the spleen. (D) These splenic 
monocytes are however predominantly CD115 negative. (E) Total spleen cellullarity is 
significantly increased after sustained AP20187 treatment in MaFIA mice compared to controls.  
(F, G) Flow cytometry analysis of the spleen indicated that Lineage-/Sca-1-/c-Kit+ (LK) cells were 
reduced upon treatment (F), however within this subset granulocyte/macrophage progenitors 
(GMP) (G) were increased. (H, I) Colony forming unit (CFU) assay showed that total number of 
colonies and macrophage colony forming units (M-CFU) were increased after 1 and 2 weeks of 
treatment in MaFIA mice, as could also be observed in representative pictures of CFU assay (I). * 
p < 0.05, ** p < 0.01, *** p < 0.001 
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Myelopoiesis shifts to spleen after AP20187 treatment 
As there was an unexpected increase in myeloid cells in the circulation (figure 
3) and spleen (figure 4A-D), hematopoiesis was analyzed more in depth. As the 
spleen was enlarged (data not shown) and splenic cell content was increased 
(figure 4E), myelopoiesis was analyzed in the spleen to determine whether 
extramedullar hematopoiesis did occur in these treated MaFIA mice. In spleen, 
no effects on the LK fraction could be observed after one week of treatment. 
Two weeks treatment did result in a significant decrease of this progenitor 
subset (figure 4F). More in depth analysis did show that the decrease in LK cells 
was accompanied by an increase in GMP cells after both one and two weeks of 
treatment (figure 4G). Indeed, splenic myelopoiesis was dramatically increased 
after 1 and 2 weeks of treatment with AP20187. Total CFU was more than 3-
fold increased, which was almost completely attributable to increased 
numbers of macrophage colony forming units (M-CFU), while GM-CFU and G-
CFU were not significantly increased (figure 4H).  
Macroscopically, it could be noted that there was a clear distinction 
between the bones (femur and tibia) from ApoE-/- mice and ApoE-/- MaFIA+/+ 
mice treated with AP20187. MaFIA mice had paler bone marrow which already 
indicated effects on bone marrow composition (figure 5A), which was 
confirmed by the decreased number of cells in the bone marrow (figure 5B). 
When myelopoiesis in bone marrow was analyzed by colony forming unit (CFU) 
assays it could be observed that there was a decrease in total CFU after 1 week 
of treatment, while after two weeks of treatment with the dimerizer levels 
normalized (figure 5C). These effects were similar to the effects observed in 
blood regarding monocyte and granulocyte numbers (figure 3). There were no 
specific subsets that were responsible for the decreased number of CFUs in the 
bone marrow compartment, as all subsets showed equal responsiveness to the 
treatment after one and two weeks of treatment (figure 5C). To confirm these 
results from the CFU assays, flow cytometry was performed to determine 
progenitors in bone marrow compartment. It could be observed that Lineage-
/Sca-1-/c-Kit+ (LK) cells were significantly diminished in bone marrow after one 
week of treatment (figure 5D), which is in line with the effects observed in the 
CFU assays. Within this LK fraction the relative percentage of 
granulocyte/macrophage progenitors (GMP) was increased, indicative of a 
relatively small decrease or even expansion of this progenitor subset in the 
bone marrow (figure 5E). Overall, it could be shown that in spite of treatment 
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myelopoiesis did expand. Most likely this is a compensatory effect for the 
depleted mature myeloid cells in the periphery. Especially, the splenic 
hematopoiesis is thought to be responsible for the effects observed in blood 
and spleen regarding the recovery of myeloid cells after prolonged treatment.  
Systemic treatment results in bone marrow osteoclast depletion 
As we observed massive extramedullar hematopoiesis in MaFIA mice treated 
systemically (i.v. injections), we sought out to investigate which mechanism is 
responsible for the peripheral phenotype observed. Since we observed a shift 
in hematopoiesis from the bone marrow to the splenic compartment, we 
wanted to analyze the effect of the dimerizer (AP20187) treatment on cells 
involved in maintaining normal bone marrow niches. Staining for osteoclasts in 
decalcified femur sections showed that osteoclast levels were mildly reduced 
in MaFIA mice (supplemental figure 4).  
 
Figure 5 - Stromal hematopoiesis is decreased in treated MaFIA mice 
(A) Femurs from AP20187 treated MaFIA mice were visibly paler than femur from control 
animals. (B) Total cells per bone were decreased in MaFIA mice. (C) Colony forming unit (CFU) 
assay showed that total number of colonies (and subsets) were decreased after 1 week of 
treatment, but recovered after two weeks of sustained treatment in MaFIA mice. (D, E) Flow 
cytometry analysis of the bone marrow indicated that Lineage-/Sca-1-/c-Kit+ (LK) cells were 
reduced upon treatment (D), however within this subset granulocyte/macrophage progenitors 
(GMP) (E) were increased. (F) Representative dot plots indicating relevant gating strategy. ** p < 
0.01, *** p < 0.001 
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Local treatment with AP20187 accelerates atherogenesis 
To exclude any systemic effects on atherosclerosis development, we 
performed a second atherosclerosis study in which animals received a collar 
around the carotid arteries combined with an osmotic minipump with 
catheters attached to the perivascular side of the carotid arteries near the 
collar. The dimerizer AP20187 was constantly delivered for two weeks at a 
dose of 0.01 mg/kg body weight, which did not affect plasma cholesterol 
(supplemental figure 2C). Analysis of the carotid arteries after two weeks of 
treatment showed that total plaque area was over two-fold increased when 
the animals were treated continuously and locally compared to treated ApoE-/- 
controls (figure 6A). Necrotic core (figure 6B) and collagen content (figure 6C) 
were equally expanded in the treated MaFIA mice. As expected, macrophages 
were not increased in the plaques from MaFIA mice compared to the controls 
despite the massively expanded plaque size (figure 6D). Intra-plaque smooth 
muscle cells were in contrast to the systemic study not affected by the local 
treatment with the dimerizer (figure 6E+F). Analysis of circulating leukocytes 
did not reveal any significant differences between ApoE-/- MaFIA+/+ mice and 
ApoE-/- controls (supplemental figure 5).  
 
Figure 6 - Local treatment to the atherosclerotic lesion increases lesion formation 
(A) Local treatment with AP20187 results in aggravated atherosclerosis formation in MaFIA 
mice. (B, C) Local treatment does not affect necrotic core (B), and plaque collagen content (C) in 
MaFIA mice compared to controls. (D) Intimal macrophage content is reduced upon treatment. 
(E, F) However, smooth muscle cell (SMC) content (E), and SMC apoptosis (F) are unaffected by 
local treatment. (G) Representative pictures of haematoxylin and eosin (H&E) stained lesions 
from control and MaFIA mice. * p < 0.05 
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Discussion 
The MaFIA model for induction of CD115+ cell apoptosis in ApoE-/- pro-
atherosclerotic mice was used for this study. Cells of the myeloid lineage 
express an inducible suicide gene under transcriptional control of the CD115-
promoter 32. Apoptosis is prompted by administration of AP20187 which 
results in dimerization of extracellular FK domains and subsequently their 
cytoplasmic FAS domains triggering the extrinsic pathway of cell apoptosis 32. 
Macrophages are essential in atherosclerotic lesion development and 
progression, and contribute to clinical outcomes by destabilizing the 
atherosclerotic lesion 35,36. Macrophages have an important role throughout 
atherogenesis, from early intimal thickening until advanced rupture-prone 
atheromas 37. However, it has been difficult to unravel the role of plaque 
macrophages, next to circulating myeloid cells, in relation to the progression of 
the lesions. Here, we show that specific depletion of these cells, in a FAS 
dependent manner, exposed both local and systemic effects which contribute 
differentially to atherosclerosis, but also to the conservation of normal 
hematopoiesis.  
Lesion composition in general was not affected by systemic ablation of 
macrophages, despite a substantial reduction of plaque resident macrophages. 
Vascular smooth muscle cells (VSMC) were partially reduced by the whole 
body treatment. However, it has been shown that VSMC which are in contact 
with an atherosclerotic lesion can express the M-CSF receptor 38,39, explaining 
the depletion of these cells in vivo. These smooth muscle cells show also other 
characteristics of the monocyte/macrophage lineage such as phagocytic 
capacity and even the transdifferentiation into foam cells 38. Nevertheless, the 
increased apoptosis of VSMC and macrophages did not contribute to any 
effects on atherosclerotic lesion phenotype.  
Peripheral leukocyte analysis revealed a dramatic decrease in total 
leukocytes after seven days of AP20187 treatment. This reduction was almost 
completely contributable to ablation of myeloid cells, both 
monocytes/macrophages and granulocytes, with minor effects on B-
lymphocytes. The effects on granulocytes and B-cells were in part unexpected, 
however could be explained by the role of PU.1 in controlling M-CSF receptor 
expression 40,41.  PU.1 was already shown to be involved in myeloid cell 
development and B-cell development in a PU.1 knock-out model 42.  The 
ablation of granulocytes, but also B-cells, can be related to the PU.1 dependent 
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transcription of the M-CSF receptor and thus also transcription of the MaFIA 
transgene. The transcription, and even expression, of the M-CSF receptor on 
both B-cells and granulocytes has only been scarcely described so far, but 
could have profound impact on the current knowledge on myelopoiesis and 
cell maturation.  
Systemic ablation of M-CSF receptor (CD115) positive macrophages 
and monocytes was shown to result in disturbed myelopoiesis with increased 
extra-medullar hematopoiesis and the release of immature myeloid cells into 
the circulation. The production and release of progenitors in the bone marrow 
is amongst others controlled by bone marrow monocytes, macrophages, and 
osteoclasts, which are considered to be related to the myeloid lineage 43. 
Osteoclasts respond to similar cytokines as macrophages, and also express 
comparable surface markers, including the M-CSF receptor 44. We were able to 
show that in vivo treatment with AP20187 results in decreased numbers 
osteoclasts. As macrophages as well as osteoclasts are ablated upon AP20187 
treatment, the relevant contribution of each these cell types to the observed 
neutrophilia cannot be directly derived from these data 44-46. However, in a G-
CSF mobilization study Winkler et al argued that bone marrow macrophages 
are the most important cell type in regulating stromal release 45. Furthermore, 
osteoclast activation is associated with decreased stromal release 47, yet 
osteoclast activation is increased under inflammatory conditions 48. Osteoclast 
depletion may also be responsible for the observed effects on B-lymphocytes 
as the development of mature B-cells also is regulated by these cells in the 
bone marrow 49. Overall, systemic AP20187 treatment was shown to have 
profound effects on myelopoiesis, which could, at least in part, be explained by 
depletion of cells responsible for maintaining normal bone marrow niches. 
As the unanticipated effects observed on the myelomonocytic cells 
after systemic dimerizer administration could well have masked local effects of 
macrophage ablation, we analyzed plaque-specific effects in a separate study. 
The dimerizer was administered locally to the carotid arteries via catheterized 
osmotic minipumps. Site-restricted administration of the dimerizer was shown 
not to result in any significant systemic effects. In the atherosclerotic lesion we 
did observe a completely inhibited expansion of the number of intimal 
macrophages. In contrast to systemic administration of the dimerizer, plaque 
size was increased more than two-fold in animals treated locally. As 
macrophage content was similar between the treated MaFIA mice and 
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controls, the plaque and necrotic core expansion were most likely caused by 
the immediately induced cell death of newly infiltrating monocytes. As 
monocytes are not ablated peripherally in mice treated locally, more 
monocytes will migrate towards the inflammatory locus 50. Hereby, more cells 
will enter the lesion, where AP20187-dependent apoptosis is induced. Due to 
an inhibited expansion of mature macrophages, and thus decreased 
efferocytosis, these apoptotic monocytes will be cleared less efficiently giving 
rise to secondary necrosis and progressive development of the necrotic core 
and total plaque. Taken together, our data confirm the current paradigm that 
influx of monocytes might be more important than reduction of plaque 
macrophages via efflux of apoptosis for controlling atherosclerotic plaque 
development 50-53. Another explanation may lie in the mildly shifted Ly6Chigh to 
Ly6C-/low monocyte balance which may have favored the differentiation into 
classically activated pro-inflammatory macrophages 54-56.  
Overall, we can conclude that macrophages, and other M-CSF receptor 
positive cells, are critical controllers of many processes essential to 
atherogenesis, including hematopoiesis. Depletion of macrophages will result 
in disturbed physiology indicative of the essential role of myeloid cells in 
maintaining health and reducing plaque development. 
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Supplemental figures 
 
Supplemental figure 1 - M-CSF reduces CD115 expression on bone marrow derived 
macrophages 
(A, B) M-CSF containing medium (LCM) results in down regulation of CD115 (M-CSF receptor) 
within 24 hours compared to M-CSF free cultured bone marrow derived macrophages. 
 
 
Supplemental figure 2 - Plasma cholesterol is not affected by AP20187 treatment 
(A, B, C) Plasma cholesterol is not affected at baseline (A), after intravenous treatment with 
AP20187 (B), or after local treatment (minipump) with AP20187 (C) of MaFIA mice compared to 
controls. (D) Plasma M-CSF levels after 1 and 2 weeks intravenous AP20187 administration. 
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Supplemental figure 3 - At baseline no differences in plaque size and morphology could be 
detected 
At baseline no differences in total plaque area (A), necrotic core (B), collagen content (C), intimal 
macrophage content (D), smooth muscle cell content (E), and apoptosis (F) could be detected 
between control animals and AP20187 treated MaFIA mice. 
 
Supplemental figure 4 - Osteoclasts are depleted from the bone upon AP20187 treatment 
(A) Osteoclasts were stained and quantified in the bones of solvent-treated (control) animals 
(white bar) and dimerizer (AP) treated animals (black bar). A clear reduction in the number of 
osteoclasts could be shown in the AP-treated animals. (B) Representative pictures of bones from 
control and AP-treated animals. Osteoclasts are stained in purple, arrowheads indicate the 
positive cells. Note that in the AP-treated animals the staining is less pronounced than in the 
control animals. * p < 0.05 
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Supplemental figure 5 - Local treatment does not induce systemic disturbances in leukocyte 
composition 
After local treatment with AP20187, no differences could be detected in circulating lymphocytes 
(A), granulocytes (B), and monocytes (C) between control animals and AP20187 treated MaFIA 
mice. 
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Abstract 
Leukocyte chemotaxis is deemed instrumental in initiation and progression of 
atherosclerosis. It is mediated by G-protein-coupled receptors (e.g., CCR2 and 
CCR5), the activity of which is controlled by G-protein-coupled receptor kinases 
(GRKs). In this study, we analyzed the effect of hematopoietic deficiency of a 
potent regulator kinase of chemotaxis (GRK2) on atherogenesis. LDL receptor-
deficient (LDLr-/-) mice with heterozygous hematopoietic GRK2 deficiency, 
generated by bone marrow transplantation (n=15), displayed a dramatic 
attenuation of plaque development, with 79% reduction in necrotic core and 
increased macrophage content. Circulating monocytes decreased and 
granulocytes increased in GRK2-/- chimeras, which could be attributed to 
diminished granulocyte colony-forming units in bone marrow. Collectively, 
these data pointed to myeloid cells as major mediators of the impaired 
atherogenic response in GRK2-/- chimeras. LDLr-/- mice with 
macrophage/granulocyte-specific GRK2 deficiency (LysM-Cre GRK2flox/flox; n=8) 
failed to mimic the aforementioned phenotype, acquitting these cells as major 
responsible subsets for GRK2 deficiency-associated atheroprotection. To 
conclude, even partial hematopoietic GRK2 deficiency prevents atherosclerotic 
lesion progression beyond the fatty streak stage, identifying hematopoietic 
GRK2 as a potential target for intervention in atherosclerosis. 
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Introduction 
Leukocyte migration toward atherosclerotic lesions is deemed instrumental in 
atherosclerosis initiation and progression 1. By releasing cytokines 2 and 
proteolytic enzymes, infiltrated leukocytes may also promote plaque 
destabilization, a process generally preceding thrombotic rupture and 
subsequent acute cardiovascular events. Because leukocyte migration may be 
a potentially attractive target for the prevention or control of plaque 
destabilization and ischemic disease, this research focuses on the pivotal role 
of leukocyte migration in atherosclerosis.  
Chemokines, a family of cytokines with strong chemotactic capacity 3,4, 
are key regulators of leukocyte transmigration into the vessel wall during 
atherogenesis 5,6. Chemokines are inducible and control cellular recruitment, 
especially to inflammatory sites 7. In response to inflammatory stimuli, 
chemokines can be released by various cell types relevant to atherosclerosis, 
including endothelial cells, platelets, and leukocytes 8-11. They act by binding to 
dedicated receptors of the G-protein-coupled receptor (GPCR) family. GPCRs 
are coupled to heterotrimeric G proteins and induce, after ligand binding, 
activation of downstream signaling cascades 12,13.  
The expression and activity of GPCRs is regulated not only at the mRNA 
or protein level but also functionally. One such mechanism is receptor 
desensitization, which dampens the response to prolonged or repeated stimuli 
14,15. Dedicated GPCR kinases (GRKs) can induce receptor desensitization by 
phosphorylation of the ligand-occupied receptor, thereby enhancing its affinity 
for arrestin proteins. Binding of arrestins to the phosphorylated receptor will 
result in uncoupling and internalization of the receptor 16,17. The GRK family 
comprises 7 serine/threonine kinases 18,19. They regulate a range of processes, 
including cell migration 20,21, neuronal pathways 22, and cell survival 23. 
Dysfunction of GRKs, particularly GRK2, has been implicated in various human 
pathologies, such as multiple sclerosis 24, rheumatoid arthritis 25, chronic pain 
26, and heart failure 27, whereas GRK2 overexpression induces hypertension 
28,29. Recently, GRK5 was shown to be involved in atherogenesis in mice 
through smooth muscle cells and endothelial cells. However, monocyte 
migration and function were also affected by GRK5 deficiency 30. Because key 
chemokine receptors in atherosclerosis [CC-motif chemokine receptor (CCR) 2 
and CCR5] are targeted by GRK2 ref 31, decreased levels of this receptor kinase 
conceivably result in excessive migration of inflammatory cells toward 
  
A9R6637.tmp   67 15-9-2013   19:30:49
Chapter 03 
________________________________________________________________ 
68 
atherosclerotic lesions. Therefore, the aim of this study was to assess the role 
of leukocyte specific GRK2 deficiency on the development of atherosclerosis in 
LDL receptor (LDLr)-deficient mice.  
 
Materials & Methods 
Animals 
Female LDLr-/- mice 32 were obtained from the animal breeding facility at 
Maastricht University (Maastricht, The Netherlands). Mice were fed a regular 
chow diet (RM3; Special Diet Services, Essex, UK) or a Western-type diet (WTD; 
0.25% cholesterol; Special Diet Services). Drinking water and food were 
provided ad libitum. Experiments were performed at the Maastricht University 
animal facility. Male heterozygous GRK2 (GRK2-/-) mice 33, LysM-Cre GRK2flox/flox 
mice 34,35, and littermate controls were used as donors for bone marrow 
transplantations and in vitro assays. Donor mice were maintained at the 
Utrecht University Medical Center (Utrecht, The Netherlands) animal facilities. 
All experimental protocols were approved by the Maastricht University ethics 
committee for animal experiments. 
Bone Marrow Transplantation 
Female LDLr-/- mice were lethally irradiated with a single dose (9 Gy, 0.5 
Gy/min, MU 15 F/225 kV; Philips Healthcare, Best, The Netherlands) total-body 
irradiation 1 day before transplantation. On the next day, irradiated recipients 
received an intravenous tail vein injection of 5 x 106 bone marrow cells. Bone 
marrow was isolated from GRK2-/- and littermate controls or LysM-Cre 
GRK2flox/flox and littermate controls by flushing femurs and tibiae. Drinking 
water supplemented with antibiotics [60 U/mL polymyxin B sulfate (Sigma-
Aldrich, St. Louis, MO, USA) and 100 g/mL neomycin (Sigma-Aldrich)] was 
provided starting 1 week before the bone marrow transplantation. After 6 
weeks of recovery, mice were fed a WTD for 12 weeks and subsequently 
euthanized. 
In vivo Migration and Proliferation 
Female wild-type (WT) controls and GRK2-/- chimeras (n=4/5) were 
intraperitoneally injected 24 hours before euthanasia with PBS or CC-motif 
chemokine ligand (CCL) 5 [RANTES; 200 ng/mouse; Peprotech, London, UK] to 
 
A9R6637.tmp   68 15-9-2013   19:30:49
Hematopoietic GRK2 deficiency Attenuates Atherosclerosis 
________________________________________________________________ 
69 
stimulate cell migration. At euthanasia, leukocytes were isolated by peritoneal 
lavage (sterile PBS), and lavages were subsequently analyzed for leukocyte 
content on an automated differential cell counter (XT-2000i; Sysmex, 
Norderstedt, Germany). 
Splenocytes were isolated from spleen, after the tissue was gently 
homogenized over a 70 μm cell strainer (BD Biosciences, San Diego, CA, USA). 
To remove erythrocytes, cell suspensions were incubated in ice-cold 
erythrocyte lysis buffer (155 mM NH4Cl in 10 mM Tris/HCl, pH 7.2) for 3 min. 
Splenocytes (n=6/group) were then resuspended in RPMI 1640 medium 
(Invitrogen, Paisley, UK) supplemented with l-glutamine, 100 U/mL 
streptomycin/penicillin, and 10% FCS and cultured for 48 h in quadruplicate in 
a 96-well round-bottom plate (2 x 105 cells/well; Corning, Lowell, MA, USA). 
Cells were stimulated with CCL5 (RANTES; 100 ng/mL). Concanavalin A (ConA; 
8 g/mL; Sigma-Aldrich) was used as a positive control. Proliferation was 
determined after addition of [3H]thymidine (0.5 Ci/well; Amersham 
Biosciences, Roosendaal, The Netherlands), incubation of the cells for the last 
16 h, and measurement of cell-associated (incorporated) [3H]thymidine by a 
liquid scintillation analyzer (Tri-Carb 2900R; PerkinElmer, Waltham, MA, USA).  
Histological Analysis 
For the GRK2-/- study, aortic roots were isolated, and 10-μm cryostat sections 
were stained with Oil-Red-O. Total plaque area and necrotic core size were 
determined in 7 sections/animal. Corresponding sections on separate slides 
were stained immunohistochemically with a macrophage-specific antibody 
(MOMA-2; Serotec, Oxford, UK). For the LysM-Cre GRK2flox/flox study, aortic root 
sections were collected, formalin-fixed, and paraffin-embedded. Subsequently, 
4 μm-thick sections were stained with hematoxylin and eosin. Lesion size and 
necrotic core area were determined in 3-7 sections/animal. Corresponding 
sections on separate slides were stained immunohistochemically with a 
macrophage-specific antibody (MAC-3; BD, Franklin Lakes, NJ, USA). Movat’s 
pentachrome stain was used to elastin and to obtain insight into plaque 
progression stage and stability. Plaque collagen content was quantified based 
on Sirius Red staining and subsequent analysis of the plaques under polarized 
light. Vascular smooth muscle cells were analyzed more in depth by α-smooth 
muscle cell-specific actin (αSMA; Sigma-Aldrich) staining. T-lymphocyte 
infiltration was quantified based on staining with a CD3ε-specific antibody 
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(CD3ε; Dako, Glostrup, Denmark). Apoptosis was visualized using a TUNEL kit 
(Roche, Woerden, The Netherlands). Apoptotic cell content was determined by 
assessment of the TUNEL-positive area per section. Histological analyses were 
performed in a blinded manner by an independent operator using Quantimet 
(Leica, Wetzler, Germany) with QWin3 quantification software (Leica).  
In vitro Macrophage Culture 
Bone marrow cells were isolated from WT and GRK2-/- mice, and cells were 
pooled and cultured in RPMI 1640 medium supplemented with fetal calf serum 
and L929 conditioned medium to generate bone marrow-derived macrophages 
(BMDMs) as described previously 36. Medium was replaced every 3 days, and 
differentiated BMDMs were used for in vitro assays after 7 days.  
Macrophage Foam Cell Formation Assay 
BMDMs were cultured and plated in 24-well cell cluster plates (Corning). 
Macrophages were incubated for 24 hours with VLDL (25 μg/mL) to induce 
foam cell formation. Subsequently, Oil Red O staining was performed to 
visualize the cellular lipid accumulation. Pictures were taken using a DM IL LED 
fluorescence microscope (Leica) with QWin3 software, and foam cell formation 
was scored in a blinded manner by an independent operator, calculating the 
number of positive Oil Red O-stained cells, as well as the staining intensity at a 
per cell basis in >3 fields/condition (x100 view).  
Macrophage Apoptosis and Phagocytosis Assay 
BMDMs were cultured and plated in 48-well cell cluster plates (Corning). 
Macrophages were incubated for 18 hours in plain medium or medium 
supplemented with camptothecin (CPT; 500 μM) or oxidized LDL (oxLDL; 50 
μg/mL). oxLDL was produced as described previously 37. Cells were labeled with 
annexin V-Alexa 488 (Invitrogen) and stained with propidium iodide to detect 
apoptosis and necrosis, respectively. Pictures were taken using a DM IL LED 
fluorescence microscope with Qwin3 software. Overlays were analyzed with 
ImageJ software (U.S. National Institutes of Health, Bethesda, MD, USA) to 
quantify the number of apoptotic and necrotic cells per field.  
To investigate phagocytic capacity, cultured BMDMs were labeled with 
Cell Tracker Red (Invitrogen). Jurkat T cells labeled with Cell Tracker Green 
(Invitrogen) were exposed to a UV light source (UVS-26, 6-W bulb, 0.02 
J/s/cm2; UVP, Upland, CA, USA) for 20 minutes and incubated (37°C with 5% 
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CO2) for 45 minutes to induce apoptosis. Apoptotic Jurkat cells were added to 
the BMDMs at a ratio of 5:1 and incubated for 50 minutes. Macrophages were 
fixed with 1% paraformaldehyde and counterstained with DAPI (Invitrogen). 
Pictures were taken (DM IL LED fluorescence microscope), and overlays were 
analyzed with ImageJ. 
Flow Cytometry 
At euthanasia, blood, spleen, and peritoneal leukocytes were collected. Blood 
and peritoneal leukocytes were analyzed for cellular composition on an 
automated differential cell counter (XT-2000i). Single-cell suspensions were 
made from spleen by crushing the tissue over a 70-μm cell strainer (BD) after 
treatment with DNase and Liberase (Roche). Erythrocytes in blood and spleen 
were removed by incubation with hypotonic lysis buffer (8.4 g of NH4Cl and 
0.84 g of NaHCO3 per liter of distilled water). Nonspecific Fc receptor binding 
was blocked by the addition of anti-CD16/CD32 antibody (eBioscience, San 
Diego, CA, USA). To determine lymphocyte subsets, cells were labeled with 
CD3ɛ-FITC, CD8α-eFluor450, B220-PE-Cy7, CD25-APC (all eBioscience), and 
CD4-PerCP (BD). To detect monocytes and granulocytes, the cells were labeled 
with CD11b-PE-Cy7, Ly6G-PE (BD), and Ly6C-FITC (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Dendritic cells were detected by labeling with CD3ɛ-
PerCPCy5.5, CD19-PerCP-Cy5.5, MHC II-FITC, CD8α-eFluor450 (all eBioscience), 
CD11c-PE-Cy7, and CD4-APC-H7 (both BD) for resident dendritic cells. 
Chemokine receptor expression was determined by labeling peripheral blood 
leukocytes with CCR5-PE, CCR7-PerCP-Cy5.5, CD3e-eFluor450, NK1.1-APC (all 
eBioscience), CD11b-PE-Cy7, Ly6G-APC-Cy7, B220-V500 (all BD), and Ly6C-FITC 
(Miltenyi). After labeling, the samples were washed and analyzed on a 
FACSCanto II flow cytometer (BD). Samples and buffers were kept on ice 
throughout the experiment. Gating strategies used for the different flow 
cytometry stainings are shown in the supplemental data. 
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Colony-Forming Unit (CFU) Assay 
Bone marrow cells were isolated from one tibia and one femur per mouse. WT, 
GRK2-/- and LysM-Cre GRK2flox/flox chimeras were used for the CFU assays. Cells 
were counted twice using a count chamber, and the concentration was 
calculated for each sample. A total of 10,000 bone marrow cells/well were 
added to 2 mL of methylcellulose medium with recombinant cytokines 
(MethoCult Medium; StemCell Technologies, Grenoble, France). After 
incubation for 7 days (37°C with 5% CO2), the total number of colonies was 
quantified by an independent operator, and granulocyte-macrophage CFU 
(GM-CFU), granulocyte CFU (G-CFU), and macrophage CFU (M-CFU) colonies 
were specified based on morphology of the individual cells and the colony as a 
whole.  
Statistical Analysis 
Data are expressed as mean ± sem. To compare individual groups, a 2-tailed 
Student’s t test was used; nonparametric data were analyzed using a Mann-
Whitney U test. All analyses were performed using GraphPad Prism 5 software 
(GraphPad Software Inc., LA Jolla, CA, USA), and values of P < 0.05 were 
considered statistically significant. 
Results 
Partial Leukocyte GRK2 Deficiency Attenuates Atherosclerosis 
Partial hematopoietic GRK2 deficiency did not affect body weight and total 
cholesterol levels (Supplemental Fig. S1). Hematopoietic GRK2-/- chimeras in 
LDLr-/- mice (n=15) showed significantly decreased atherosclerotic lesion 
development in the aortic root compared with that of controls (403.0 ± 43.8 x 
103 vs. 585.0 ± 56.4 x 103 μm2, P=0.017; Fig. 1A). The necrotic core size was 4-
fold smaller in heterozygous GRK2 than in WT chimeras (9.5 ± 2.3 vs. 44.6 ± 
6.1%, P<0.0001; Fig. 1B). The TUNEL-positive apoptotic cell burden (Fig. 1C) did 
not differ between GRK2 and WT chimeras. Further differentiation for TUNEL-
positive cell density in the cap vs. the atheroma revealed that in both WT and 
GRK-/- chimeras 95% of TUNEL-positive cells were located in the atheroma 
(data not shown). Moreover, because we did not observe a shift in localization 
over these two compartments and because the atheroma mainly consists of 
macrophages (next to cell debris), we may infer that partial GRK2 deficiency 
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has not affected macrophage apoptosis. Next, collagen content was not 
affected in GRK2-/- chimeras compared with WT chimeras (Fig. 1D).  
Surprisingly, intimal MOMA-2-positive macrophage content in 
heterozygous GRK2 chimeras was 2-fold higher than that of controls (32.3 ± 2.9 
vs. 15.3 ± 2.4%, P=0.00015; Fig. 1E). Analysis of the lesions did not reveal 
significant differences in intimal (CD3ɛ+) lymphocyte numbers (data not 
shown). Intimal smooth muscle cell content, as assessed by smooth muscle 
cell-specific actin staining, was  increased by heterozygous GRK2 deficiency 
(Fig. 1F). General assessment of plaque morphology, from Movat’s 
pentachrome staining, showed a significant reduction of overall necrosis in 
lesions from GRK2-/- chimeras (Supplemental Fig. S2A). In line with the results 
obtained based on MOMA-2 staining, foam cell macrophage content was 
significantly increased in GRK2-/- lesions (Supplemental Fig. S2B). For neutrophil 
infiltration, it was observed that the number of granulocytes per lesion were 
very low, which was confirmed by the virtual absence of positive Ly6G staining 
(data not shown), whereas intraplaque/adventitial neutrophil numbers tended 
to be decreased in heterozygous GRK2 animals, based on morphological 
scoring of the lesions (Supplemental Fig. S2C). We did, however, observe a 
significant decrease in the amount of cells adhering to the luminal side of the 
atherosclerotic lesions in the GRK2-/- chimeras (Supplemental Fig. S2D), which 
could not be further attributed to a specific cell type. Overall, atherosclerotic 
lesions in GRK2-/- chimera were considered less advanced and more stable than 
those of controls, despite unchanged collagen levels (Supplemental Fig. S2E), 
based on plaque morphology and composition.  
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Figure 1 - Atherosclerotic plaque development is attenuated in GRK2+/- chimeras.  
(A) Plaque area and (B) necrotic core size were determined based on Oil-Red-O staining. (C) 
Relative number of apoptotic cells was determined by TUNEL staining. (D) Collagen content was 
measured by analysis of Sirius Red staining under polarized light. (E) Macrophage content was 
measured in sections stained for the monocyte/macrophage marker MOMA-2. (F) Smooth 
muscle cell content was measured by an staining against alpha-smooth muscle cell actin (αSMA). 
(G) Representative pictures of Oil-Red-O, Sirius Red (polarized light; insert bright field image), 
and MoMa-2 staining are shown for wild type and GRK2+/- chimeras. The top panels represent 
WT and the bottom panels GRK2 chimeras. Wild type controls (WT) are shown in white and 
GRK2+/- chimeras are shown in black; scale bars are 100 μm. * p < 0.05 and *** p < 0.001 
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Macrophage GRK2 Deficiency does not affect Phagocytosis, Apoptosis, 
or Foam Cell Formation 
The major differences in plaque composition, regarding necrotic core and 
intimal macrophage content, prompted us to study the effect of GRK2 
deficiency on macrophage function. Reduced GRK2 expression did not affect 
phagocytosis of apoptotic Jurkat T cells by BMDMs (Fig. 2A), rendering it 
unlikely that the reduced necrotic core size is attributable to increased 
phagocytosis.  
In line with the unchanged TUNEL+ cell density observed in plaques 
from WT and GRK2-/- chimeras, in vitro we observed no effects of GRK2 
 
 
Figure 2 – Phagocytosis, apoptosis, and foam cell formation of bone marrow derived 
macrophages is not affected in vitro. 
(A) The phagocytic capacity of BMDM for apoptotic Jurkat T-cells was determined in vitro. 
Phagocytosis was determined by scoring yellow staining in overlays from macrophages (cell 
tracker red), apoptotic Jurkat T-cells (cell tracker green) and nuclei (DAPI; blue). (B) In vitro 
apoptosis and (C) necrosis of bone marrow-derived macrophages was measured at baseline (-) 
and upon camptothecin (CPT), or oxidized LDL (oxLDL) exposure. Cell death was quantified 
based on Annexin V-Alexa488 (apoptosis; green) and propidium iodide staining (necrosis; 
red/orange). (D) In vitro foam cell formation was measured upon VLDL exposure for 24 hours 
using Oil-Red-O staining (red; 400 x magnification). White bars represent wild type controls 
(WT) and black bars GRK2+/- chimeras (GRK2+/-). ** p < 0.01. 
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heterozygosity (n=9) on the susceptibility for apoptosis of BMDMs at baseline 
or in the presence of CPT (Fig. 2B), nor did we observe differences in necrosis 
between BMDMs at baseline and after camptothecin (CPT) treatment (Fig. 2C). 
Notably, oxLDL-induced necrosis was markedly attenuated in GRK2-/- compared 
with WT BMDMs (30.1 ± 7.2 vs. 57.2 ± 7.6%, P=0.019; Fig. 2C). Thus, partial 
GRK2 deficiency was seen to reduce oxLDL-induced necrosis, which could have 
contributed to the phenotypic differences in necrotic core size in vivo.  
 
Figure 3 - GRK2+/- chimeras have perturbed leukocyte patterns in circulation. 
(A) Absolute number of white blood cells (WBC) were measured using a Sysmex differential cell 
counter. The relative fractions of leukocyte subsets were measured using flow cytometry 
analysis on a FACS Canto II (BD). (B) Granulocytes, (C) monocytes, (D) monocyte Ly6C subsets, 
(E) B-cells, and (F) T-cells were measured in the circulation of WT control (white bars) and 
GRK2+/- chimeras (black bars). (G) Myeloid subsets were measured in bone marrow of donor 
mice. (H) Representative histograms of Ly6Chigh and Ly6Clow distribution in blood of WT and 
GRK2+/- chimeras.  * p < 0.05 and ** p < 0.01.  
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Because macrophage and foam cell macrophage content was 
significantly increased in the GRK2+/- lesions compared with the WT lesions, we 
investigated in vitro whether GRK2 heterozygosity by itself influences foam cell 
formation. However, we were unable to detect any effects on the number of 
macrophage-derived foam cells nor on the level of lipid accumulation per cell 
after VLDL incubation (Fig. 2D), indicating that the observed plaque foam cell 
effects are not caused by GRK2 deficiency-associated changes in macrophage 
lipid handling. 
Circulating Leukocytes are affected by GRK2 Deficiency 
Peripheral blood analysis revealed increased circulating leukocyte numbers in 
GRK2-/- chimeras (5.9 ± 0.6 x 106 vs. 4.1 ± 0.4 x 106 cells/mL, P=0.03; Fig. 3A). In-
depth analysis of peripheral blood samples from WT and GRK2-/- chimeras fed a 
WTD (0.25% cholesterol) by flow cytometry indicated that there was no 
relative difference in granulocyte (CD11b+/Ly6G+) abundance (Fig. 3B). 
Circulating monocyte (CD11b+/Ly6G-) numbers were significantly lowered in 
GRK2-/- compared with those in WT chimeras (12.09 ± 0.61 vs. 16.09 ± 1.58% 
monocytes, P=0.039; Fig. 3C) and displayed a decreased Ly6Chigh/Ly6Clow ratio 
(Fig. 3D). No genotype-related differences were observed in B cells (B220+; Fig. 
3E) and T cells (CD3ɛ+; Fig. 3F) or in T-cell subsets (CD4+/CD8+; data not shown). 
Spleen resident dendritic cell content (CD11c+) and resident dendritic cell 
composition (CD4+/CD8+/double-negative; data not shown) did not reveal any 
differences between WT and GRK2-/- chimeras. In spleen, we did not observe 
any significant differences other than a relative decrease in the number of 
granulocytes in the GRK2-/- chimeras compared with that in WT controls (3.30 ± 
0.32 vs. 2.15 ± 0.21% granulocytes; Supplemental Fig. S3A). B cells and T cells 
did not show any differences in spleen (Supplemental Fig. S3B, C), while splenic 
monocytes, and in particular the Ly6Chigh subset, showed a tendency toward 
reduced numbers, as observed in peripheral blood (Supplemental Fig. S3D, E). 
In bone marrow, on the other hand, we observed no differences in monocytes 
or monocyte subsets (Fig. 3G). This result also indicates that impaired egress 
might be underlying the observed monocytopenia. Granulocytes are 
accumulating in the bone marrow of GRK2-deficient mice (Fig. 3G), but this 
does not translate into any effects on the atherosclerotic lesion. In short, these 
findings indicate that the effects of GRK2 deficiency on plaque formation and 
on circulating leukocytes mainly affect the myeloid lineage, monocytes and 
granulocytes, in blood, spleen, and bone marrow.  
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Figure 4 – Chemokine receptor expression on leukocytes from WT and GRK2+/- chimeras. 
Chemokine receptor (CCR5 and CCR7) expression was measured on circulating leukocytes from 
WT control (white bars) and GRK2+/- chimeras (black bars). (A) CCR5 expression on T-cells, B-
cells, NK-cells, granulocytes, and (B) monocytes. (C) Ly6C monocyte subsets showed differential 
CCR5 expression. (D) CCR7 expression on T-cells, B-cells, NK-cells, and granulocytes.  
 
The reported role of GRK2 in chemokine receptor desensitization led 
us to investigate effects of GRK2-/- deficiency on leukocyte expression of 
relevant chemokine receptors such as CCR5 and CCR7 by flow cytometry. No 
statistically significant increase in CCR5 expression could be observed in any of 
the leukocyte subsets at baseline (Fig. 4A). However, CCL5-stimulated 
monocytes and, in particular, the proinflammatory Ly6Chigh subset, showed 
borderline significance toward increased CCR5 expression in GRK2-/- chimeras 
compared with WT controls (P=0.051; Fig. 4B, C). For CCR7 we could not detect 
any significant differences in expression for any leukocyte subset tested (Fig. 
4D).  
Baseline Proliferation and CCL5-mediated Migration are increased in 
GRK2-/- Animals 
Proliferation was measured by [3H]thymidine incorporation in total 
splenocytes under baseline conditions (PBS) or after stimulation for 16 h with 
CCL5 (RANTES) or with the general mitogen ConA. It was observed that 
baseline proliferation (control) was increased in GRK2-/- splenocytes compared 
with that in WT controls (P<0.05; Fig. 5A). However, the proliferation index in 
CCL5 or ConA stimulated cells, corrected for baseline proliferation, was 
unaffected in GRK2-/- splenocytes (Fig. 5B).  
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Figure 5 – Baseline proliferation and migration upon CCL5 stimulation is increased in GRK2+/- 
chimeras 
(A) Baseline proliferation (unstimulated) was determined in WT and GRK2+/- splenocytes. (B) 
Proliferation index (corrected proliferation for control condition) was determined for CCL5 (100 
ng/mL; RANTES) or Concanavalin A (100 ng/mL; ConA) stimulation. (C) Total cell migration and 
(D) monocyte migration in WT control and GRK2+/- chimeras upon i.p. CCL5 (200 ng; RANTES) 
challenge. * p < 0.05 and # p < 0.05 compared to GRK2+/- PBS-treated. 
 
Peritonitis is considered an established model to study leukocyte 
chemotaxis and activation and expansion outside of the atherosclerotic lesion. 
We opted to use CCL5-dependent peritonitis, because CCL5 is one of the 
chemokines desensitized by GRK2, which at the same time is considered to be 
relevant in atherosclerosis. In vivo migration was measured after 
intraperitoneal injection of PBS (control) or CCL5 (RANTES; 200 ng/mouse). 
CCL5 challenge led to increased peritoneal leukocyte presence compared with 
that in PBS treated animals for GRK2-/- chimeras (P<0.05) but not for WT 
animals (Fig. 5C). In-depth analysis of monocyte migration into the peritoneal 
cavity of GRK2-/- chimeras showed a significant increased migration in CCL5-
challenged animals compared with that in PBS-treated animals (Fig. 5D).  
GRK2 Deficiency decreases Myeloid Hematopoiesis 
The observed effects of decreased GRK2 levels on the myeloid lineage and in 
particular on granulocytes and macrophages could reflect altered 
myelopoiesis. CFU assays with bone marrow cells from WT (n=6) and GRK2-/- 
mice (n=5) showed that bone marrow from GRK2-/- mice contained fewer CFUs 
(43.0 ± 4.2 vs. 57.2 ± 2.8 CFUs, P=0.017; Fig. 6A). This result was solely caused 
by a decreased number of G-CFUs in GRK2-/- chimeras (21.4 ± 1.0 vs. 33.2 ± 2.1 
G-CFUs, P<0.001; Fig. 6B); GM- and M-CFUs were unaffected. Thus, GRK2-/- 
bone marrow cells show an attenuated G-colony stimulating factor (CSF) 
response, explaining the decreased myeloid (monocytes/granulocytes) over 
lymphoid (B cells/T cells/NK cells) cell ratio in the circulation (Fig. 6C).  
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Figure 6 - Myeloid progenitor cells are decreased in GRK2+/- bone marrow; which is associated 
with reduced blood monocyte and granulocyte numbers. 
Colony forming unit (CFU) assays were performed on bone marrow from wild type and GRK2+/- 
donors. (A) The total number of colonies in WT control compared to heterozygous GRK2 
chimeras. Based on morphological analysis Granulocyte/Macrophage-CFU (GM-CFU), 
Macrophage-CFU (M-CFU), and Granulocyte-CFU (G-CFU) were differentiated (C) Myeloid 
(granulocytes + monocytes) over lymphoid (B-cells + T-cells) ratio in the circulation of GRK2+/- 
deficient mice compared to controls. (D) Representative pictures showing Macrophage-CFU (M-
CFU), Granulocyte-CFU (G-CFU), and Granulocyte/Macrophage-CFU (GM-CFU) colonies (100x 
magnification). Wild type controls (white bars) and GRK2+/- chimeras (black bars).* p < 0.05;  *** 
p < 0.001 
Granulocyte and Macrophage GRK2 Deficiency does not explain 
Phenotype 
Because our results pointed to GRK2-deficient myeloid cells as the underlying 
cause for the phenotypic changes observed in the atherosclerotic lesion in 
GRK2-/- chimeras, we studied the effect of granulocyte-and macrophage-
specific GRK2 deficiency in a LysM-Cre GRK2flox/flox bone marrow transplant 
model in LDLr-/- mice (n=8/9). To our surprise, no difference was observed in 
total plaque area between LysM-Cre GRK2flox/flox and WT chimeras (Fig. 7A). In 
addition, necrotic core size was unchanged in these myeloid cell-specific GRK2-
deficient chimeras compared with that in controls (Fig. 7B), as were plaque 
collagen levels (Fig. 7C). Because the LysM-Cre GRK2flox/flox model results in 
lowered macrophage GRK2 levels, we quantified intimal macrophage content 
in the aortic root lesions, revealing no differences between groups (Fig. 7D).  
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Figure 7 - Atherosclerotic plaque development and intimal macrophage accumulation are 
unaffected in LysM-Cre GRK2flox/flox chimeras. 
 (A) Plaque area and (B) necrotic core size were determined based on haematoxylin and eosin 
(H&E) staining. (C) Collagen content was measured by analysis of Sirius Red staining under 
polarized light. (D) Macrophage content was measured in sections stained for the 
monocyte/macrophage marker MAC-3. (E) Representative pictures of H&E, Movat’s 
Pentachrome, and MAC-3 staining are shown for wild type and LysM Cre GRK2flox/flox chimeras. 
The top panels represent WT and the bottom panels LysM Cre GRK2flox/flox chimeras. Wild type 
controls (WT) are shown in white and LysM Cre GRK2flox/flox chimeras are shown in grey; scale 
bars are 100 μm.  
 
In analogy with the GRK2-/- chimera study, flow cytometry of peripheral 
blood showed marked changes in granulocytes and Ly6C monocyte subsets in 
the granulocyte- and macrophage-specific GRK2-deficient chimeras (Table 1). 
These differences did not translate to plaque phenotypic effects. It appears 
that granulocyte- and macrophage-specific GRK2 deficiency does not affect 
atherogenesis, despite perturbed leukocyte patterns in circulation. The 
involvement of GRK2-deficient leukocytes, other than monocytes, cannot be 
excluded. However, total monocyte counts were not affected in LysM-Cre 
GRK2flox/flox chimeras but were decreased in GRK2-/- chimeras, indicating that 
monocytes, rather than granulocytes or macrophages, were probably the cell 
type responsible for the atheroprotective phenotype in hematopoietic GRK2 
deficiency. 
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Table 1 - Blood leukocyte composition is affected in macrophage/granulocyte specific GRK2 
deficiency. 
Leukocyte populations were determined in the blood from wild type (WT) and LysM-Cre 
GRK2flox/flox chimeras. Numbers shown are the relative percentages of living cells, except for 
CD4 and CD8 (% of CD3ɛ+ cells) and Ly6C high/low monocytes (% of monocytes). * p<0.05 
compared to WT. 
 
Discussion 
A role of GRK2 in atherosclerosis has not yet been documented but could be 
inferred from its key regulatory role in CCL2 (monocyte chemotactic protein-1) 
and CCL5 (RANTES) function, which are instrumental in leukocyte chemotaxis 
and transmigration during atherogenesis 20,31,38. Moreover, GRK2 levels were 
shown to be decreased in rheumatoid arthritis, an inflammatory disease 
sharing many features with atherosclerosis. Further, GRK2 expression was 
shown to be responsive to atherogenic cytokines such as IFN-ϒ and IL-6 ref 25,39. 
Our data identify a role for hematopoietic GRK2 in atherogenesis, excluding 
GRK2 deficiency in granulocytes and macrophages being responsible for the 
observed effects.  
First, we mapped the effect of heterozygous hematopoietic GRK2 
deficiency on atherosclerosis in LDL-/- mice. The donor mice were on a C57BL/6 
background but were LDLr-/-. LDLr expression in hematopoietic cells did not 
affect either repopulation of the hematopoietic lineage or atherosclerosis 
development and is widely accepted as the donor genotype in atherosclerosis 
research 40. The GRK2-/- genotype results in an approximately 50% reduction in 
GRK2 protein levels as shown before 41. Homozygous GRK2-deficient mice 
could not be used in these experiments because GRK2 deficiency is 
embryonically lethal, and embryos do not survive beyond gestational day 15.5. 
Most likely the in utero mortality is caused by cardiac dysfunction 33. Partial 
GRK2 deficiency resulted in reduced plaque burden and delayed plaque 
progression. In fact, GRK2-/- plaques did not progress beyond a fatty streak 
stage and contained more macrophages and intimal smooth muscle cells but 
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showed profoundly diminished necrotic core formation. The latter pointed to a 
direct effect of GRK2 deficiency on macrophage phagocytosis or apoptosis. 
Indeed, GRK2 was previously shown to influence cytoskeleton function 42,43, 
thereby potentially modifying macrophage phagocytic capacity. As shown 
previously, disrupted apoptotic cell clearance can accelerate atherosclerosis in 
mice 44. However, analysis did not support the notion that the GRK2-/--
associated reduction in necrotic core size is due to increased phagocytosis, 
because apoptotic cell handling by macrophages was not affected.  
Impaired necrotic core expansion is not caused by altered apoptosis of 
plaque macrophages. However, GRK2-/- macrophage necrosis in vitro was 
sharply attenuated after oxLDL exposure. The actual effect of macrophage 
death on atherosclerosis is still a matter of debate. Several studies have shown 
that in early and intermediate plaques, enhanced macrophage apoptosis is 
beneficial 45,46, albeit others suggested otherwise 47. In advanced 
atherosclerosis, the consensus is that macrophage death promotes necrotic 
core expansion and plaque destabilization 48,49.  
Enhanced plaque macrophage content and reduced lesion burden in 
GRK2-/- chimeras could reflect changes in peripheral inflammation. GRK2-/- 
chimeras showed decreased monocyte counts. Total leukocyte numbers were 
increased, an effect that was mainly attributable to augmented granulocyte 
counts in circulation. Myelopoiesis, assessed by CFU assay, was attenuated in 
GRK2-/- bone marrow, and G-CFUs, in particular, were decreased. Although it 
remains to be established how GRK2 exactly interferes with G-CSF response at 
a molecular level, this process may be linked to granulocyte release or life span 
because granulocyte numbers also increased in the bone marrow. At a 
functional level, mobilization of macrophages to inflammatory sites seemed to 
be increased with partial GRK2 deficiency, which is compatible with the 
desensitizing effect of GRK2 on chemokine receptor activity 50. Indeed, we 
could show that CCR5 chemokine receptor expression was increased on 
peripheral monocytes from GRK2-/- chimeras. At a functional level, this 
increase was accompanied by increased monocyte migration in response to a 
CCL5 (RANTES) challenge, as shown in a model of chemokine-induced 
peritonitis. However, the roles of other cell types such as T lymphocytes, 
dendritic cells, and macrophages cannot be excluded, and they might 
contribute to the increased monocyte migration indirectly, because relevant, 
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potentially GRK2-responsive chemokine receptors (CCR1, CCR2, and CCR7) are 
also expressed by lymphocyte subsets 51,52.  
The involvement of the chemokine receptor and ligand axis in 
regulating stromal release of Ly6Chigh monocytes from the bone marrow has 
already been shown for the CCL2/CCR2 axis 53. However, the decreased Ly6Chigh 
monocyte levels in circulation and spleen are not likely to be due to GRK2-
dependent tuning of CCR2 egress because in that case increased monocyte 
levels would be expected. We did, however, observe that mobilization of 
monocytes is affected at some level because there are no differences observed 
in the bone marrow. On the other hand, mice deficient for CCL2 or CX3CR1 had 
decreased atherogenesis. Inhibition of the CCL5/CCR5 axis by treatment with a 
CCR5 antagonist (Met-CCL5) resulted in an even more dramatic reduction of 
atherogenesis 54. A similar reduction in atherosclerosis development was 
observed in this study, indicating that GRK2-dependent processes other than 
receptor desensitization may be responsible for the phenotype observed.  
Major effects of GRK2 deficiency on myeloid differentiation and 
mobilization have prompted us to address the contribution of granulocyte and 
macrophage GRK2 deficiency to the atheroprotection. The LysM-Cre 
GRK2flox/flox transgenic mouse was previously shown to confer effective deletion 
efficiency in macrophages and granulocytes 55,56. Contrary to our expectations, 
the LysM-Cre GRK2flox/flox bone marrow chimeras did not mirror the previously 
observed GRK2-/- phenotype. In fact, LysM-Cre GRK2flox/flox chimeras completely 
lacked a plaque phenotype, disqualifying granulocyte and macrophage GRK2 
deficiency as the major culprit, although the possibility that the phenotype of 
homozygous GRK2 deficiency differs from that of GRK2-/- cannot be excluded. 
On the other hand, in sepsis, it was recently shown that macrophage- and 
granulocyte-specific deficiency resulted in no clear phenotype attributable to 
these cells 57. Flow cytometry of the LysM-Cre GRK2flox/flox chimeras and 
controls revealed a reduction in relative granulocyte abundance in blood of the 
GRK2flox/flox animals and in keeping the granulocyte- and macrophage-specific 
deletion, monocyte levels in circulation were not affected in the LysM-Cre 
GRK2flox/flox model. It has previously been shown that the LysM expression in 
circulating monocytes is not sufficient to get the CRE levels necessary for 
effective deletion of the floxed gene, in this case GRK2 ref 58. In contrast to this 
ineffective deletion in F4/80-negative immature macrophages or monocytes, 
the construct is highly efficient in the deletion of the floxed genes in F4/80-
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positive macrophages and in granulocytes 59,60. Taken together, these data 
point to monocytes or potentially even T cells (albeit we did not observe overt 
effects of GRK2 deficiency on the number of circulating or plaque T cells) as 
responsible factors in the profound GRK2-/- plaque phenotype.  
Overall, our data indicate an equally complex and critical role of GRK2 
in monocyte homeostasis and mobilization in the context of atherosclerosis. 
Partial hematopoietic GRK2 deficiency appeared to have a profound effect on 
atherogenesis. Whereas all data seem to pinpoint the myeloid lineage as the 
major effectors, reduced GRK2 levels in granulocytes and macrophages cannot 
be held directly accountable for this effect. Cumulatively, these data lead us to 
propose a major role for monocyte GRK2 in the observed phenotypic changes. 
It should be noted, however, that although we did not observe any major 
effects of GRK2-/- on other leukocyte subsets known to affect atherogenesis, 
such as T lymphocytes and dendritic cells, the possibility that these subsets 
may nevertheless have modified the atherogenic response in an indirect 
manner cannot be excluded. Because even partial inhibition of GRK2 function 
already suffices to halt plaque progression at a fatty streak stage, our studies 
warrant further investigation into the perspective of GRK2 antagonists in 
atherosclerosis treatment and in determining the cell type responsible for 
effects on atherosclerosis development.  
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Supplemental Figures 
 
Supplemental figure 1 – Body weight development and cholesterol levels are unaffected in 
GRK2+/- chimeras. 
(A) Body weight was monitored during the course of the experiment for WT (○) and GRK2+/- (•) 
chimeras. (B) Cholesterol levels were determined at baseline (week 0), week 9, and prior to 
sacrifice (week 18), for WT (white bars) and GRK2+/- (black bars) chimeras. 
 
 
Supplemental figure 2 – Morphological scoring of atherosclerotic lesions. 
Atherosclerotic lesions from WT and GRK2+/- chimeras were scored for (A) necrosis, (B) foam cell 
content, (C) neutrophil content, (D) cell adhesion, and (E) collagen by an independent operator 
based on Movat’s Pentachrome staining. (F) Representative pictures for Movat’s Pentachrome 
staining. WT controls (white bars) and GRK2+/- chimeras (black bars); scale bars are 100 μm. * p < 
0.05, ** p < 0.01 
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Supplemental figure 3 – Splenic leukocyte subsets. 
Splenic (A) granulocytes, (B) B-cells, (C) T-cells, (D) monocytes, (E) Ly6Chigh monocytes, and (F) 
Ly6C- monocytes were determined in spleens from GRK2+/- chimeras and WT controls. WT 
controls (white bars) and GRK2+/- chimeras (black bars). * p < 0.05 
 
  
A9R6637.tmp   87 15-9-2013   19:30:51
Chapter 03 
________________________________________________________________ 
88 
 
 
Supplemental figure 4 – Gating strategies for flow cytometry analyses. 
(A) Monocytes/granulocyte gating in blood and spleen. (B) T-cell and B-cell gating in blood and 
spleen. (C) Resident dendritic cells (rDC) gating in spleen. (D) Chemokine receptor gating. 
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Abstract 
Increased cholesterol levels are a known risk factors for cardiovascular disease. 
Plaque macrophages accumulate oxidized cholesterol present in the 
atherosclerotic lesion. Despite the extensively described role of cholesterol  in 
atherogenesis, little is known about the interaction between plasma 
cholesterol and circulating monocytes. Nowhere we analyzed not only the 
accumulation of lipoproteins and lipids in peripheral monocytes, but we also 
studied the effects of intracellular cholesterol accumulation on monocyte 
function to unravel processes in circulating monocytes contributing to 
atherogenesis. LDLr-/- mice (n = 8) were fed a Western type diet (WTD) for up 
to three weeks to induce hypercholesterolemia and study the effects on early 
atherogenesis. After 0, 0.5, 1, and 3 weeks of WTD diet animals were sacrificed 
and cholesterol accumulation was determined. Flow cytometry data showed 
increased granularity, which was caused by intracellular cholesterol/lipid 
accumulation as determined by electron microscopy and Oil-red-O staining. 
Plasma cytokine levels (IL-10, IL12p70, TNFα, mKC, IL-6, and IL-1β) were 
increased, with the most pronounced increase occurring in the first week of 
WTD. Increased granularity, and thus cholesterol accumulation, resulted in 
enhanced ROS production and increased monocyte rolling along and 
adherence to activated endothelium in mice on WTD. Taken together, we 
show that hypercholesterolemia induces lipid accumulation in circulating 
monocytes, thereby increasing both ROS production in these monocytes as 
well as stimulating monocyte-endothelium interactions. Overall, our data 
indicates that hypercholesterolemia in early atherosclerosis affects circulating 
monocytes and might contribute to unraveling novel pathways for intimal 
cholesterol accumulation through circulating monocytes. 
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Introduction 
Hypercholesterolemia is a well-known risk factor for the development of 
cardiovascular disease (CVD) and more in particular atherosclerosis, the main 
cause of CVD 1,2. Indeed, increased levels of low density lipoprotein (LDL) 
cholesterol have been associated not only with increased CVD risk, but also 
plaque burden 3. Classically, LDL is thought to permeate into the 
atherosclerotic plaque and after modification into oxidized LDL (oxLDL). Cells 
from the myeloid lineage, in particular monocyte-derived macrophages,  will 
scavenge the oxLDL present in the lesion, identifying infiltrating monocytes 
and plaque macrophages as a major player in atherosclerosis. 
 Monocytes can be divided into two distinct subsets based on the 
expression of specific surface markers. In humans inflammatory CD14high/CD16- 
and patrolling CD14low/CD16++ monocytes have been described 4. In mice 
monocytes are separated based on Ly6C expression into inflammatory Ly6Chigh 
and patrolling Ly6C- monocytes 5,6. CC-motif chemokine receptor 2 (CCR2) is 
expressed at high levels by inflammatory monocytes 7, whereas CX3C-motif 
chemokine receptor 1 (CX3CR1), or fractalkine receptor, is more abundant on 
patrolling monocytes 8,9. Inflammatory monocytes are generally thought to be 
the most important subtype in early atherogenesis, being efficiently recruited 
to the lesion in a CCR2 dependent manner 10. However experimental loss-of-
function studies as well as expression studies were supportive of a role for 
patrolling monocytes as well, at later stages of disease progression 11. 
Nevertheless, the exact role of both subsets in plaque macrophage 
accumulation and plaque progression has not yet been elucidated completely.  
 Accumulation of cholesterol in macrophages is mediated by scavenger 
receptors such as SR-A and CD36 12,13. In atherosclerosis, the efflux of oxLDL 
from macrophages via ATP binding cassette (ABC) transporters, ABCA1 and 
ABCG1, is hampered causing progressive intracellular buildup of free 
cholesterol and eventually cholesterol crystals 14,15. Both intracellular 
cholesterol, as well as free cholesterol in the lesion, can trigger several pro-
inflammatory pathways, contributing to the progression of early 
atherosclerotic lesions. Main downstream signaling pathways triggered upon 
(ox)LDL dependent macrophage activation are NF-κβ signaling via toll-like 
receptor (TLR) 4 and TLR 6 16, ERK signaling via TLR2/TLR4, and ER stress 17-19. 
Besides the effects described for oxLDL, also cholesterol crystals can trigger 
inflammatory signaling via the inflammasome through lysosomal damage 20,21.  
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LDL cholesterol can also affect arterial endothelial cell function, 
upregulating integrins like intercellular adhesion molecules (ICAMs) 22 and 
vascular cell adhesion molecule (VCAM) 1 23 as well as inducing monocyte 
chemotactic molecule secretion (e.g. CXCL1 and CCL2) 19,24,25. Although ample 
evidence points towards increased monocyte adhesion and transmigration 
under hypercholesterolemic conditions 26,27, this effect was generally 
attributed to endothelial activation, not to direct impact of hyperlipidemia on  
monocytes.    
Nevertheless, hypercholesterolemia, in combination with reduced 
cholesterol efflux, is known to induce monocytosis in animal models such as 
LDL receptor deficient (LDLr-/-) and apolipoprotein E deficient (ApoE-/-) mice, 
but also in patients with familial hypercholesterolemia (FH) 28, or non-genetic 
hypercholesterolemia 29. This phenomenon could be attributable to 
intracellular cholesterol accumulation induced lipid raft formation, stimulating 
proliferation of myeloid progenitors via IL-3 and granulocyte/macrophage-
colony stimulating factor (GM-CSF) signaling 30,31. In the current study we 
investigated implications of acute hypercholesterolemia on differentiation, 
function, and dynamics of circulating monocytic cells. Pro-atherogenic (LDLr-/-) 
mice were monitored after onset of Western type diet (WTD) feeding and 
monocyte subsets were analyzed.Our study shows that circulating monocytes 
rapidly accumulate cholesterol in situ, resulting in diet-induced functional 
aberrations.  
Materials & Methods 
Animals 
Male low density LDLr-/- mice were obtained from the animal breeding facility 
at Maastricht University (Maastricht, The Netherlands). Mice were fed a 
regular chow diet (RM3; Special Diet Services [SDS], Essex, UK) or a Western-
type diet (WTD; 0.25% cholesterol, 15% cocoa butter, 1% corn oil, 40.5% 
sucrose, 10% corn starch, and 5,95% cellulose; SDS). Drinking water and food 
were provided ad libitum. Experiments were performed at the Maastricht 
University animal facility. All experimental protocols were approved by the 
Maastricht University ethics committee for animal experiments. 
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In vivo monocyte-endothelial cell interaction measurement 
Monocyte-endothelial cell interactions were measured in male LDLr-/- mice 
either on normal chow (n = 3) or WTD (n = 3). Alexa568-coupled anti-CD115 
antibody (5 μg/mouse, eBioscience) and FITC-conjugated anti-CD31 antibody 
(35 μg/mouse, BD Bioscience) were administered intravenously. Immediately 
hereafter, mice were anesthetized by a dorsal subcutaneous injection with 
ketamine (100 mg/kg body weight, Nematek) and xylazine (10 mg/kg body 
weight, Sedamun). Subsequently, mice were prepared for multiphoton laser 
scanning microscopy (MPLSM) by exposing the sternohyoid muscle by 
dissection. MPLSM imaging was performed on a Leica SP5 imaging platform 
(Leica Microsystems, Germany) that integrates multiphoton microscopy with 
fast resonant scanning, and uses a Compact Ultrafast Ti:Sapphire Laser 
(Chameleon, Coherent, USA). An excitation wavelength of 820 nm was used in 
all experiments. Tissue was observed using a 20x NA 1.0 water immersion 
objective (HCX PL APO L, Leica Microsystems) with a numerical aperture of 
1.00 and an integrated optical zoom mechanism allowing magnification up to 
60x. Photo-multiplier tubes (PMT) were used to detect three spectral regions: 
PMT1: 500 - 550; PMT2: 565 - 605. In vivo MPLSM imaging was performed at a 
frame size of 400 x 400 pixels (pixel size: 1.0882 x 1.0882 μm), scanning at 
8000 Hz for fast recording (20 frames/sec) and using a line average of 2 (10 
frames/sec) for more detailed scans. Per time series a total of 500 frames was 
recorded. After in vivo imaging, the animal was sacrificed and additional in situ 
imaging was performed to examine the vasculature at higher resolution and an 
increased signal-to-noise ratio without motion artifacts. In situ imaging was 
performed at a frame size of 512 x 512 pixels (pixel size: 0.847 x 0.847 μm), 
scanning at 200 Hz, and an interplanar distance of 1.00 μm. 
Flow cytometry 
Blood, spleen, and bone marrow were collected upon sacrifice. Absolute 
leukocyte counts in blood were obtained using BD Trucount tubes, according 
to the manufacturers protocol (BD Biosciences). In short, Fc-receptor blocking 
antibody was added to the Trucount tubes. Subsequently, 50 μL anti-
coagulated whole blood was added and the tube was gently vortexed. After 
incubation for ten minutes, the antibody cocktail (supplemental table 1) was 
added and the suspension was incubated at room temperature in the dark for 
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an additional 20 minutes. Finally, hypotonic lysis buffer was added and after 15 
minutes samples were analyzed.  
Myeloid progenitor densities were measured in spleen and bone 
marrow. Single cell suspensions were made from spleen by crushing the tissue 
over a 70 μm cell strainer (BD Biosciences, NJ, USA). One femur and one tibia 
per mouse were flushed with ice-cold PBS and single cell suspensions were 
prepared using a 70 μm cell strainer (BD). subsequently, spleen and bone 
marrow cells were stained with biotin-conjugated antibodies against lineage 
(Lin) markers (CD5, CD45RA [B220], CD11b, Gr-1 [Ly6C/G], 7-4, and Ter-119; 
Miltenyi Biotec) and Lin+ positive cells were depleted using streptavidin 
conjugated magnetic beads (Miltenyi Biotech) and LS columns (Miltenyi 
Biotech). Lin- cell pools were stained with antibodies for Sca-1, c-Kit (CD117), 
CD34, CD16/32, CD115, and lineage markers (CD5, CD45RA [B220], CD11b, 
Ly6C, Ly6G, Ter-119).  
Mature leukocytes in spleen and bone marrow were analyzed after 
initial removal of erythrocytes by incubation with hypotonic lysis buffer (8.4 g 
NH4Cl and 0.84 g NaHCO3 per liter distilled water). Non-specific Fc-receptor 
binding was blocked by the addition of anti-CD16/CD32 antibody (eBioscience, 
San Diego, USA). Subsequently, single cell pools were stained with antibody 
mix (supplemental table 1).  
Intracellular interleukin-1 production was measured in blood leukocyte 
subsets. After lysis of erythrocytes, leukocyte pools were incubated for 4 hours 
in RPMI-1640 medium (supplemented with 10% fetal calf serum and 0.1% 
GolgiPlug [BD]) to induce intracellular cytokine accumulation. Cells were 
resuspended in FACS buffer and after FC-receptor block, surface markers were 
labeled with antibodies against CD3ɛ, CD45RA (B220), NK1.1, CD11b, Ly6G, and 
Ly6C. Subsequently, cells were fixed using Fix/Perm solution (eBioscience). 
Next, cells were permeabelized and stained with interleukin (IL) 1α, IL-1β, and 
pro-IL-1 antibodies.  
Intracellular reactive oxygen species accumulation in blood and splenic 
leukocyte subsets were determined by staining of cells with 100 μL 20 μM 
DCFDA in PBS and incubated for 20 minutes at 37°C. Cells were washed once in 
PBS and resuspended in FACS buffer. After Fc-receptor block, surface markers 
were labeled with antibodies against CD3ɛ, CD45RA (B220), NK1.1, CD11b, 
Ly6G, and Ly6C and analyzed.  
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All samples and buffers were kept on ice throughout the experiment 
unless indicated otherwise. All measurements were performed on a FACS 
Canto II (BD Biosciences) and analysis of acquired data was performed using 
FACS Diva software (BD Biosciences). 
FACS Sorting 
Upon sacrifice blood and spleen were collected and single cell suspensions 
were prepared. Fc-receptor blocking antibody was added to the cell 
suspension. Subsequently, antibodies against CD3ɛ, CD45RA (B220), NK1.1, 
CD11b, Ly6G, and Ly6C were added and incubated at 4°C in the dark for 30 
minutes. Finally, monocyte Ly6C subsets were sorted in RPMI-1640 medium 
supplemented with 10% FCS on a FACS ARIA flow cytometer (BD Biosciences).  
Cytokine multiplex 
Plasma samples were frozen and stored at -80°C until further use. Samples 
were thawed and selected cytokines mKC (CXCL1), tumor necrosis factor (TNF) 
α, IL-1β, IL-6, IL-10, IL-12p70, and interferon (IFN) ϒ were measured using 
Multi-array electrochemiluminescence platform (K15012A-5,  detection range 
2.4 pg/ml to 10,000 pg/ml; MesoScaleDiscovery, Gaithersburg, MD, USA). 
Analysis was performed as described by Van Bussel et al 32. Each sample was 
analyzed in duplicate on the same array plate.  
Electron microscopy 
Monocytes were FACS sorted and fixed in 3% glutaraldehyde (GTA; Ted Pella, 
Redding, CA, USA) in 0.1M phosphate buffer (pH = 7.6) for 15 minutes. After 
several washes, cells were post-fixed in 1% osmium tetroxide solution and 
routinely dehydrated through 100% ethanol, cleared with propylene oxide, and 
embedded in epoxy resin. Ultra-thin sections (70 - 90 nm) were cut on an ultra-
microtome, mounted on Formvar (1595 E, Merck) coated 75 mesh copper 
grids, and counterstained with uranyl acetate and lead citrate before analysis 
on a Philips CM100 transmission electron microscope. 
Oil-red-O staining 
FACS sorted monocytes were spotted on glass slides using Cyto-Tek centrifuge 
(Sakura Finetek, Torrance, CA, USA). Cells were fixed in 4% formalin for 10 
minutes and subsequently washed twice in PBS. Next, slides were incubated 
for 15 minutes in 60% isopropanol, followed by 60% Oil-red-O solution for 20 
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minutes. Cells were washed gently with 60% isopropanol and once with water. 
Finally, the cells were counterstained with haematoxylin and slides were 
mounted with aquamount. Pictures were made at 40x magnification (Leica). 
Statistical Analysis 
Student’s t test was used; nonparametric data were analyzed using a Mann-
Whitney U test. All analyses were performed using GraphPad Prism 5 software 
(GraphPad Software Inc., LA Jolla, CA, USA), and values of P < 0.05 were 
considered statistically significant. 
Results 
Monocyte intra-cellular complexity is increased upon WTD 
Flow cytometry analysis of whole blood from mice on WTD showed that the 
monocyte fraction displayed markedly increased side scatter (SSC) compared 
to chow fed control animals as early as half a week of WTD feeding (figure 1A). 
As expected, plasma cholesterol levels progressively increased upon onset of 
WTD feeding to plateau at 3 weeks (figure 1B). Of note, the average monocyte 
SSC correlated to the plasma cholesterol levels (R2 = 0.726; p < 0.0001; data 
not shown). 
 
 
 
Figure 1 - Monocyte granularity correlates to plasma cholesterol levels 
(A) Representative dot plots indicating increased side scatter profile of monocytes (orange and 
blue) from LDLr-/- mice on normal chow or 3 weeks Western type diet (WTD). (B) Plasma 
cholesterol levels measured at baseline (normal chow), and after 0.5, 1, and 3 weeks of WTD 
feeding. ** p < 0.01 and *** p < 0.001 
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 Next, we investigated whether WTD induced SSC changes manifested 
in both inflammatory Ly6Chigh and patrolling Ly6C- monocytes. Interestingly, the 
enhanced scattering was predominantly observed in Ly6C- monocytes (figure 
2A+B). Inflammatory Ly6Chigh monocytes displayed significantly increased side 
scattering (granularity), albeit much less pronounced, than that of Ly6C- 
monocytes (figure 2A+B). 
To pinpoint the cause of this increased monocyte granularity, Ly6C- 
and Ly6Chigh monocytes were sorted and electron microscopic (EM) images 
were made. EM analysis indicated the overt presence of lipid droplets and 
even cholesterol crystals in circulating monocytes from WTD fed animals, but 
not chow fed animals (figure 2C). Additional, Oil-red-O staining confirmed that 
monocytes, both Ly6C- and Ly6Chigh, contained lipid droplets (figure 2C). 
Hypercholesterolemia induces leukocytosis 
Total leukocyte levels were up by almost 45% in WTD compared to chow fed 
mice (figure 3A). This increment could be ascribed to elevated granulocyte 
(figure 3B) and monocyte levels (figure 3C), which in fact more than doubled in 
WTD fed animals, confirmative of previous data on hypercholesterolemia 
induced monocytosis 30,31. Furthermore, the Ly6Chigh to Ly6C- ratio was doubled 
after 3 weeks of WTD (figure 3D+E). Marked leukocytosis and increased 
monocyte granularity were also observed in spleen (supplemental figure 1A-E) 
and bone marrow (supplemental figure 2A-D) of LDLr-/- animals after 3 weeks 
of WTD. Despite a small reduction in LK-cells, no significant effects could be 
observed on erythrocyte/megakaryocyte progenitors (EMP), common myeloid 
progenitors (CMP), or granulocyte/macrophage progenitors (GMP) after 3 
weeks WTD feeding compared to normal chow (supplemental figure 2E+F). 
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Figure 2 - Lipid accumulation is responsible for increased monocyte granularity 
(A) Monocyte granularity was determined for Ly6C- and Ly6Chigh monocytes at baseline (normal 
chow, and after 0.5, 1, and 3 weeks WTD feeding. (B) Representative dot plots indicative of Ly6C- 
and Ly6Chigh monocyte granularity. Circles depict outline of populations under chow conditions. 
(C) Representative electron microscopy (EM) images for Ly6C- (left column) and Ly6Chigh (right 
column) monocytes on normal chow (top row) or WTD (middle row). Bottom panels show 
representative images for Oil-Red-O staining.  
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Figure 3 - Circulating leukocyte levels are increased upon cholesterolemia 
Absolute leukocyte levels were measured in blood upon sacrifice using BD TruCount tubes. (A) 
Total CD45+ leukocytes, (B) CD11b+/Ly6G+ granulocytes, (C) CD11b+/Ly6G- monocytes, and (D) 
Ly6C monocyte subsets were measured. (E) Representative histograms indicating Ly6C- and 
Ly6Chigh monocytes in chow fed and WTD fed animals. * p < 0.05 and *** p < 0.001 
 
Cytokine profile indicates systemic diet-induced inflammatory profile 
Plasma cytokine levels increased rapidly after the onset of WTD. After three to 
seven days, cytokine levels of IL-10, IL-12p70, IFN-ϒ, IL-1β, mKC, and IL-6 on 
average doubled compared to baseline values (normal chow) (figure 4A-F). TNF 
plasma levels were either not detectable or just above the detection limit. 
While elevated IL-10, IL12p70, and IFN-γ levels, and to a lesser extend IL-6, 
persisted for 3 weeks (figure 4A-D). Plasma levels of the pro-inflammatory 
cytokines IL-1β and mKC almost reverted to baseline after 3 weeks of WTD 
feeding (figure 4E+F).  
 
A9R6637.tmp   105 15-9-2013   19:30:52
Chapter 04 
________________________________________________________________ 
106 
 
Figure 4 - Cytokine levels increase in response to hypercholesterolemia  
Plasma cytokine levels were measured for (A) IL-10, (B) IL-12p70, (C) IFN-γ, (D) IL-6 (E) IL-1β, and 
(F) mKC at baseline (normal chow; open circles) and after 0.5 week (pale blue), 1 week (light 
blue), and 3 weeks (dark blue) of WTD. * p < 0.05 ** p < 0.01 and *** p < 0.001 
 
Intra-cellular lipoproteins trigger ROS production 
In macrophages intra-cellular lipid accumulation was previously reported to 
trigger the production of reactive oxygen species in an ER stress and ERK-
signaling dependent manner 19. Since, we observed similar lipid accumulation 
in circulating monocytes from WTD fed LDLr-/- mice, we analyzed ROS 
production in these monocytes. Indeed, both high granular Ly6C- and Ly6Chigh 
monocytes had significantly increased levels of ROS compared to their low 
granular counterparts (figure 5A+B). The amount of intra-cellular lipids did not 
appear to affect the ROS production as the levels in Ly6C- and Ly6Chigh high 
granular monocytes was comparable. As Ly6Chigh monocytes showed less 
accumulation of intra-cellular lipids this subset conceivably is more susceptible 
to lipid associated ROS formation.  
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Figure 5 - Reactive oxygen species are augmented in all high granular monocytes, while IL-1β 
levels are only affected in high granular Ly6C- monocytes 
Reactive oxygen species (ROS) were measured in (A) Ly6C- and (B) Ly6Chigh monocytes for both 
the low granular and high granular fractions, based on normal chow gating control. In the dot 
plots the gating for the low and high granular monocyte subsets are indicated. IL-1β levels were 
measured in (C) Ly6C- and (D) Ly6Chigh monocytes for both the low granular and high granular 
fractions. * p < 0.05 ** p < 0.01 and ***p < 0.001    
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As shown by Latz et al, macrophage cholesterol accumulation induces 
inflammasome activation. We therefore assessed intracellular production of 
the inflammasome cytokine IL-1β in monocytes from mice on WTD for 3 
weeks. High granular Ly6C- monocytes had significantly increased IL-1β levels 
compared to low their granular counterparts (figure 5C). In contrast, Ly6Chigh 
monocytes did not show any difference in intra-cellular IL-1β levels between 
low and high granular fractions (figure 5D). Unfortunately, we were unable to 
reliably determine intra-cellular pro-IL-1 levels. Overall, increased granularity, 
and as such intracellular lipids, did only mildly affect IL-1β levels in Ly6C- 
monocytes, suggesting that monocyte lipid ingestion is not or only marginally 
associated with inflammasome activation.  
Hypercholesterolemia increases monocyte-endothelial cell interactions 
Increased plasma cholesterol levels were shown to induce inflammatory 
cytokine levels already after 1 week of WTD feeding. Further, ROS have been 
implicated to increase monocyte-endothelial cell adhesion in vitro 33,34. To 
address the combined effect of lipid accumulation, pro-inflammatory milieu, 
and ROS production on monocyte function we performed in vivo monocyte-
endothelium adhesion experiments. At baseline, no CD115+ cells adhered to 
the endothelium of the vessels in the sternohyoid muscle in either mice on 
normal chow or 1 week WTD (data not shown). 
 After activation of the local vasculature with 50 μL LPS (100 ng/mL) a 
clear increase in rolling and adhering CD115+ monocytes could be observed 
compared to baseline condition, where only an occasional rolling or adhering 
cells could be observed. CD115+ cells were considered rolling if their speed was 
reduced by at least two-fold and showed direct contact to the endothelial 
layer, adhering cells did not change position for at least 280 frames (30 
seconds). Due to the small number of animals (n = 3 per group) examined no 
statistical analyses were performed. The increase in monocyte-endothelial cell 
interaction was most pronounced in animals on WTD. Animals on WTD showed 
increased adhering (figure 6A) and rolling CD115+ cells (figure 6B). Compared 
to baseline both animals on normal chow and WTD displayed more adhering 
and rolling cells, yet this increment was more pronounced in animals on WTD 
(figure 6C).  
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Figure 6 - In vivo monocyte-endothelial cell interaction is stimulated by intracellular 
cholesterol accumulation 
Monocyte interaction with the endothelial layer for LDLr-/- animals was measured in vivo in the 
sternohyoid muscle after activating the endothelium with 100 ng/mL LPS. (A) Number of 
steadily adhering cells (> 30 seconds) was determined and corrected for the area of vascular 
endothelium examined. (B) Number of rolling cells along the vascular endothelium was 
determined and corrected for the total time of imaging. (C) Representative 3D reconstructions 
of the vasculature for animals on normal chow (top panel) and WTD (bottom panel) are shown. 
Endothelial cells are labeled with anti-CD31-FITC (green) and monocytes are labeled with anti-
CD115-Alexa568 (red).  
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Discussion 
The role of circulating monocytes in the development of atherosclerosis has 
been extensively studied over the last few years. Monocyte subsets have been 
reported to play differential roles in atherogenesis. Ly6Chigh monocytes are 
widely considered to be the most important progenitor of plaque 
macrophages 10,35, while Ly6C- monocytes are attributed mainly vascular 
patrolling functions and are thought to give rise to CD11c+ dendritic cells in the 
lesion 36-38. Recently, Wu et al have demonstrated that cholesterol can induce 
CD11c expression in monocytes, and enhance their adhesion to the 
endothelium 39. This might implicate a more important role for Ly6C- 
monocytes in atherogenesis. In this study we show that monocytes, both 
Ly6Chigh and Ly6C-, respond differentially to the hypercholesterolemia 
induction.  
We demonstrate that circulating, next to splenic and bone marrow, 
monocytes rapidly accumulate lipids under hypercholesterolemic conditions, 
before entering the atherosclerotic lesion, an effect accompanied by generally 
transient elevation in plasma cytokine levels. Moreover we show that 
hypercholesterolemia not only induces ROS buildup, but also upregulates IL-1β 
production by Ly6Chigh and Ly6C- monocytes, the latter likely without activating 
the inflammasome pathway. The progressive accumulation of cholesterol in 
these peripheral monocytes could also induce the pro-inflammatory milieu 
observed during atherogenesis, however additional studies are necessary to 
support this notion. We do observe increased interaction of circulating 
monocytes with (activated) endothelium under hypercholesterolemic 
conditions. 
The initial observation of progressively increased side scattering of 
circulating monocyte subsets, and in particular the Ly6C- subset, upon WTD 
feeding of LDLr-/- mice, has led us to investigate the cause of increased 
granularity in more detail. Here, we present three lines of evidence that 
increased granularity reflects monocytic lipid accumulation: (I) plasma 
cholesterol correlated strongly to the increased granularity of monocytes; (II) 
electron microscopy showed the overt presence of intracellular vacuoles; and 
(III) Oil-red-O staining established the presence of intracellular lipids in 
monocytes from WTD-fed LDLr-/- mice. Interestingly, this effect was more 
pronounced in ly6C- monocytes, however the responsible mechanism needs to 
be determined. As monocyte development is thought to develop from Ly6Chigh 
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towards Ly6C- monocytes 40, the turnover from lipid-laden Ly6Chigh to Ly6C- 
monocytes could add to the more distinct lipid accumulation in the 
downstream Ly6C- monocyte pool. On the other hand, we cannot exclude that 
passive or active cholesterol/lipid accumulation, but also difference in efflux, 
between monocyte subsets contribute to the differences observed. 
Lipid accumulation in circulating monocytes appears to have many 
similarities to scavenging of (ox)LDL by plaque macrophages. As lipid 
accumulation in macrophages activates the inflammasome, due to intracellular 
cholesterol crystals 20, the question arose whether lipid ingestion by circulating 
monocytes would in analogy to macrophages also here result in inflammasome 
activation. Despite the presence of cholesterol crystals in circulating 
monocytes and the transient increase of plasma IL-1β levels upon diet change, 
involvement of the inflammasome in circulating monocytes could not be 
confirmed conclusively. Preliminary data supported that the IL-1β effects were 
inflammasome independent, as pro-IL-1 levels seemed to increase, reflective 
of transcriptional induction rather than inflammasome activation. This was 
reinforced by unaltered caspase 1 activity in these monocyte subsets (data not 
shown). Nevertheless, inflammasome-independent IL-1β has been implicated 
to be essential for sustaining extra-medullar monocytopoiesis  41.  
Reactive oxygen species did increase significantly in high granular 
monocytes carrying intracellular cholesterol deposits. While in macrophages 
cholesterol accumulation has already been linked to ROS production, only one 
single study has investigated cholesterol-dependent ROS production in 
monocytes 42. Although the actual molecular pathway linking lipid to ROS 
accumulation in monocytes remains to be determined, as shown by Huang et 
al indicated that in humans ROS production might be mediated via C-reactive 
protein expression and the subsequent upregulation of NADPH oxidase (NOX) 
2 and MCP-1 levels 33. As increased NOX2 and MCP-1 levels might affect 
chemotaxis of monocytes, hypercholesterolemia induced ROS production 
could well have effects on the migratory behavior towards activated 
endothelium.  
Indeed our intravital microscopy studies showed that monocyte 
adhesion to and rolling along activated endothelium was substantially 
increased in WTD fed LDLr-/- mice.  Apart from a ROS associated phenomenon, 
the increased endothelial cell adhesion could also result from lipid 
accumulation induced upregulation of integrins on circulating monocytes 
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26,43,44. However, as we did not determine a broad set of membrane markers, 
such as ICAM-1, very late antigen (VLA) 4, and CD62L, on these circulatory 
monocytes, the actual contribution of this pathway to the increased 
endothelial adhesion remains unclear. Nevertheless, our study clearly shows 
that hyperlipidemia impacts not only circulating monocyte constitution but 
also function, already within 1 week of WTD exposure.  
To what extent this is relevant to for early atherogenesis is yet to be 
determined, given that our in vivo studies involving LPS activated small vessels 
rather than major arteries. However, since endothelial cells covering the 
(early) atherosclerotic lesion do express TLRs 45,46, the LPS stimulation used in 
our experiments is representative for atherosclerotic endothelium. Especially 
since TLR4 polymorphisms as well as MyD88 deficiency have been shown to 
decrease atherogenesis 47,48. Therefore, we expect cholesterol-loaden 
monocytes to adhere as efficiently to the endothelium covering the 
atherosclerotic plaques under hypercholesterolemic conditions. 
Atherosclerosis development might be further stimulated by ROS generation in 
circulating monocytes, as this contributes to the formation of oxLDL 42.  
Indeed monocytes in compartments relevant for myeloipoiesis, such as 
spleen and bone marrow, also showed pronounced lipid accumulation, 
although at present we cannot exclude that these monocytes had 
compartimentalized upon lipid ingestion or whether they ingestion had 
occurred after monocyte grafting in these tissues 10,36,41. Nagareddy et al 
recently showed that monocytosis might in part result from hyperglycemia, 
next to hypercholesterolemia 49. However, this was mediated via increased 
proliferation and expansion of granulocyte/macrophage progenitors in the 
bone marrow, which we did not observe in our study.  
Monocyte development is often considered to be a linear process, 
inflammatory (Ly6Chigh) monocytes produced in the bone marrow migrate 
towards the spleen and at least a subset will maturate towards patrolling 
(Ly6C-) monocytes 10. In atherosclerosis Ly6Chigh monocytes appear to be most 
critical as precursor for plaque macrophages 35, however the role of Ly6C- 
monocytes is still debated. In human atherosclerosis, the role of inflammatory 
CD14highCD16- monocytes and patrolling CD14-CD16+ monocytes is even less 
defined, as no trafficking studies have been performed in human disease. 
Nevertheless, especially patrolling Ly6C- monocytes show massive lipid 
accumulation, suggesting an important role in hypercholesterolemia and 
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possibly a role in atherosclerosis development, which is more important than 
currently thought. 
 Downregulation of the cholesterol transporters ABCA1 and Niemann-
Pick disease type C protein 1 (NPC1) was recently identified as the central actor 
responsible for lipid accumulation in human monocytes in FH patients, with 
manifest hypercholesterolemia 50 and in familial coronary artery disease 
patients 51. ABCA1/G1 deficiency results in hypercholesterolemia-associated 
monocytosis 52, however ABCA1/G1 deficiency also results in lipid 
accumulation in macrophages 53, and potentially circulating monocytes. Not 
only accumulation of lipoprotein fractions in circulating monocytes have been 
observed before, but also accumulation of fatty acids 54, in our study we have 
not yet discriminated between these subsets. In contrast to Swirski et al 35, the 
current study has shown that Ly6C- monocytosis might be an additional 
process contributing to atherosclerosis, at least in LDLr-/- mice.  
In conclusion, we show that hypercholesterolemia not only results in a 
rapid, but transient pro-inflammatory adaptive response in plasma. 
Furthermore, almost immediate intracellular changes in circulating as well as 
tissue resident monocyte subsets, including lipid accumulation and ROS 
production, which functionally translate in enhanced monocyte adhesion to 
activated endothelium. Altogether, our study reveal a novel pathway through 
which circulating monocytes contribute to atherosclerosis not only by fostering 
the subendothelial macrophage invasion but also potentially by conveying 
cholesterol into the atherosclerotic lesion. 
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Supplemental data 
 
Supplemental table 1 - Overview of FACS antibodies used for these studies 
 
 
 
 
Antibody Conjugate Company Tissue 
CD3ɛ eFluor450 eBioscience Blood 
CD3ɛ PerCP-Cy5.5 BD Bone marrow 
CD4 APC-H7 BD Blood, bone marrow 
CD8α FITC eBioscience Blood 
CD8α eFluor450 eBioscience Bone marrow 
CD8α APC-H7 BD Spleen 
CD11b PE-Cy7 BD Blood, spleen 
CD11b BV510 BD Bone marrow 
CD11b eFluor450 eBioscience Spleen 
CD11c PE-Cy7 BD Bone marrow, spleen 
CD45 PerCP Biolegend Blood 
CD45RA (B220) PerCP BD Bone marrow 
CD45RA (B220) V500 BD Blood, spleen 
CD115 PE BD Bone marrow 
CD317 (PDCA-1) PE BD Spleen 
Ly6C APC Miltenyi Blood, spleen, bone marrow 
Ly6G APC-Cy7 BD Blood, spleen, bone marrow 
MHC II FITC BD Bone marrow, spleen 
NK1.1 PE BD Blood, spleen 
NK1.1 PerCP-Cy5.5 BD Bone marrow 
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Supplemental figure 1 - Splenic leukocyte subsets increase upon WTD comparable to 
circulating leukocytes 
Absolute leukocyte levels were measured in spleen upon sacrifice using BD TruCount tubes. (A) 
Total CD45+ leukocytes, (B) CD11c+ cDC, (C) pDCA1+ pDC, (D) CD11b+/Ly6G+ granulocytes, (E) 
CD11b+/Ly6G- monocytes, and (F) Ly6C monocyte subsets, and (G) monocyte granularity per 
subset were measured. * p < 0.05, ** p < 0.01, and *** p < 0.001 
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Supplemental figure 2 - Bone marrow leukocyte subsets increase upon WTD comparable to 
circulating leukocytes 
Relative leukocyte levels were measured in bone marrow after 3 weeks of normal chow or 
WTD. (A) CD11b+/Ly6G+ granulocytes, (B) CD11b+/Ly6G- monocytes, (C) monocyte subsets, (D) 
granularity monocyte subsets, (E) progenitor cell population, and (F) LK subsets were 
measured. * p < 0.05, ** p < 0.01, and *** p < 0.001 
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Abstract 
Unstable angina pectoris is generally diagnosed based on clinical parameters, 
in default of accessible, sensitive, and selective biomarkers. In this study, we 
sought to identify novel and unstable angina pectoris-specific biomarkers on 
circulating monocytes, by phage display VHH antibody repertoire screening. 
Hereto, a dedicated antibody library was generated from plasma cells isolated 
from llamas, immunized with unstable angina pectoris patient monocytes. 
Affinity selections on human LPS-activated THP-1 monocytes, afforded several 
clones with increased affinity to LPS-activated THP-1 monocytes. Subsequent 
validation of selected clones on CD14 positive monocytes derived from 
unstable angina pectoris patients versus monocytes derived from healthy 
volunteers, identified clones which preferentially recognized unstable angina 
pectoris patient monocytes. Finally, selected clones specifically bound 
circulating human monocytes (ELISA) as well as monocytic cells in the 
vulnerable atherosclerotic lesion (immunohistochemistry). In conclusion, we 
have identified novel monocyte binding phage clones and provide proof of 
concept for their potential as biomarker in unstable angina pectoris diagnosis 
and in molecular imaging approaches for vulnerable plaque detection. 
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Introduction 
Acute coronary syndromes continue to be a major cause of morbidity and 
mortality in the Western society 1,2. The clinical manifestations generally are 
caused by rupture of an unstable atherosclerotic lesion 3. Nowadays, there is 
increasing interest in the characteristics of such unstable, rupture-prone 
lesions, not only from a mechanistic, but also from a diagnostic point of view, 
as unstable plaque markers are deemed very useful for molecular imaging 
purposes 4,5. However, many of these proposed markers are non-selective or 
difficult to monitor using non- or minimally invasive methods 6. Growing 
evidence suggests that information on localized events in the vasculature or 
even focal processes in the vulnerable atherosclerotic lesion can probably be 
deduced from information accessible in the periphery 5,7,8. The current study 
explores the possibilities of employing circulating monocytes as a read-out for 
diagnostic and potentially prognostic markers for unstable angina pectoris and 
acute, but also future, cardiovascular events. 
 Monocytes may be a particular relevant source for novel biomarkers, 
as monocyte-derived macrophages are instrumental in plaque inflammation, a 
major risk factor in plaque rupture 9. Furthermore, membrane protein 
expression on circulating leukocytes, and especially monocytes, are highly 
responsive to external influences, such as pathogens 10, trauma released 
factors,  and inflammatory disease 11,12. In response to these pathological 
processes foreign material can be presented on specialized cells. Cell types 
most famous for presenting antigens on MHC class I or II molecules are 
dendritic cells 13 and macrophages 14. Moreover, many of the differentially 
expressed membrane proteins, such as MHC class II, TLR4, and CD14 are 
associated with functional alterations or adaptations of the monocytes as they 
trigger or dampen the activity of downstream effectors. Overall, the 
modifications of surface marker expression on circulating monocytes due to 
local vascular events are of interest as these may harbor biomarker potential. 
Leukocyte membrane markers, or the expression level of these 
markers, have repeatedly been shown to be affected by localized vascular 
events. Acute cardiovascular events was seen to result in altered receptor 
expression profiles on monocytes 15,16. Conceivably, the CD14+CD16+ subset of 
monocytes which have a patrolling function, would be among the first to react 
to vascular injury or trauma. The information on local pathophysiological 
processes may therefore be directly analyzed from peripherally sampled blood 
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specimen, or possibly even using (non-invasive) imaging techniques. The latter 
could be further optimized using novel, highly specific markers for vulnerable 
atherosclerotic lesions. At the moment knowledge about the relation between 
monocyte expression profiles and cardiovascular disease are largely lacking.  
We therefore opted for an unbiased approach to screen for antibodies 
that target membrane markers which are differentially expressed between 
monocytes from healthy controls and patients with unstable angina pectoris. 
The advantages of phage display derived VHH antibodies are the direct 
application of the encoded antibody for targeted monocyte-based biomarker 
assays or imaging approaches. Further, the ability of these antibodies to bind 
targets non-accessible with conventional antibodies, such as pockets, could 
reveal targets unknown so far. Hereto, phage display was used as a tool to 
determine differences between monocyte populations, without any a priori 
knowledge. Normally, phage display is used to obtain (VHH) antibodies against 
known targets, preferentially purified or recombinant proteins 17, as well as 
cellular or plasma derived (purified) proteins 18,19. In this study the protocol 
was adapted to be able to determine novel targets specific for unstable 
atherosclerotic disease on circulating mononuclear cells 20. Screening was 
performed using an immune library, produced by immunization of a llama with 
UAP patient-derived circulating monocytes. We now present data on 
phage/antibody selections on UAP CD14+ monocytes specific phage clones, and 
show that selected clones preferentially bind monocytic cells in the advanced, 
vulnerable lesion. The high affinity for UAP monocytes indicates prospective 
potential for use in the clinics as diagnostic marker in blood or for detection of 
vulnerable plaques by imaging.  
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Materials & Methods 
Subjects 
Monocytes (CD14+ fraction) isolated from seven patients admitted to the 
University Medical Center Maastricht with unstable angina pectoris, were 
included for the analysis performed. One patient was later excluded as clinical 
parameters indicated no aberrations the ECG, all other patients were 
confirmed to have unstable angina pectoris by the clinician. For an optimal 
signal-to-noise ratio compared to non-diseased monocytes we included CD14+ 
monocytes from four healthy volunteers, without any known cardiovascular 
disease, as reference population. All participants provided written informed 
consent prior to participation. This study was approved by the local ethics 
committee. 
Monocyte Isolation 
Whole blood samples isolated from patients and healthy controls were 
centrifuged at 156 x g for 15 min without break. Next, plasma was removed 
and stored for future analysis at -80°C. A leucosep tube (Greiner) was filled 
with 15 mL Ficoll (Sigma) at room temperature. Tubes were centrifugated for 
30 seconds at 1,000 x g and 25 to 30 mL of PBS diluted blood was added on top 
of the filter and centrifuged for 20 min at 1,000 x g without breaks. Liquid 
above the peripheral blood mononuclear cells (PBMC) enriched interphase was 
removed and the PBMC fraction was transferred to a fresh 50 mL tube and 
washed twice with cell selection buffer (PBS; 0.5% BSA, 2 mM EDTA, 0.09% 
sodium azide). Cells were resuspended in 1 mL cell selection buffer and a 20 μL 
aliquot was saved as reference. After centrifugation the pellet was 
resuspended in 75 μL anti-human CD14 antibody conjugated magnetic beads 
(BD) and incubated for 60 min on ice. Subsequently, 1 mL cell selection buffer 
was added and cell suspension was placed on the BD Imagnet (BD) for 10 min. 
With the tube on the magnet the CD14 negative fraction was aspirated and 
saved for other analyses. The CD14 positive fraction was removed from the 
magnet resuspended in cell selection buffer and incubated for an additional 4 
min on the magnet. The positive cell fraction was resuspended in freezing 
medium and stored at -80°C until further use. 
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Cell lines 
Unless stated otherwise, THP-1 monocytes, either lipopolysaccharide (LPS) 
stimulated or non-stimulated, were used for phage selection assays and 
affinity screenings. Cells were cultured in RPMI-1640 medium supplemented 
with glutamine and HEPES (Life Technologies) at 37°C and 5% CO2. Cells were 
incubated for 1 hours with LPS (100 ng/mL; activated THP-1) or PBS (non-
activated THP-1), prior to the experiment, to induce cell activation and 
emulate the inflammatory conditions as observed during unstable angina 
pectoris. 
Phage library 
The immune library was produced by injecting a llama (Lama glama) with 
whole cell CD14+ monocytes from unstable angina pectoris (UAP) patients. Two 
llamas were immunized at weekly intervals for a period of 6 weeks with CD14+ 
monocyte pools from 4 UAP patients. Peripheral blood lymphocytes (PBL) were 
isolated from immunized animals to create an immune VHH library, as 
previously described 21. In short, PBL were isolated by Ficoll gradient and 
subsequently total RNA was isolated and transcribed into cDNA. Next, the 
repertoire of Ig heavy chain-encoding gene segments were amplified with the 
use of a framework 1 (FR1) specific primer and an oligo-dT primer. Finally, 
selected and purified cDNA fragments were ligated in a phagemid vector for 
display on filamentous bacteriophage 22 and electrotransformed to Escherichia 
coli TG1 (K12, _(lac-pro), supE, thi, hsdD5/F’traD36, proA+B+, lacIq, lacZ_M15). 
This resulted in a immune phage library with a diversity of approximately 8 x 
107. The animal experiments were reviewed by the ethical committee and 
approved by the board of Utrecht University.  
Whole Cell VHH Selections 
The phage library was rescued by inoculation in 2xTY medium (supplemented 
with ampicillin) and grown for 75 min at 37° C and 270 rpm. Subsequently, 
M13-helperphage (with kanamycin selection vector) was added in 10:1 ratio 
and incubated another 30 min. Cells were pelleted and grown overnight in 
2xTY medium supplemented with ampicillin and kanamycin at 30° C and 270 
rpm. Next day, phages were PEG-precipitated and blocked using 2% non-
skimmed milk powder (Marvel) in PBS to prevent non-specific binding or 
sticking of phages to cells. Cell suspensions were also blocked for 30 min in 
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2%Marvel-PBS prior to selection. Blocked phages were added to control and 
CFSE-labeled, LPS-activated THP-1 cells (10:1 ratio), or CD14+ monocytes from 
healthy controls and CFSE-labeled CD14+ monocytes from UAP patients (10:1 
ratio) and incubated for 30 min rotating at RT. Activated THP-1 cells or CD14+ 
monocytes from UAP patients were isolated by FACS sorting using a BD FACS 
Aria (BD) cell sorter based on the CFSE expression. Sorted cells were 
resuspended in 200 mM triethylamine (TEA; pH=12), incubated for 
approximately 10 min and subsequently neutralized with an equal volume 1M 
Tris-HCl (pH=6.8). Isolated phages were used to infect exponential TG1 
(OD=0.5) and masterplates and titrations of input and output titer were 
determined, to determine enrichment for each selection round. Masterplates 
were used to prepare new glycerol solution, which was used as starting library 
for subsequent selection round (figure 1).  
Whole Cell VHH Screenings 
Screenings were performed on either libraries from complete selection rounds 
or on individually selected clones. Marvel blocked control and LPS activated 
cells were incubated with 120 μL phage suspension in blocked 96-wells V-
shaped ELISA plates (Greiner) for 30 minutes at RT. Subsequently, 100 μL of 
either control cells or activated cells were added to 100 μL phage suspension 
and incubated for 60 minutes at 37°C. Plates were washed with Marvel-PBS 
three times and PBS two times.  
 Phages bound were detected using an HRP-conjugated anti-M13 
antibody which was incubated with the cells for 30 minutes at 37°C. After 
three more wash steps bound phages were detected using TMB (KPL Inc., MD, 
USA) and analyzed in a plate reader (BioRad) at 450 nm (figure 1). 
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Figure 1 - Selection and screening using whole cell phage display 
Phage display selections were performed according to the steps 1 – 5. In short, 1. B-cells were 
isolated from immunized llamas; 2. Heavy chain (VHH) coding RNA was isolated and amplified; 3. 
VHH cDNA was cloned/transfected into phagemid vector; 4. Selection on whole cells; 5. 
Recovery of selected phages. Subsequent affinity screening (step 6) was performed according 
to the steps 7 – 10 of the procedure shown. In short, 7. production of complete library of 
individual clone followed by binding to whole cells; 8. Washing to remove unbound phages; 9. 
Labeling of bound phages using anti-M13-HRP; 10. Detection of bound phages. Adapted in part 
from Hoogenboom (2005) 17. 
Flow Cytometry 
Purity of isolated CD14 positive monocytes was analyzed using anti-CD14 PC7 
and anti-CD16 PC5 (both BD). Measurements were performed on a BD Canto II 
flow cytometer (BD). In short, cells were pelleted and incubated with 1:25 
diluted anti-CD14 PC7 and 1:25 diluted anti-CD16 PC5 antibodies for 30 min on 
ice in the dark. Subsequently cells were washed twice, dissolved in 200 μL FACS 
buffer, and measured. 
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CD14 positive monocytes from unstable angina pectoris patients were 
labeled for 15 min with 1 µM carboxyfluorescein diacetate succinimidyl ester 
(CFSE; Invitrogen) in serum-free medium. Subsequently, cells were washed 
twice in medium supplemented with 10% fetal calf serum. Phages were added 
to control monocytes and CFSE-labeled UAP monocytes. After incubation for 
60 minutes, monocytes from UAP patients were recovered by FACS sorting 
based on CFSE signal. In short, cells were spun down after incubation with the 
phages and washed twice in PBS-2%Marvel and twice in PBS. Next cells were 
resuspended in PBS and sorted on a BD FACS Aria Cell sorter (BD). Both CFSE 
positive and CFSE negative fractions were isolated to determine efficiency and 
enrichment of the selection rounds. 
Immunohistochemistry 
Formalin fixed paraffin embedded sections from human carotid 
endarterectomy samples were deparrafinized and rehydrated. Sections were 
blocked for 30 minutes using 2% Marvel-PBS. Pre-blocked phages were added 
at a concentration of approximately 107 phages/mL in a total volume of 150 μL 
per section and incubated for 60 minutes at RT. Sections were washed in 
subsequently 2%Marvel-PBS and PBS. Pre-blocked mouse anti-M13-HRP 
antibody (1:5000) was added to the sections and incubated for 30 minutes at 
37°C. Next, slides were washed in PBS and Envision anti-mouse-HRP was added 
for 30 minutes to amplify the signal. After an additional wash step staining was 
developed using DAB and counterstained with haematoxylin. Finally, slides 
were dehydrated and coverslips were placed using Entellan.  
Statistical analysis  
Data are expressed as mean ± SEM. To compare individual groups, 2-tailed 
Students t-test was used; non-parametric data were analyzed using Mann-
Whitney U test. All analyses were performed using GraphPad Prism 5 software 
(GraphPad Software Inc, La Jolla, CA, USA) and p-values below 0.05 were 
considered statistically significant. 
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Results 
 
Figure 2 - THP-1 selection rounds reveal subtle yet increasing binding affinity 
(A) Enrichment of the complete library after each selection round (R), indicating increased 
binding affinity towards activated THP-1 cells over control THP-1 cells. (B) Enrichment after 
selection round 4 showed heterogenous affinity to activated cells for 19 different clones 
selected from this selection round. Results are based on a minimum of three screenings per 
clone. Results are shown as mean ± SEM, solid line indicates differential OD = 1 and dashed line 
indicates differential OD = 2. (C) Sequencing analysis of 20 clones showed variability in CDr1 
(red), CDr2 (green), and mainly CDr3 (blue) region of VHH antibodies. 
 
THP-1 selection rounds revealed small number of high affinity clones 
Initial selection rounds were performed on the THP-1 human monocytic cells, 
which were LPS-activated to simulate the pro-inflammatory milieu in CVD 
patients. After 4 selection rounds we analyzed the complete phage libraries of 
each selection rounds (figure 2A) as well as a number of individual clones from 
selection round 4 (figure 2B) to assess the general enrichment in monocyte 
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binding phages in the library as well as to pinpoint individual clones with 
highest affinity for LPS-activated monocytes. We observed a small increase in 
the affinity of the whole library. However, when analyzing the individual clones 
a large variety in affinity was observe for all selection rounds. 
 To determine whether the variety of clones present after the different 
selection rounds was affected between the different selection rounds we 
performed sequence analysis of the variable region for randomly selected 
clones from multiple selection rounds. Overall, enrichment resulted in 
diminished sequence variety. Still, at least some variety could be observed 
indicating the absence of a, possibly non-specific, dominant clone (figure 2C).  
 
Figure 3 - Monocyte isolation is highly efficient and does not result in monocyte activation 
(A) Monocytes were isolated from PBMC fractions. Quantification indicated that the hardly any 
monocytes were left in the CD14 negative (-) fraction, while the CD14 positive (+) fraction was 
very pure. This is also shown in the flow cytometry dot plots for the total PBMC and CD14+ 
fraction. (B) Histograms showing fluorescence intensity for CD11b of isolated monocytes at 
baseline (left panel) and after activation with 100 μM LPS (right panel). 
CD14 isolation was effective and reproducible 
Isolation of monocytes resulted in highly pure CD14+ monocyte pools (96.3% ± 
2.1%) at a recovery of more than 80% for all samples. Recovery was 
determined by calculating the residual CD14+ population in the CD14 negative 
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fraction. Of note, there was hardly any spillover of CD14 negative cells in the 
isolated CD14+ monocyte  pools (figure 3A). 
The efficiency and purity observed for the isolation of fresh PBMCs did 
not differ from that obtained from frozen PBMCs. Freezing and thawing, either 
before or after CD14 isolation, did not show any effects on the CD14+ 
monocyte surface expression of CD11b, CD62L, and CCR2 (data not shown), 
illustrating that membrane markers are well preserved during the 
experimental procedure. Activation potential of isolated monocytes was 
neither influenced by the isolation procedure nor by the freezing/thawing step, 
as all cells still could be efficiently activated and showed no baseline increase 
of CD11b expression (figure 3B).  
To verify whether the clones selected on activated THP-1 monocytes 
also had a higher affinity for monocytes derived from UAP patients, whole cell 
ELISA was performed comparing phage binding to control and UAP monocytes, 
isolated by CD14+ bead selection. Indeed, one clone (C10) showed significantly 
increased affinity for UAP-derived monocytes compared to monocytes from 
healthy individuals (figure 4A).  
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Figure 4 – Screenings on THP-1 cells, monocytes, and atherosclerotic lesions reveals that 
markers selected have biomarker potential 
(A) Whole cell ELISA on human monocytes isolated from healthy controls and UAP patients 
showed increased affinity for UAP monocytes for some clones, compared to a control (G8) clone 
(B) Optical density (OD) of selected phages for binding on LPS-activated cells compared to 
control cells. Three clones were selected: G8C (Control; black bar), A12 (high affinity; blue bar), 
and C10 (intermediate affinity; orange bar). (C) Immunohistochemistry pictures for control 
(G8C), A12, and C10 clones on advanced atherosclerotic lesions. Inserts show positive cells for 
A12 and C10 staining.  
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Despite, the enrichment observed for the total phage libraries per 
selection round (figure 2A), as well as the enrichment for the individual clones 
was rather limited (figure 2B), we investigated the capacity of selected clones 
to bind monocytic cells in atherosclerotic lesions. We selected two clones for 
further testing; clone A12 which showed high affinity for activated THP-1 cells 
and clone C10 displaying moderate affinity for activated cells but increased 
affinity for UAP monocytes, as well as clone G8 (control) which had no 
increased affinity for binding to activated THP-1 cells or UAP monocytes (figure 
4A+B). Early lesions (intimal thickening), advanced lesions (thick fibrous cap 
atheroma), or advanced, vulnerable lesions (intraplaque hemorrhage/plaque 
rupture)were stained with selected clones, after which binding was detected 
using a HRP-conjugated anti-M13 antibody. Early lesions did not stain positive 
for any of the tested clones (data not shown). However, clone A12 as well as 
C10, but not G8 (control), gave detectable staining signal for advanced 
atherosclerotic lesions (figure 4C).  
Moreover, clones A12 and C10 were found to specifically stain cells in 
highly vascularized regions of the atherosclerotic plaque. Cells that showed 
positive staining were morphologically assigned to be monocytic cells, based 
on their size and nuclear shape. Interestingly, clones A12 and C10 showed a 
different staining pattern, with intra-cellular localized staining for A12, and 
clear plasma membrane staining for clone C10. Nevertheless, for both clones 
staining was very specific with regard to binding to monocytic cells in highly 
vascularized regions of advanced, vulnerable lesions. 
Discussion 
Diagnostic and prognostic markers used are generally based on levels of  
soluble proteins, lipids, carbohydrates, miRNAs, or levels of specific cell types 
in bodily fluids 7,23. One of the most frequently used markers in the field of 
cardiovascular medicine is troponin 24. This marker has very high specificity and 
also sensitivity for the diagnosis of an acute myocardial infarction (AMI) 24,25. 
For atherosclerosis and more in particular unstable angina pectoris no 
(protein) markers have been defined until now and therefore diagnosis is 
merely based on clinical parameters and exclusion of AMI 5. In this study we 
show that circulating monocytes carry information on local vascular disease 
status which could be applicable to diagnose or even predict (future) acute 
cardiovascular syndromes.  
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Phage display is a powerful technique that yields high efficiency for the 
unbiased discovery of novel antibodies against known as well as unknown 
epitopes 17. The technique has already been successfully applied in the 
cardiovascular field, to identify plaque proteins targeting autoantibodies 26 and 
to design binders of known candidates for molecular imaging and intervention 
such as P-selectin 27 and SR-AI 28, or of whole cells 29,30. In this study we applied 
phage display to identify antibodies able to differentiate between activated 
and non-activated on monocytes, for use in molecular diagnosis of unstable 
angina pectoris. Standard selection and screening protocols20 were adapted to 
be able to accommodate whole cells as template. One of the challenges to be 
met, especially in the validation phase, was that, contrary to most phage 
display efforts thus far, antibody and antigen both were unknown at the start 
of the study.  We opted for activated THP-1 monocyte cells as selection 
platform, to circumvent interpatient variability; taken advantage of the recent 
findings that UAP and AMI patient monocytes show altered TLR4 response 
and/or basal activation status 31-34, patient disease status was emulated by pre-
activating monocytes with the TLR4 agonist lipopolysaccharide (LPS). 
For the verification stage we used patient-derived CD14+ monocytes. 
Importantly, the activation status of CD14+ monocytes was not impacted by 
cell isolation and CD14+ still retained full responsiveness to stimuli such as 
lipopolysaccharide (LPS). Thus, differential binding of phages to UAP 
monocytes versus monocytes from healthy volunteers was very likely 
reflecting disease state, although we cannot completely exclude that 
differences between patient groups in other parameters such as medication or 
diet could have had an effect on proteins expressed by circulating monocytes. 
Further validation in larger cohorts of risk factor matched  patient groups will 
be required to address this point.  
As TLR4 activation was applied for the initial biomarker discovery 
phase, the specificity of the binders found does not have to be restricted to 
monocytes in relation to advanced or unstable atherosclerosis. TLR4 has been 
implicated in rheumatoid arthritis 35 and systemic lupus erythromatosus, 
however TLR4 appears to be non-involved or downregulated in these auto-
immune diseases 36,37. Still, TLR4 activation is implicated to be involved in 
multiple sclerosis 38 and possibly asthma 39,40. Therefore, TLR4 activation 
dependent biomarkers could contribute at least to some of the 
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aforementioned diseases. Nevertheless, TLR4 signaling is most often linked to 
CVD , underpinning the relevance of our approach in a cardiovascular setting.  
 Monocytes have a pivotal role in all phases of atherosclerosis 
development 41 and interact with the vessel wall 42. These cells are the first 
cells to enter the initial lesion upon injury43, and the main source of 
macrophages which were seen to exert important functions in plaque 
progression44 and eventual plaque destabilization, resulting in clinical 
manifestations such as myocardial infarction and stroke 45. This key role in 
disease ontogenesis, combined with their innate patrolling function renders 
them highly sensitive sentinels of local vascular disease. Despite the cognition 
of macrophages as biomarker source for CVD status 46, circulating monocytes 
have hardly been considered as carrier of information on plaque or vessel 
status, apart from their rolling and adhesion behavior. However, interaction 
with the diseased endothelium, as well as with blood containing cells and 
cytokines, can impact monocyte phenotype as we show in the current study. 
This notion concurs well with previous studies, which investigated disease-
associated changes in monocyte expression and their potential as biomarker in 
cardiovascular diseases, as reviewed by Gratchev et al 47. Different types of 
monocyte markers are described including monocyte (subset) numbers, 
protein markers, and functional markers. Both total monocyte counts 48 as well 
as subpopulations 49,50 (e.g. CD14++/CD16- monocytes) can function as 
biomarker for CVD. Further, activation markers as CD18, CD11b, and CXCR1 
give information on morbidity in heart failure 51. Finally, increased monocyte-
endothelial cell interactions 52 and increased activation potential upon IL-4 
stimulus 47 can also give information on local atherogenic disease. The mere 
fact that our phage marker is able to distinguish between vulnerable and 
stable plaque monocytes is highly supportive of cross-interaction between 
lesion and monocyte. 
 To conclude we offer proof of concept of phage display aided 
identification of monocyte markers with increased affinity for circulating and 
plaque monocytes in unstable or advanced atherosclerosis. While holding 
promise, the actual target of the phage exposed antibody remains to be 
determined and its specificity assessed, before this observation can be 
translated into a clinically viable diagnostic test. Defining the exact epitope will 
also give a better insight in the disease associated downstream signaling 
events and its consequences for monocyte phenotype in vascular pathologies 
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such as investigated in this study, but potentially also in other inflammatory 
diseases, especially since TLR4 activation is present in acute inflammatory 
conditions. Taken together, we present novel markers for circulating and 
plaque monocytes in patients with unstable angina which could contribute to 
improvement of diagnosis of disease. 
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Abstract 
Angina pectoris is considered to be one of the hallmarks of advanced 
cardiovascular disease and it often precedes ischemic events such as 
myocardial infarction and stroke. The current study investigates the 
differences between stable and unstable angina pectoris on a 
transcriptomics/genomic level to determine processes involved and to 
discover biomarkers to distinguish between stable and unstable angina 
pectoris. Circulating monocytes from patients included in the CTMM 
Circulating Cells cohort were isolated upon admission to the hospital. 
Monocytes were analyzed on a cellular level by flow cytometry and on a 
genomic level using micro-array analysis. Both the analysis on a proteomic and 
genomic level indicated the absence of distinct differences between the stable 
and unstable angina pectoris patients, however both analyses indicated the 
involvement of migratory pathways, as chemokine and cytokine signaling were 
limitedly affected. Despite major clinical differences between patients 
suffering from stable and unstable angina, we were unable to segregate these 
patient populations on a cellular or genetic level, indicative of only minor 
alterations of circulating monocytes in response to local atherosclerotic vessel 
disease. 
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Introduction 
Cardiovascular diseases are one of the leading causes of death in Western 
societies and prevalence is increasing in developing countries 1. Despite the 
growing public health efforts in preventive medicine, most patients will be 
referred to the hospital when already suffering clinical symptoms such as chest 
pain. These symptoms, also referred to as angina pectoris, are caused by 
reduced availability of oxygen (and nutrients) to the myocardium. Almost 
ubiquitously the underlying cause is represented by stenosis or impaired 
dynamics of the coronaries due to atherosclerotic disease 2. Distinction 
between stable angina pectoris (SAP) and unstable angina pectoris (UAP) is 
made based on clinical history and semeiotics. Since this is a subjective 
process, and plaque stability in general is an important variable when it comes 
to the prognosis of a patient with angina, there is increasing need for 
alternative markers which can be used to classify angina pectoris into stable or 
unstable.  
Preferably, such markers should also be able to quantitatively estimate 
the risk of developing future cardiovascular events, with high reproducibility, 
or at least reflect key processes in disease development. Additionally, it would 
desirable to identify circulating biomarkers, easily measurable with an easy 
and stress-free blood sampling procedure, to minimize the physical burden for 
patients and to seamlessly combine testing within the already established 
clinical procedures (e.g. troponin measurement 3). Further, markers for SAP 
and UAP should have prognostic features to ensure optimal assessment of the 
long term risk of cardiovascular events and develop personalized medicine 
strategies. 
 In recent years, biomarker research has broadened its focus to also 
include cellular markers besides more classical (soluble) circulating proteins. 
Established protein biomarkers include C-reactive protein (CRP) for acute 
coronary syndrome 4,5, but also cytokines like growth differentiation factor 15 
(GDF15) for CVD in general 6. Recently, increasing numbers of various UAP 
specific biomarkers have been proposed, including serum levels of placental 
growth factor 7, deoxyribonuclease I 8, matrix metalloproteinase (MMP) 8 ref 9. 
Cytokines, like soluble CD40 ref 10, pro-brain type natriuretic peptide (BNP) 11, 
and myeloperoxidase (MPO) 12, have also been suggested as biomarkers for 
CVD. Furthermore, monocyte subset (CD14+/CD16+/CX3CR1+) counts 13, as well 
as levels of specific membrane markers as the fractalkine receptor (CX3CR1) 14 
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have been linked to plaque stability in UAP patients. Nevertheless, most of 
these markers are either restricted to specific patients populations 15, or 
influenced by drug use 13, limiting the clinical application as biomarker.  
 Novel cellular markers for CVD are circulating endothelial cells, which 
could be promising prognostic biomarkers 16. Also markers on circulating 
leukocytes have been shown to have potential as diagnostic or even prognostic 
CVD biomarker. In fact, CD14 expression on monocytes is commonly studied to 
determine monocyte activation and disease progression 17-19, however the 
results are still contradictive. It has been shown that inflammatory membrane 
markers such as toll-like receptors 20,21 and CD11b/CD18 ref 22,23 are also 
associated with progression of CVD in general. However, many biomarker 
studies have a lack of discriminative power, are not specific to cardiovascular 
disease, or do not show diagnostic potential and risk prediction for individual 
patients.  
These data nevertheless demand a more elaborate screening of 
proteome and transcriptome on relevant leukocyte species. As cells from the 
monocyte/macrophage lineage are accepted as one of the key players in 
atherosclerosis development, we focused on the potential of circulating 
monocytes as biomarker for angina pectoris. Furthermore, a transcriptome 
approach is very suitable for identifying novel biomarkers 24, and can also give 
insight in underlying pathway regulation 25,26. Here, we present data on 
transcriptomics analysis on UAP patient monocytes compared to SAP 
monocytes to identify novel targets for diagnosis and prognosis. 
Materials & Methods 
Patients 
This study included 25 patients with stable angina pectoris and 25 patients 
with unstable angina pectoris from the Center for Translational Molecular 
Medicine (CTMM) – Circulating Cells Cohort that were presented to the 
Maastricht University Medical Center, The Netherlands between July 2009 and 
June 2011. Patient groups were matched for age, sex, smoking habit, 
dyslipidemia, and hypertension (table 1). As negative control, 11 healthy 
individuals without any known cardiovascular disease were included. These 
controls presented to the hospital with chest pain of suspected cardiovascular 
origin, but did not show any overt stenosis and scored negative on ST elevation 
and/or troponin T (TnT). All participants provided written informed consent 
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prior to participation. This study was approved by the local ethics committee. 
Exclusion criteria were active inflammatory conditions, autoimmune disease, 
malignancies, use of immunosuppressive drugs, and known hematological 
disorders. Patients with ST-elevation myocardial infarction (STEMI) were also 
excluded. Blood of patients with suspected unstable angina or non-STEMI was 
studied but retrospectively excluded from this analysis. 
Cell Isolation 
Upon inclusion, blood samples were collected in ethylenediaminetetraacetic 
acid (EDTA) anti-coagulated vacuum tubes and processed according to 
standardized procedures to analyze leukocyte subsets. In short, blood was 
transferred to a 50 mL tube (Greiner) and centrifuged for 15 minutes at 156x g 
without brake. Subsequently, plasma was removed and 30 mL PBS-diluted 
blood was added on top of 15 mL Ficoll-Paque plus (Sigma) and spun for 20 
minutes at 1000x g without brake. The leukocyte-enriched interphase was 
collected and washed twice with PBS before CD14+ monocyte isolation 
according to the manufacturers protocol (BD Bioscience). Isolated CD14+ 
monocytes were gently frozen and stored at -80°C until further use. 
Flow Cytometry 
To assess expression of surface markers 50 µl of heparin anti-coagulated whole 
blood was incubated with fluorescent antibodies (supplemental table 1) for 30 
minutes. After washing and whole blood erythrocyte lysis, the samples were 
analyzed by flow cytometry (Beckman Coulter FC 500). Granulocytes were 
gated based on their scatter properties, and confirmed based on CD16 
expression. Monocytes were identified based on their scatter properties and 
monocyte subsets were quantified (percentage positive cells and mean 
fluorescence intensity [MFI])based on surface expression of CD14, CD16, CCR2, 
and CX3CR1. 
RNA Isolation and Micro-Array Analysis  
Monocyte samples were shipped to AROS (Aarhus, Denmark) for RNA isolation 
and subsequent micro-array analysis. RNA was isolated using Illumina 
TotalPrep RNA Amplification Kit (Illumina, San Diego, CA, USA) and cDNA was 
produced. The RNA quality and integrity was very good, as the lowest RNA 
integrity number (RIN) was 8.3 besides on outlier with a RIN of 2.4. The 
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average RIN was 9.22 ± 0.14, indicative of very good quality of the RNA 
samples.  
Next, labeled cRNA was prepared and used on the array for 
hybridization according to manufacturer’s instructions. HumanHT-12 v4 Bead 
chips were scanned by Illumina BeadStation (Illumina Inc., San Diego, CA, USA). 
Raw image analysis and signal extraction was performed with Illumina 
Beadstudio Gene Expression software with default settings (no background 
subtraction) and no normalization. Data were exported as text files. 
Computational methods  
Raw data were imported in R ref 27 and analyzed within the Bioconductor suite 
28. Quality control, background correction, and robust spline normalization 
have been performed by lumi 29. Differential expression analysis was 
performed by fitting a linear model to the paired set of expression values, and 
by applying a Bayesian empirical method for shrinkage of the standard errors 
towards a common value, in limma 30. P-values have been adjusted for False 
Detection Rate 31.  
To evaluate the reproducibility of our differential expression analysis, 
the package GeneSelector 32 was used. First the differential expression test was 
repeated using a set of diverse statistical methods (Wilcoxon statistics 
empirical Bayes 33, Wilcoxon statistics, Bayesian t-statistics 34, and SAM 35). 
Finally we repeated the analysis for altered (jackknife, label exchange, 
bootstrapping, and noise addition) datasets, to estimate the bias and variance 
of the data. A principal component analysis was ran to explore the relationship 
among the samples. Arbitrarily selecting the top 500 genes from the 
differential expression analysis results, pathway enrichment analysis was 
performed using signaling pathway impact analysis (SPIA) 36 which leverages on 
a system biology approach to integrate information concerning gene ID, 
differential expression and pathway topology to calculate the pathway 
significance and its activation or inhibition. 
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Statistical Analysis 
All data on patient characteristics and flow cytometry are presented as mean ± 
SEM. To compare individual groups, 2-tailed Students t-test was used; non-
parametric data were analyzed using Mann-Whitney U test; discrete data was 
analyzed using Chi square test. All analyses on patient characteristics and flow 
cytometry were performed using GraphPad Prism 5 software (GraphPad 
Software Inc, La Jolla, CA, USA) or IBM SPSS statistics 20 (IBM, Amsterdam, The 
Netherlands). p-values < 0.05 were considered statistically significant. 
Results 
Patient characteristics 
In total 25 stable angina pectoris (SAP) patients, 25 unstable angina pectoris 
(UAP) patients, and 11 controls were included in this study. However one UAP 
patient was reclassified as SAP by the clinicians after initial selection procedure 
was performed. A second UAP patient was excluded as no adequate monocyte 
sample was available. As a result the study comprised 23 UAP patients, 26 risk 
factor-matched SAP patients, and 11 controls for final analysis.  
 
Table 1 – Patient characteristics 
Baseline characteristics for healthy controls (controls), stable angina pectoris patients 
(SAP), and unstable angina pectoris patients (UAP). Indicated is: number (percentage 
of group), except for Age (mean); BMI = Body Mass Index, MI = Myocardial Infarction  
 Controls SAP UAP p-value 
  N = 11 N = 26 N = 23   
Age 59.55 63.23 63.7 0.50 
Sex 7 (63.6) 14 (53.8) 13 (56.5) 0.86 
BMI 28.34 26.92 26.97 0.70 
Smoker 3 (27.3) 9 (34.6) 11 (47.8) 0.45 
Hypertension 4 (36.4) 15 (57.7) 16 (69.6) 0.18 
Diabetes Mellitus 2 (18.2) 3 (11.5) 7 (30.4) 0.25 
Dyslipidemia 5 (45.5) 21 (80.8) 16 (69.6) 0.10 
Peripheral artery disease 2 (18.2) 3 (11.5) 3 (13.0) 0.86 
Previous MI 0 (0.0) 7 (26.9) 3 (13.0) 0.11 
Cerebrovascular attack 0 (0.0) 2 (7.7) 5 (21.7) 0.13 
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 No statistically significant differences in patient characteristics were 
detected for age, sex, and body mass index (BMI) between healthy controls, 
SAP and UAP patients (table 1). In the healthy control group 7 patients were 
male (63.6%) and the mean age was 59.6 years (59.6 ± 3.2 years). It should be 
noted that accepted risk factors as smoking, hypertension, diabetes mellitus, 
and dyslipidemia, additional matching criteria for patient group buildup, did 
not differ between groups (table 1). Despite the absence of previous 
myocardial infarction and cerebrovascular attacks in the control group, no 
statistically significant difference could be observed between healthy controls, 
SAP, and UAP patients (table 1). 
Leukocyte counts are unaltered between SAP and UAP patients 
No statistically significant differences were observed in total leukocyte counts 
between controls, SAP, and UAP patients (table 2). Also lymphocyte and 
granulocyte counts were unchanged between controls and patient groups 
(table 2). Both lymphocytes and granulocytes tended to increase with severity 
of disease (controls  SAP  UAP), albeit these results did not reach 
significance. Of note, monocyte counts were significantly reduced in SAP 
patients compared to both healthy controls and UAP patients, but did not 
differ between the latter two groups (table 2). 
 
Table 2 – Leukocyte profile of patients included  
Absolute cell counts from healthy controls (controls), stable angina pectoris patients 
(SAP), and unstable angina pectoris patients (UAP) upon inclusion. Indicated is mean ± 
SEM. * p < 0.05 vs UAP 
 Controls SAP UAP p-value 
  N = 11 N = 26 N = 23   
Leukocytes 7.00 (± 0.42) 6.90 (± 0.66) 7.47 (± 0.80) 0.82 
Lymphocytes 1.66 (± 0.17) 1.83 (± 0.19) 2.27 (± 0.20) 0.15 
Monocytes 0.55 (± 0.04) 0.39 (± 0.03)* 0.51 (± 0.04) < 0.01 
Neutrophils 4.68 (± 0.65) 5.35 (± 0.35)  5.99 (± 0.42)  0.23 
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Flow cytometry excludes polarization bias between patient groups 
Flow cytometry analysis confirmed the above findings, in that there were no 
differences in granulocytes between stable and unstable angina (figure 1A). 
Relative total monocyte counts measured by flow cytometry (figure 1B), as 
well as CD14highCD16- and CD14+CD16+ monocyte subsets were unaltered in 
UAP versus SAP patients (figure 1C+D). The CCR2 and CX3CR1 chemokine 
receptor density on CD14highCD16- and CD14+CD16+ was not affected as mean 
fluorescence intensity (MFI) for these chemokine receptors on both monocyte 
subsets was unaltered in SAP and UAP patients (table 3). 
 
Figure 1 - Flow cytometry indicates no differences in chemokine receptor expression. 
Flow cytometry data showing (A) granulocytes, (B) total monocytes, (C) CD14highCD16- 
monocytes, and (D) CD14+CD16+ monocytes for SAP and UAP patients. White bars are stable 
angina pectoris patients (SAP) and black bars are unstable angina pectoris (UAP) patients. * p < 
0.05 and ** p < 0.01 
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Table 3 – Corrected mean fluorescence intensity for chemokine receptor expression 
on monocyte subsets 
Corrected MFI  Controls SAP UAP p-value 
   N = 11 N = 26 N = 23   
CD14highCD16- CCR2 0.283 (± 0.011) 0.288 (± 0.007) 0.284 (± 0.009) 0.93 
 CX3CR1 0.290 (± 0.003)  0.293 (± 0.004) 0.289 (± 0.003) 0.52 
CD14+CD16+ CCR2 0.309 (± 0.022) 0.297 (± 0.013) 0.304 (± 0.010) 0.84 
 CX3CR1 0.339 (± 0.005) 0.344 (± 0.004) 0.344 (± 0.003) 0.56 
 
Principal component analysis does not reveal any segregation between 
patient groups 
Flow cytometry based quality control for the monocyte isolation confirmed 
that CD14 positive monocytes could be isolated at high purity (> 99.5%) and 
moderate to high recovery (> 80%; figure 2A). Bead-purified monocytes were 
still viable and still able to react to subsequent lipopolysaccharide activation, 
indicating that the selection method did not (completely) activate the 
monocytes (figure 2B). 
 Density histogram of raw log‐intensities from patient samples before 
(upper panel) and after (lower panel) preprocessing revealed that the micro 
array analyses were of good quality. This was confirmed by the overlap of 
samples after normalization, which indicates that batch effects have been 
eradicated and that all the signals share the same scale (figure 3A).  
 
Figure 2 - Monocyte are isolated efficiently and without massive activation. 
(A) Representative dot plots for monocyte population based on CD14 and CD16 
expression before (left panel) and after (right panel) CD14+ bead isolation. (B) 
Histograms showing CD11b expression on isolated monocytes before (upper panel) 
and after (lower panel) stimulation with 100 ng/mL lipopolysaccharide (LPS). 
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Initial principal component analysis (PCA) was performed on the raw 
data to identify whether the attributes of the data were able to show 
clustering of the datasets. PCA indicated that there was no segregation of the 
data based on the patients disease state (control, stable angina pectoris, 
unstable angina pectoris) before normalization and background correction 
(figure 3B). Normalization of the data and subsequent background correction, 
did not reveal additional information, as there was no clustering of patient 
groups (or controls) visible (figure 3C).  
Monocyte show subtle differences on transcriptomics level 
Differential expression analysis, after false discovery rate (FDR) adjustment (to 
correct for multiple testing), was used to determine genes of interest for 
further analysis. Analysis revealed the presence of both up- and down-
regulated gene sets in UAP versus SAP patients after correction for the controls 
(figure 4A). However, after stringent multiple testing correction we could no 
longer observe any statistically significant gene sets (data not shown) for the 
used conditions (p<0.01 and/or foldchange >30%). 
To verify whether the results were influenced by the statistical test 
used for these analyses, multiple tests were compared, including Wilcoxon 
statistics empirical Bayes (WilcEbam), Wilcoxon statistics (Wilcoxon), Bayesian 
t-statistics (BaldiLongT),  and statistical analysis of micro arrays (SAM). All tests, 
expect for WilcEbam, resulted in similar outcomes regarding macroscopic 
clustering of the results as our default procedure linear models for micro-array 
data (Limma), suggesting that our analysis was not biased by the procedure 
used for analysis (figure 4B).  
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Figure 3 - Micro-array analysis does not result in clustering of patient groups. 
(A) Micro-array analysis quality was assessed using density histograms of log2 intensity. Density 
histograms before (upper panel) and after (lower panel) processing are shown. Overlay of the 
lines after processing is indicative of good quality. (B + C) Principal component analysis (PCA) 
showed the absence of clustering of patient populations before (B) and after (C) background 
correction and normalization of the data. 
 
Figure 4 - Differential expression analysis indicate minute, yet significant differences. 
(A) Volcano plot indicating differentially expressed genes (blue dots) with fold change over 30% 
and/or p-value below 0.01. Red dots are genes not differentially expressed between SAP and 
UAP patients. (B) Macroscopical ordering of the results based on different statistical tests does 
not reveal test dependent bias of our results. 
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Monocyte chemokine pathways are minimally affected in UAP patients 
Pathway analysis, arbitrarily using the top 500 genes differentially expressed 
between SAP and UAP patient monocytes, indicated seven pathways which 
were significantly inhibited in UAP patients compared to SAP patients after 
correction for the controls. Two additional pathways were activated in UAP 
versus SAP patients (figure 5A). Four pathways remained significant after 
Bonferroni correction, and all nine were significant after FDR correction. The 
top four pathways were all immune-related: chemokine signaling pathway 
(inhibited; p < 0.001), cytokine-cytokine receptor interaction (inhibited;  p < 
0.01), vibrio cholera infection (inhibited; p < 0.05), and epithelial cell signaling 
in H. pylori infection (inhibited; p < 0.05; figure 5B). The other five pathways, 
Shigellosis (inhibited), cell cycle (inhibited), salivary secretion (inhibited), 
pathogenic E. coli infection (activated), and Alzheimer’s disease (activated), did 
not pass Bonferroni correction (figure 5A+B). Besides cell division control 
protein 42 homolog (Cdc42) and adenylyl cyclase (AC), chemokines and 
chemokine receptor genes were most predominantly affected in the top 
dysregulated pathway (chemokine signaling pathway; figure 5C). 
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Figure 5 - Pathway analysis reveals subtle differences between SAP and UAP patients. 
(A) SPIA pathway analysis reveals differentially regulated pathways between SAP and UAP 
patients based on Bonferroni correction (red dots) and FDR (blue dots). The red line and blue 
line indicate p < 0.05 for Bonferroni and FDR correction, respectively. (B) Table indicating 
differentially regulated pathways including KEGG-ID, adjusted p-value, and status 
(activated/inhibited). (C) Chemokine pathway including the differentially expressed genes (red 
genes) within this pathway. 
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Discussion 
Distinguishing between stable angina pectoris (SAP) and unstable angina 
pectoris (UAP) patients at an early time point is essential for treatment of 
cardiovascular disease and risk prediction for future cardiovascular events. 
Furthermore, it is also essential to exclude patients with non-cardiovascular 
chest pain early to avoid additional, time-consuming, and expensive 
examinations and procedures. Various studies have investigated circulating or 
even cellular biomarkers to determine the disease state of the patient 37-39. So 
far, no biomarker has been defined that is superior to commonly used clinical 
parameters, in discriminating SAP from UAP patients 40,41. Cellular markers can 
not only give insight in the disease state of a patient, but can also contribute to 
understanding of underlying mechanisms. 
 The current study has explored the possibilities of using blood derived 
cellular markers for determination of disease state. The underlying notion is 
that circulating cells, and more in particular monocytes, can on the one hand 
sense the local and systemic milieu by either reacting to released cytokines 42 
and chemokines 43, and on the other hand directly interact with the vessel wall 
5,43-45, activating (patrolling) monocytes due to increased integrins in response 
to advanced atherosclerotic vessel disease 44,46. Conceivably, the transient 
accumulation of activated platelets at lesioned foci in coronary arteries 47, one 
of the processes underlying angina, will be sensed at an early stage by 
circulating monocytes. Moreover, dysregulated plasma cytokine and 
chemokine levels constitute a markedly altered microenvironment to which 
circulating monocytes are exposed. Overall, monocytes have the capacity to 
detect multiple targets associated with the pathogenesis of angina pectoris, 
and to respond to such stimuli on a cellular level.  
 The possibilities of using circulating leukocytes as target for biomarker 
discovery is not completely novel, as a limited number of studies has 
investigated peripheral blood mononuclear cells (PBMC) as messenger of 
atherosclerotic vessel disease using an transcriptomics approach 48. Moore et 
al found a panel of differentially expressed genes, including genes involved in 
monocyte activation (CD14, TLR2) and scavenger receptors (CD163, CD36), 
which could identify stroke patients 49. Furthermore, Patino et al identified 
Finkel–Biskis–Jinkins osteosarcoma (FOS) gene to be upregulated in circulating 
CD14+ monocytes from patients undergoing carotid endarterectomy compared 
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to healthy controls 50. However, in contrast to our study, these studies focused 
on endpoints (surgery and stroke) rather than diagnosis of patients at risk. 
 In this study, the SAP and UAP patients selected were matched for risk 
factors related to cardiovascular disease. The healthy controls did not suffer 
from cardiovascular disease before or upon inclusion. Leukocyte analysis 
indicated that total leukocytes, as well as lymphocytes and granulocytes were 
not different between healthy controls, SAP and UAP patients. Unexpectedly, 
circulating monocytes were slightly decreased in SAP patients, but not UAP 
patients, compared to healthy controls. Overall, patient demographics are not 
expected to have any influence on our analysis as parameters were very 
comparable between controls, SAP and UAP patients.  
Flow cytometry did not show any differences in monocyte numbers, 
both total monocytes and subsets, as well as in chemokine receptor 
expression. With regard to monocytes, inflammatory CD14highCD16- and 
patrolling CD14+CD16+ monocyte subsets, we could not detect any differences 
in relative abundance. Recently CD14+CD16+ monocyte enrichment was 
proposed as a measure of disease severity 51, however this study did not 
differentiate between stable and unstable angina. On the protein level, we did 
not observe any changes in expression of two prototypic chemokine receptors 
instrumental in CD14highCD16- and CD14+CD16+ trafficking, CCR2 and CX3CR1 as 
examined by flow cytometry. These data indicate that our transcriptomics 
analysis is not confounded by basal differences in SAP or UAP monocyte 
skewing. This supports, at least in part, the subtle differences in monocyte 
phenotype between SAP and UAP patients. 
 More detailed analysis of our transcriptomics data by principal 
component analysis failed to reveal clustering of patient groups. Previously, 
individual genes were suggested to be useful as a biomarker for coronary 
artery disease 52,53, or as prognostic marker for disease progression 54. 
However, as Venet et al showed individual genes tested might be as predictive 
for a specific disease as randomly chosen genes 55. To prevent detection of 
non-specific genes, we conducted in-depth genome wide analysis to 
specifically detect gene clusters predictive for disease state. Differential 
expression analysis unveiled, in contrast to our flow cytometry data, subsets of 
genes to be up- or downregulated in unstable angina pectoris patients 
compared to stable angina pectoris patients after correction for the healthy 
controls, demonstrating that transcriptomic differences, though subtle, do 
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exist between the patient populations. Pathway analysis indicated chemokine 
and cytokine pathways, as well as pathways related to infection and 
inflammation to be inhibited in UAP patients. This confirmed the notion that 
local ischemia and/or unstable atherosclerosis, and their resulting signals can 
impact circulating monocyte functions such as chemotaxis. The initially 
unexpected inhibition of chemokine – chemokine receptor interaction in UAP 
patients may also explain the elevated monocyte levels in this group compared 
to SAP patients, as the most response monocytes in UAP patients might be 
recruited to the site of injury, in this case the atherosclerotic lesion. 
In conclusion, we were able to show that circulating cells do harbor 
hallmarks of local atherosclerotic disease, as UAP monocytes showed subtle 
transcriptomics differences on e.g. chemokine and cytokine receptor 
regulation compared to SAP monocytes. However, the detected effects are too 
small to justify circulating monocyte transcriptomics for biomarker derivation. 
Additional research is necessary to investigate the best approach to amplify or 
detect the subtle genomic or even downstream proteomic differences 
between SAP and UAP in a bed-side setting.  
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Supplemental data 
 
Supplemental table 1 - Antibodies for flow cytometry 
 
Antibody Company Dilution 
CD14 PC7 BD Biosciences 1:10 
CD16 PC5 BD Biosciences 1:10 
CCR2 PE BD Biosciences 1:5 
CX3CR1 FITC BD Biosciences 1:5 
CD3 ECD BD Biosciences 1:10 
CD4 PE-Cy7 BD Biosciences 1:10 
CD8 FITC BD Biosciences 1:5 
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Main findings in perspective 
The role of the monocyte/macrophage lineage has already been considered 
detrimental in atherosclerosis development for many years. Especially plaque 
macrophages have been studied extensively in relation to pathogenesis 1. 
Thereby, the focus was not only on unraveling processes involved, but also on 
the determination of biomarkers for diagnosis and prognosis of cardiovascular 
disease (CVD) in general 2,3. Over the last years, research has shifted its focus 
from plaque macrophages to circulating monocytes in relation to 
atherogenesis. In fact, it is acknowledged nowadays that these circulating 
monocytes might be as important for disease as the macrophages present in 
the atherosclerotic plaques 4-7. Nevertheless, many functional aspects of 
circulating monocytes are not yet elucidated completely, e.g. the functional 
effects of hypercholesterolemia on circulating monocytes. Furthermore, these 
cells might yield so far unknown potential as biomarker, due to their 
monitoring capabilities of the vasculature. 
This thesis focused on the role of circulating monocytes in 
atherosclerosis, and the question whether these cells exert effects locally in 
the lesion or systemically in the periphery. We set out to assess the effects of 
(I) depleting monocytes/macrophages from the circulation and lesion, as well 
as (II) the role of migration of circulating myeloid cells in relation to 
atherogenesis. Further, we studied (III) the functional effects of 
hypercholesterolemia on monocytes, and (IV) set out to gain more insight in 
the potential of circulating monocytes as biomarker for cardiovascular disease.  
The main findings of this thesis are: 
 
1. Depletion of both CD115+ circulating monocytes and intimal 
macrophages attenuates plaque progression (Chapter 2) 
2. Increased monocyte chemotaxis towards the lesion, and thus 
augmented intimal macrophage numbers, reduces atherogenesis 
(Chapter 3)  
3. Hypercholesterolemia induces excessive cholesterol accumulation and 
functional changes in circulating monocytes (Chapter 4) 
4. Activated circulating monocytes harbor potential as (diagnostic and 
imaging) biomarkers in human atherosclerotic vessel disease (Chapter 
5 and 6) 
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The effects of monocyte influx on plaque progression 
In Chapter 2, we investigated the effects of depleting both plaque-resident and 
systemic myeloid cells on atherosclerosis development. Here, a clear role for 
both plaque macrophages and circulating monocytes could be deduced from 
our results. In the first study we assessed the impact of whole body CD115+ 
leukocyte ablation, as CD115 (or M-CSF receptor) is essential to 
monocyte/macrophage development. In contrast to our expectations, no 
effects on plaque development could be observed, which was only in part 
comparable to other studies on monocyte/macrophage ablation as reviewed 
by Croons et al 8. These studies used genetic approaches in which human 
diphtheria toxin receptor (hDTR) expression was controlled by the myeloid 
specific promotor CD11b 9,10, pharmacological ablation using clodronate 
liposomes 11,12, and several other approaches. Even though the approaches 
differ substantially, the level of depletion of myeloid cells achieved in our study 
was at least comparable to these studies. 
The difference between earlier studies and the study we performed 
was the combination of local apoptosis of plaque macrophages combined with 
systemic apoptosis of monocytes and granulocytes, but also osteoclasts. Calin 
et al already reported that depletion of monocytes and macrophages can act 
as a two-edged sword 12. On the one hand, depletion of the 
monocyte/macrophage reduces the proteolytic and pro-inflammatory signals 
in the lesion. On the other hand, secondary necrosis accompanied by the 
release of cellular cholesterol and lipid deposits into the lesion contributes to 
plaque progression. Indeed, Döring and Soehnlein et al reported that 
interferon regulatory factor (IRF) 8 deficiency affects monocyte/macrophage 
function, resulting in defective intracellular lipid accumulation and disturbed 
efferocytosis. In combination with increased lesional neutrophil influx this led 
to accelerated atherosclerosis 13.  
Unexpectedly, CD115+ leukocyte ablation affected hematopoiesis in 
which osteoclasts and bone marrow macrophages were depleted. This ablation 
resulted in uncontrolled release of immature leukocytes and progenitor cells 
from the bone marrow, as macrophages and osteoclasts are important 
regulators of hematopoiesis 14-16. This contributed to the extramedullar 
myelopoiesis and monocytosis, in particular in spleen. Colony forming unit 
assays confirmed a shift in hematopoiesis from bone marrow to spleen. 
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Overall, not only plaque monocytes/macrophages, but also peripheral ablation 
of CD115+ cells affected atherogenesis. 
 Furthermore, local induction of apoptosis in the atherosclerotic lesion 
resulted in plaque progression rather than attenuation of plaque development. 
Also here an important role for circulating monocytes could explain for the 
effects observed. Massive intimal macrophage apoptosis will lead to the build-
up of inefficiently cleared apoptotic cellular debris 17. Ineffective efferocytosis 
indeed was shown to result in secondary necrosis and increased necrotic core 
formation, which has major implications for atherosclerotic plaque progression 
17-19. Consequently, a more pro-inflammatory, rather than anti-inflammatory 
milieu will develop resulting in the attraction of monocytes from the blood and 
enhanced plaque development 20. In conclusion, our study identified an 
important contribution of CD115+ myeloid cells outside the atherosclerotic 
plaque affecting lesion progression. Nevertheless, localized modulation of 
monocytes/macrophages in the lesion could potentially be a valid target for 
therapeutic intervention as circulating monocytes do affect atherogenesis. 
 
Next to ablation of monocytes/macrophages, the role of chemokine receptor 
desensitization was investigated in Chapter 3. In this study, we addressed the 
effects of hematopoietic GRK2 deficiency in atherosclerosis. GRK2 is a receptor 
kinase mediating desensitization and receptor recycling of G-protein coupled 
receptors for monocyte function and chemotaxis, such as CCR2 and CCR5 21,22. 
Inhibited desensitization of chemokine receptors in monocytes resulted in 
expanded plaque macrophage content, but decreased plaque size. Chemokine 
receptor signaling is a central process in atherogenesis 23, but also in 
hematopoiesis, in particular for regulating stromal release of mature 
monocytes 24. Indeed, inhibition of the CCL2, CX3CR1, or the CCL5/CCR5 axis 
results in dramatically reduced atherogenesis, indicative of the importance of 
both the chemokine receptor and ligands 25. Besides involvement of GRK2 in 
chemokine receptor desensitization, the GRK2 interactome has been extended 
to endocytic proteins, but also non-receptor targets, e.g. growth arrest specific 
(Gas) 8 ref 26. GRK2 dysfunction is involved in several diseases, including 
cardiovascular pathologies (e.g. heart failure) 27 and chronic inflammatory 
disease (e.g. rheumatoid arthritis) 28. From the target receptors in combination 
with diseases with comparable pathogenesis, we deduced that GRK2 may also 
play an important role in atherosclerosis. 
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 Hematopoietic GRK2 deficiency led to enhanced monocyte migration, 
but attenuated plaque development. The role of circulating monocytes was 
inferred by excluding granulocytes and macrophages being responsible for the 
plaque phenotype. GRK2 deficiency resulted in increased proliferation as well 
as monocyte migration. Overall, increased monocyte chemotaxis resulted in 
plaque attenuation, most likely due to more efficient efferocytosis of apoptotic 
material, explaining the dramatic reduction in necrotic core size. These data 
show that stimulating monocyte chemotaxis towards the atherosclerotic lesion 
might be a promising target for intervention, especially in early atherosclerosis. 
Hypercholesterolemia modifies circulating monocytes and their 
function 
Next to inflammation-induced recruitment of monocytes towards the 
atherosclerotic lesion, hypercholesterolemia is the second hallmark of, and risk 
factor for, atherosclerosis 29. Despite, the well-known association between 
hypercholesterolemia, especially increased LDL cholesterol levels, and the risk 
for cardiovascular disease, still little is known about the impact of 
hypercholesterolemia on circulating monocytes in the context of early 
atherosclerosis development. Most research focuses on the effects of long 
term (> 10 weeks) hypercholesterolemia on monocytes 30,31. In our study we 
analyzed the short term (< 3 weeks) effects on monocyte function upon 
Western type diet feeding and subsequent hypercholesterolemia.  
 In Chapter 4 we analyzed the early effects of diet-induced 
hypercholesterolemia on circulating monocyte subsets. Interestingly, and in 
contrast to the current paradigm, cholesterol does not only accumulate in 
plaque macrophages, but is also engulfed by circulating and splenic 
monocytes. Despite earlier observations of this phenomenon in murine and 
human monocytes by Mosig et al 32,33 and Tolani et al 34 the functional 
implications of this intracellular lipoprotein accumulation and its consequences 
for atherosclerosis development are not recognized completely. 
 Traditionally, LDL cholesterol is thought to preferentially accumulate in 
the arterial intima at places with reduced shear stress 35. This process is 
followed by the influx of monocytes/macrophages, which scavenge the 
subendothelial oxLDL. We could now show that next to the cholesterol 
accumulation, monocyte-endothelial cell interaction is also enhanced in 
animals with increased cholesterol levels. As this increment was only present 
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after activation of the endothelium by LPS stimulation, it is believed to reflect 
an intrinsically increased adhesive capacity of lipid-laden monocytes and this 
increased recruitment of monocytes to inflammatory vascular loci (e.g. 
atherosclerotic lesions). Nevertheless, hypercholesterolemia leads to 
endothelial cell dysfunction 36, potentially contributing to increased monocyte 
rolling and adhesion. Our findings thus point out that cholesterol might also 
enter the atherosclerotic lesion via migration of lipid-laden circulating 
monocytes into the atherosclerotic lesion.  
Intriguingly, our data indicate that hypercholesterolemia leads to a 
rapid monocytosis response, as well as an increase in plasma levels of pro-
inflammatory cytokines within days after introduction of WTD. However, after 
three weeks of WTD plasma levels for the majority of cytokines appeared to 
normalize at least in part, suggesting that sustained hypercholesterolemia does 
not lead to prolonged hyper-inflammatory status. This indicates that 
hyperinflammation represents an early adaptive response to new metabolic 
conditions. In human disease, postprandial cholesterol and lipid levels are 
associated with cardiovascular events 37,38. As we did not measure time points 
beyond three weeks or included reversal of diet to normal chow until now, it is 
still unclear to what extend cellular and systemic inflammatory and metabolic 
pathways affect systemic, or possibly local, inflammatory processes involved in 
early atherogenesis. Furthermore, the effects of these interventions on the 
regulation of cytokine levels in persistent hypercholesterolemia are to be 
determined. Recent evidence suggests that even mild reduction in cholesterol 
levels of hypercholesterolemic subjects can reduce plasma cytokine levels back 
to normal 39. Nevertheless, more research on the interaction between 
cholesterol and cytokine levels is necessary to unravel the exact pathways and 
cell types responsible. 
  
  
 
A9R6637.tmp   174 15-9-2013   19:30:58
General Discussion 
________________________________________________________________ 
175 
Circulating monocytes as biomarker for cardiovascular disease 
Monocytes and monocyte-derived proteins are still underrepresented amongst 
biomarkers for disease and this holds in particular for CVD, despite the critical 
roles exerted by this subset in its pathology, as we have shown in our murine 
atherosclerosis studies. As indicated in the introduction only a limited number 
of monocyte-derived biomarkers have been suggested thus far, such as CD163 
and IL-6 secreted by peripheral blood mononuclear cells 40,41. Besides these 
secreted proteins, non-secreted membrane markers also have been proposed 
to have diagnostic value, e.g. monocyte HLA-DR expression in acute liver 
failure 42 and sialic acid-binding Ig-like lectin 1 (Siglec-1) and Fcγ receptor I 
(CD64) expression in systemic lupus erythromatosus 43,44. However, for 
cardiovascular disease, hardly any monocyte biomarkers have been described, 
apart from plakoglobin 45. As monocytes play a critical role in the development 
of atherosclerosis and also have a patrolling function of the vasculature, they 
conceivably represent a rich and important source of diagnostic markers of 
disease status and prospect which legitimates more in depth searches for 
monocyte-derived biomarkers. In this thesis, we show that both on protein 
level (Chapter 5) and RNA level (Chapter 6) activated monocytes are 
encouraging sources of novel biomarkers for cardiovascular disease. 
 In Chapter 5 a whole cell phage display approach was applied for the 
discovery of novel membrane bound biomarkers on circulating monocytes 
from unstable angina pectoris patients. Although whole cell phage display is 
not a standardized technique, it has already been successfully applied for 
biomarker discovery 46, especially in cancer research, where small tumor 
specimens were used as target 47-50. However, also cell lines 51 and isolated 
platelets 52 have been considered as scaffold for phage display selections. 
Here, we applied whole cell phage display selection on LPS-activated THP-1 
monocytes and validated the markers found on isolated CD14+ monocytes 
from unstable angina pectoris patients. To favor selection of relevant clones, 
we incorporated a depletion step using monocytes from healthy volunteers. 
Despite limited enrichment for clones binding UAP monocytes, monocyte-
based selections were proved to be efficient as we identified two clones with 
increased affinity for UAP monocytes. In addition, these clones showed their 
value for imaging, since they specifically bound monocytes in advanced, 
vulnerable atherosclerotic lesions, but not early lesions. Overall, from our 
study, monocytes emerge as a promising target for antibody discovery, in spite 
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the large variety in surface proteins expressed on these cells. Our study also 
implies that circulating monocytes indeed can reflect local vascular processes 
such as atherosclerosis. 
 Inspired by these promising findings, we zoomed in on differences in 
RNA expression profiles between SAP, UAP, and healthy control CD14+ 
monocytes in Chapter 6. Surprisingly, we could not detect any major 
differences between the study populations based on micro-array analysis. This 
is surprising as several groups have previously identified UAP-specific markers 
53-55, albeit that none of these markers were cell-bound markers. These data 
suggest that secretome, rather than transcriptome, difference are present 
between patient populations. Still, Patel et al revealed that monocyte-platelet 
complexes did also not differ between SAP and UAP patients 56 and differential 
expression of membrane receptors was also shown for UAP 57,58. Even though 
our results did not show major differences in the transcriptome of UAP versus 
SAP monocytes, we are the first to investigate mRNA expression profiles of 
monocytes from SAP and UAP patients in a large patient cohort. In contrast to 
previous publications, we have studied differences in circulating CD14+ 
monocytes in a patient cohort without any known cardiovascular disease, 
whereas others have studied total peripheral blood mononuclear cells 59, 
specific patient populations (e.g. systemic lupus erythromatous patients 57), or 
plaque macrophages 60. Taken together, our study primarily focused on the 
discovery of diagnostic markers for discrimination between SAP and UAP 
patients, based on peripheral blood monocytes. 
 
Interestingly, our studies on the proteome (chapter 5) and 
transciptome (chapter 6) do not accord completely. On the protein level we 
were able to identify altered surface expression on UAP monocytes compared 
to control monocytes using phage display. However, our phage display 
approach used LPS-activated THP-1 monocytes for target discovery and UAP 
monocytes for validation. This approach might have boosted the 
discrimination power of our phage display analysis. Nevertheless, LPS is a 
strong stimulus for TLR-signaling, which is not specific to UAP, but also is linked 
to various infectious and non-infectious diseases 61. Preliminary data on micro-
array analysis from LPS-activated SAP monocytes with and without a CVD 
event during follow-up indicates that differences are present between the two 
study populations. However, the observation of differences within the 
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population of SAP patients might also point to heterogeneity of SAP and UAP 
patients, contributing to the lack of separation between SAP and UAP patient 
monocyte transcriptomes. Still, the above suggests that activation potential, 
rather than basal expression levels, of UAP monocytes might be different from 
SAP monocytes. Indeed, first analysis of LPS activated monocytes from patients 
with event during follow-up compared to event-free controls, revealed an 
extensive list of differentially expressed genes. More in depth research on SAP 
and UAP patient monocytes using a broad ‘omics’ approach should reveal 
novel UAP specific monocytic biomarkers useful for imaging, diagnosis, and 
potentially even risk prediction. 
 
 
 
Figure 1 - Overview of the role of circulating monocytes in atherosclerosis 
Circulating monocytes contribute to atherosclerosis development at different levels. In Chapter 
2 we showed the role of circulating monocytes in combination with plaque macrophages in 
regulating plaque progression, by induction of CD115+ cell apoptosis. Regulation of circulating 
monocyte chemotaxis via GRK2 towards the atherosclerotic lesion was discussed in Chapter 3. 
Interaction of circulating monocytes with cholesterol and the atherosclerotic lesion as well as 
the effects thereof on proteome and transcriptome biomarkers were discussed in Chapter 4 and 
Chapters 5 and 6, respectively.  
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Concluding Remarks and Future Perspectives 
The role of circulating monocytes in atherosclerosis was investigated in this 
thesis. We were able to show that monocyte migration as well as 
monocyte/macrophage apoptosis are indeed essential processes in 
atherogenesis. Next, hypercholesterolemia was proven to influence circulating 
monocyte function rapidly after onset hypercholesterolemia. Finally, we have 
explored circulating monocytes as a novel target for current, but also future 
biomarker research. Here, we identified activated monocytes as a potential 
marker for diagnosis and imaging of patients at risk for CVD, both on protein 
and RNA level. Taken together, monocytes not only appear to play a central 
role in regulating plaque progression, but are also useful biomarkers for 
diagnosis, imaging, and possibly even prognosis of cardiovascular disease. 
 Circulating monocytes are thus central actors in atherogenesis. We 
were able to identify these cells not only being essential for plaque initiation 
and progression, but also pinpoint novel opportunities for CVD biomarkers. 
Nevertheless, additional research on activation potential of monocytes will 
contribute to both unraveling mechanism involved in monocyte function and 
additional information on current and future disease and risk for 
cardiovascular events, such as myocardial infarction and stroke. Future 
research will need to focus on more in depth knowledge regarding the 
translation from local information in the atherosclerotic lesion to the 
circulating monocytes, to determine additional markers for diagnosis, risk 
prediction, and imaging. Further, screening methods which can reliably and 
successfully identify these subtle yet important differences need to be 
optimized facilitating minimally invasive and rapid measurements of these 
circulatory biomarkers. 
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Circulating monocytes in atherosclerosis: Local or systemic actors? 
The central question of this thesis was whether circulating monocytes only 
impact atherosclerosis at a local level or also systemically. Our data indicate 
that indeed both peripheral and local monocyte functions are relevant for 
atherosclerosis development. Locally, monocyte chemotaxis and 
monocyte/macrophage ablation influence plaque development as we have 
shown. Lipid-loading of circulating monocytes not only could contribute to 
cholesterol accumulation in the lesions, but also alter monocyte function 
systemically. Nevertheless, influencing monocytes systemically will not only 
affect plaque development, but also monocyte functionality (e.g. patrolling 
behavior). In the end circulating monocytes have the potential to be used as 
novel biomarker for CVD, as we have shown in this thesis, indicating the link 
between local vascular pathology and systemic effects on monocytes. 
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Cardiovascular diseases are still one of the leading causes of death in the 
Western societies and account for over 17 million deaths world-wide annually. 
Atherosclerosis is the predominant underlying pathology responsible for 
various cardiovascular diseases.  
Atherosclerosis is characterized by the accumulation of low density 
lipoprotein (LDL) cholesterol in the intima of arteries. Oxidation of intimal 
cholesterol will result in activation of the vessel wall and will trigger a pro-
inflammatory cascade. Due to the release of chemokines and upregulation of 
integrins on the endothelial cells covering the early lesion leukocytes will be 
attracted in an effort to resolve the immune response and remove the 
cholesterol. In the first stage, predominantly monocytes will migrate into the 
early atherosclerotic lesion, and give rise to plaque macrophages which will 
sequester the local oxidized cholesterol. Excessive intra-cellular cholesterol 
accumulation combined with ineffective excretion results cholesterol filled 
foamy macrophages also known as foam cells. Apoptosis of foam cells 
combined with ineffective clearance of apoptotic cells, will result in buildup of 
cell debris and (oxidized) cholesterol in the lesion, forming a lipid-rich, necrotic 
core, covered by a fibrous cap of smooth muscle cells and collagen. 
Destabilization of the fibrous cap by proteases secreted by macrophages and 
other inflammatory cells in the lesion, can eventually result in plaque rupture, 
exposing the pro-thrombotic content of the lesion to the circulation, 
potentially resulting in clinical complications, such as myocardial infarction and 
stroke. 
Monocytes and plaque macrophages are instrumental in the 
development of atherosclerosis, from initial early until advanced vulnerable 
lesion. The role of circulating monocytes in relation to atherosclerosis 
development is not completely elucidated, despite the importance of these 
subsets in the development of the disease. Therefore, this thesis investigated 
the role of circulating monocytes in atherosclerosis, to determine (I) whether 
apart from plaque residing monocytic cell pools, the peripheral monocytes are 
able to impact disease onset and progression, and (II) whether these cells have 
potential as biomarker for cardiovascular disease in humans. 
The function of circulating monocytes as well as plaque macrophages 
can be studied by specific depletion of these cell types. In Chapter 2, we 
studied the impact of systemic versus plaque-targeted ablation of myeloid cells 
on atherosclerosis in ApoE-/- mice, bearing a Macrophage FAS Induced 
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Apoptosis (MaFIA) suicide gene. Local ablation of CD115 positive plaque 
macrophages aggravated atherosclerosis, as both necrotic core and plaque size 
were expanded significantly by promoting either clonal expansion of plaque 
macrophages or monocyte influx. In contrast, systemic ablation of CD115 
positive myeloid cells did not result in changes in plaque burden but promoted 
a more vulnerable plaque phenotype. Interestingly, it was associated with 
enhanced extramedullar hematopoiesis and mobilization of immature myeloid 
cells into the circulation. Our data suggest that the augmented extra-medullar 
myelopoiesis and the increased mobilization of immature myeloid cells into 
the circulation, upon systemic induction of monocyte/macrophage apoptosis 
may have underlain the observed increase in plaque vulnerability.  
As migration of leukocytes towards the lesion is a key process in 
atherogenesis, we describe, in Chapter 3, the role of chemotaxis regulation on 
atherosclerosis development. Chemokine receptors are G protein-coupled 
receptors (GPCR) and are responsible for the directional migration of cells 
along a chemokine gradient. The activity of GPCRs is controlled by receptor 
kinases, such as GRK2. We here studied the effect of partial hematopoietic 
GRK2 deficiency on atherosclerosis development in LDL receptor knock-out 
mice. Hematopoietic GRK2+/- deficiency resulted in marked attenuation of 
plaque development. To exclude that macrophage and granulocyte GRK2 was 
responsible for the effects observed, we used a LysM-cre GRK2flox/flox 
conditional knock-out model which results in macrophage and granulocyte 
specific GRK2 deficiency. As atherosclerosis development was not affected in 
this model, we concluded that monocytes were most likely responsible for the 
phenotype observed in the GRK2+/- study and that even partial GRK2 deficiency 
already was able to prevent atherosclerotic lesion development beyond the 
fatty streak stage. 
Next to inflammation, hypercholesterolemia is one of the key 
processes in atherosclerosis development and a well-known risk factor for 
cardiovascular disease, and evidence is culminating that both actors are tightly 
associated. In Chapter 4, we analyzed the interaction between plasma 
cholesterol and circulating monocytes in LDL receptor deficient mice to unravel 
the effects of hypercholesterolemia on monocyte function and numbers in 
early atherosclerosis. We could not only show that under hyperlipidemic 
conditions, circulating monocytes carry lipoprotein depositions already before 
entering the lesion, and were able to link this to alterations in monocyte 
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function. In fact, cholesterol-laden monocytes exhibited increased reactive 
oxygen species production and rolling along and adhesion to activated 
endothelium. Combined with the inflammatory cytokine profile observed in 
these animals, hypercholesterolemia was shown to affect circulating 
monocytes already in very early phases of atherosclerosis development and 
might reveal novel pathways contributing to intimal cholesterol accumulation. 
As circulating monocyte subsets have a patrolling function in the 
vasculature we studied the biomarker potential of human circulating 
monocytes. We analyzed the clinical perspective of using circulating 
monocytes for disease detection, as well as therapy, both on a proteome and 
transcriptome level.  
In Chapter 5, we identified at least two markers which may yield 
potential as diagnostic biomarker in unstable angina pectoris, as well as in 
molecular imaging approaches. Phage display affinity selections were 
performed on activated THP-1 monocytes to identify clones of interest. 
Subsequently, these selected clones were validated on CD14 positive 
monocytes isolated from healthy controls and unstable angina pectoris 
patients, as well as on early stable and advanced vulnerable plaque tissue, 
identifying at least two clones with high specificity. 
In Chapter 6, we analyzed the transcriptome of monocytes isolated 
from stable and unstable angina pectoris patients to identify biomarkers 
specific for unstable angina pectoris. The patient populations did not differ in 
terms of monocyte markers or chemokine receptor expression as determined 
by flow cytometry. Surprisingly, we could also not detect any major differences 
in the transcriptome of these monocytes between stable and unstable angina 
pectoris, despite major differences in clinical parameters, and as reported 
plasma cytokine patterns. These data indicate that at baseline mild acute 
cardiovascular syndromes such as unstable angina pectoris do not impact the 
transcriptome of circulating monocytes.  
Finally, in Chapter 7 the findings presented in this thesis are discussed 
and future perspectives are indicated. In conclusion, we were able to confirm 
that monocytes play an important role in atherosclerotic lesion development. 
Monocyte migration towards the lesion as well as numbers and function of 
plaque macrophages were shown to be critical in atherogenesis, but also the 
interaction between plasma cholesterol and circulating monocytes was 
identified to have importance in disease development. Furthermore, 
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circulating monocytes convey information from local sites, such as 
atherosclerotic plaques, to the periphery. Indeed, we were able to show that 
circulating monocytes harbor potential as diagnostic biomarker for at least 
some cardiovascular pathologies. Future research will need to focus on 
identification of specific targets as well as on investigation of the prospective 
of activation potential of circulating monocytes in relation to biomarker 
discovery. 
 
 
A9R6637.tmp   191 15-9-2013   19:31:00
A9R6637.tmp   192 15-9-2013   19:31:00
[Geef tekst op] 
 
 
Vereenvoudigde 
Nederlandse Samenvatting 
 
A9R6637.tmp   193 15-9-2013   19:31:00
 
________________________________________________________________ 
194 
Hart- en vaatziekten zijn nog altijd een van de meest voorkomende 
doodsoorzaken in de Westerse landen en zijn verantwoordelijk voor meer dan 
17 miljoen doden per jaar wereldwijd. Aderverkalking, ook wel atherosclerose 
genoemd, is één van de belangrijkste onderliggende oorzaken 
verantwoordelijk voor de gevolgen van hart- en vaatziekten, zoals hersen- en 
hartinfarct. 
 Atherosclerose is een ziekte van de middelgrote en grote slagaders, 
waarbij cholesterol zich opstapelt in de vaatwand door een ontregeling van de 
cellen die de vaatwand bedekken op plaatsen waar de bloedstroom verstoord 
is, zoals bochten en vertakkingen van de vaatboom. Door de ophoping van 
cholesterol ontstaat er een ontstekingsreactie in de vaatwand die ervoor zorgt 
dat witte bloedcellen worden aangetrokken. In eerste instantie zullen vooral 
monocyten, dit is een type witte bloedcel, naar de vaatwand migreren. In de 
vaatwand zullen deze cellen zich verder ontwikkelen en vormen ze 
zogenaamde macrofagen, die het cholesterol dat aanwezig is in de vaatwand 
zullen gaan opnemen. Door de grote hoeveelheid cholesterol die zich ophoopt 
in de cellen zullen deze een schuimachtig uiterlijk krijgen, waardoor ze 
schuimcel genoemd worden. Als deze schuimcellen te veel cholesterol hebben 
opgenomen, zullen ze dood gaan en zal het opgenomen cholesterol, maar ook 
de resten van de gestorven cellen achterblijven in de vaatwand. Er ontstaat 
hierdoor uiteindelijk een cholesterol-rijke kern die middels een kapsel 
bestaande uit collageen en gladde spiercellen wordt afgescheiden van het 
bloed: de atherosclerotische plaque. Afbraak van het kapsel dat over de plaque 
ligt, kan resulteren in het scheuren van het kapsel, waardoor het pro-
trombotische materiaal in de plaque wordt blootgesteld aan het bloed en er 
een bloedstolsel zal ontstaan. Het is dit bloedstolsel dat door afsluiting van het 
bloedvat kan leiden tot zuurstofgebrek in het achterliggende weefsel, 
waardoor een hart- of herseninfarct ontstaat. 
 Monocyten in het bloed en macrofagen in de plaque zijn belangrijke 
cellen in de ontwikkeling van atherosclerose, zowel in beginnende plaques als 
ook in meer gevorderde stadia van het ziekteproces. De rol van monocyten in 
het bloed in relatie tot de ontwikkeling van atherosclerose is nog niet volledig 
opgehelderd, ondanks dat deze cellen worden gezien als een zeer belangrijk 
celtype tijdens de ontwikkeling van deze ziekte. Mijn onderzoek richtte zich op 
de rol van deze in het bloed circulerende monocyten in de ontwikkeling van 
atherosclerose, waarbij ik getracht heb om te achterhalen hoe deze cellen de 
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onderliggende processen beïnvloeden die ten grondslag liggen aan 
atherosclerose. Het uiteindelijke doel van dit onderzoek was te bepalen of 
deze cellen gebruikt kunnen worden als biomarker voor hart- en vaatziekten. 
 De functie van circulerende monocyten, maar ook macrofagen in de 
plaque, kan effectief worden bestudeerd door deze cellen te elimineren. In 
Hoofdstuk 2 hebben we aangetoond dat circulerende monocyten plaque 
ontwikkeling kunnen afremmen in een muismodel waarin bepaalde witte 
bloedcellen, zoals monocyten en macrofagen, na toediening van een 
chemische stof, verwijderd worden. Eliminatie van zowel plaque macrofagen 
alsook circulerende monocyten resulteerde niet in veranderingen in plaque 
ontwikkeling vergeleken met de controle. Wel werd er een verhoogde 
productie van witte bloedcellen (hematopoëse) waargenomen, waarbij er 
mogelijk sprake was van een toegenomen migratie van monocyten naar de 
plaque. Als alleen de plaque macrofagen werden verwijderd, resulteerde dit in 
een toename van de plaque ontwikkeling. Samenvattend hebben we kunnen 
aantonen dat plaque ontwikkeling beïnvloed kan worden door de 
beschikbaarheid van circulerende monocyten alsook de aanwezigheid van 
macrofagen in de plaque, waarbij de verstoorde productie van deze cellen een 
belangrijke rol speelt. 
 In Hoofdstuk 3 beschrijven we de rol van gerichte migratie van cellen 
naar een stimulus, en de regulatie van dit proces in atherosclerose. Chemokine 
receptoren zijn verantwoordelijk voor deze migratie van cellen en ze behoren 
tot de familie van G eiwit gekoppelde receptoren. De activiteit van deze 
receptoren wordt gereguleerd door bepaalde enzymen, zoals GRK2. We 
hebben het effect van gedeeltelijke uitschakeling van GRK2 in witte 
bloedcellen onderzocht in pro-atherogene knock-out muizen. Gedeeltelijke 
uitschakeling van GRK2 resulteerde in zeer sterke remming van atherosclerose 
ontwikkeling. Uitschakeling van dit enzym in granulocyten en macrofagen, 
naast monocyten zijn dit andere witte bloedcellen die GRK2 aanmaken, liet 
geen effect zien op de ontwikkeling van atherosclerose, wat suggereert dat 
GRK2 in (circulerende) monocyten verantwoordelijk is voor de remming van 
atherosclerose. 
 Naast ontstekingsreacties is ook een verhoogd cholesterol niveau 
betrokken bij de ontwikkeling van atherosclerose en een risicofactor voor de 
ontwikkeling van hart- en vaatziekten. In Hoofdstuk 4 hebben we de interactie 
tussen cholesterol in het bloed en circulerende monocyten onderzocht. We 
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konden aantonen dat naast het in de plaque opgehoopte cholesterol ook het 
in het bloed aanwezige cholesterol van belang is voor de ontwikkeling van 
atherosclerose, omdat dit wordt opgenomen door circulerende monocyten. 
Hierbij worden bepaalde functies van deze monocyten ook beïnvloed. 
Cholesterol-geladen monocyten produceren meer zuurstofradicalen en 
hechten nog beter dan normaal aan de ontstoken bloedvatwand. Samen met 
een verhoogde concentratie van bepaalde ontstekingsmediatoren in het bloed, 
die worden waargenomen na het volgen van een cholesterol/vetrijk dieet 
dragen deze veranderingen in de monocyten bij aan het ontstaan van 
atherosclerose. De toegenomen hechting van deze ontstekingscellen aan de 
vaatwand in combinatie met de ophoping van cholesterol in deze circulerende 
monocyten, zijn een nieuwe route waarlangs cholesterol vanuit het bloed in de 
vaatwand terecht kan komen, waardoor uiteindelijk een atherosclerotische 
plaque zal ontstaan. 
 Aangezien circulerende monocyten ook een functie hebben als 
verkenners van de bloedvaten, hebben we bestudeerd of deze cellen potentie 
hebben als marker voor hart- en vaatziekten in de mens. We hebben zowel het 
eiwit als het DNA niveau bestudeerd om deze nieuwe markers te vinden. In 
Hoofdstuk 5 hebben we minstens twee markers kunnen identificeren die 
potentie hebben als diagnostische marker voor instabiele angina, oftewel pijn 
op de borst in rust, maar daarnaast ook mogelijkheden bieden om gebruikt te 
worden bij detectiemethodes die gebruik maken van beeldtechnieken. 
Bindende antilichamen werden geselecteerd met behulp van faag display 
selecties op geactiveerde humane monocyten (de THP-1 cellijn). Bij faag 
display worden antilichamen gekoppeld aan virusdeeltjes, waarmee de 
antilichamen die binden aan de monocyten geselecteerd kunnen worden door 
deze te laten reageren met de monocyten en niet-bindende antilichamen weg 
te wassen. Hierna werden de geselecteerde antilichamen getest op hun 
capaciteit om te binden aan monocyten geïsoleerd uit patiënten met instabiele 
angina, maar ook aan monocyten in vroege en meer gevorderde 
atherosclerotische plaques. Minstens twee antilichamen bleken met hoge 
voorkeur te binden aan deze cellen en zijn mogelijk geschikt voor de diagnose 
van hart- en vaatziekten en mogelijk zelfs voor het opsporen van gevorderde 
plaques. 
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In Hoofdstuk 6 hebben we getracht om biomarkers te identificeren 
waarmee onderscheid gemaakt kan worden tussen stabiele angina (allen bij 
inspanning pijn-op-de-borst) en instabiele angina (ook tijdens rust pijn-op-de-
borst) patiënten. Allereerst hebben we gekeken of er verschillen aanwezig 
waren tussen de hoeveelheid eiwitten die aanwezig zijn op de buitenkant van 
de monocyten. We konden aantonen dat de monocyten van deze twee 
patiëntgroepen hierin niet van elkaar verschilden. Vervolgens hebben we 
gekeken naar de mate waarin informatie van het DNA door de cel gebruikt 
wordt om eiwitten te produceren en of hierin verschillen aanwezig waren 
tussen de patiëntgroepen. Tegen onze verwachtingen in konden we ook voor 
deze eigenschappen geen verschillen ontdekken tussen monocyten van 
stabiele angina patiënten en instabiele angina patiënten. Onze studie toont 
daarmee aan dat er geen grote verschillen aanwezig zijn in circulerende 
monocyten van stabiele en instabiele angina patiënten.  
 Tot slot worden in Hoofdstuk 7 de resultaten, gepresenteerd in dit 
proefschrift, bediscussieerd en worden toekomstige mogelijkheden voor 
onderzoek aangegeven. Samenvattend toont dit onderzoek aan dat 
circulerende monocyten essentieel zijn voor de ontwikkeling van 
atherosclerose. We hebben kunnen aantonen dat de migratie van monocyten 
naar de plaque, maar ook de hoeveelheid macrofagen in de plaque kritieke 
processen zijn in de ontwikkeling van atherosclerose. Daarnaast tonen onze 
studies aan dat cholesterol al in de bloedsomloop de functie van de 
circulerende monocyten ongunstig beïnvloedt, een tot nu onderbelicht 
mechanisme bij het ontstaan van atherosclerose. Circulerende monocyten 
weerspiegelen de lokale situatie zoals die in de plaque is. Deze informatie kan 
gebruikt worden, zoals we hebben laten zien in hoofdstuk 5, voor de diagnose 
van hart- en vaatziekten. Toekomstig onderzoek is noodzakelijk om niet alleen 
biomarkers te identificeren waaraan de door ons ontdekte antilichamen 
binden, maar ook om de perspectieven van het gebruik van andere 
eigenschappen van de monocyten zoals hun activatiepotentieel als marker 
voor hart- en vaatziekten in kaart te brengen. 
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Na ruim 4 jaar werken en het schrijven van ongeveer 75.000 woorden in deze 
thesis, zijn dit voor veel van jullie waarschijnlijk de eerste woorden die je leest. 
Het is en blijft een apart idee dat iedereen het meest geïnteresseerd is in de 
persoonlijke verhalen aan het einde van een thesis, maar hier doe ik zelf 
eigenlijk ook altijd aan mee. 
 Het is hierbij natuurlijk van belang om te weten dat ik, net zoals iedere 
andere AIO/PhD student/promovendus veel steun heb gehad van mensen 
binnen, maar zeker ook buiten ons werkveld. Daarom wil ik deze laatste 
bladzijdes van mijn boekje dan ook wijden aan het persoonlijk bedanken van 
iedereen die me geholpen, gesteund en gemotiveerd heeft tijdens deze 
indrukwekkende en leerzame periode. 
 
Professor Dr. Biessen, beste Erik, alweer meer dan 5 jaar geleden kwamen we 
voor het eerst met elkaar in contact. Na een tip van Timo, solliciteerde ik 
binnen jouw onderzoeksgroep naar een positie als PhD student. Het werd je al 
snel duidelijk dat ik een andere weg had bewandeld dan menig andere 
kandidaat, maar gelukkig zag je toch dat ik voldoende potentie en motivatie 
had. Vanwege mijn forensische achtergrond zou ik eerst een proefperiode 
krijgen, maar al snel zagen we beiden in dat het een goede keuze was. Nu ruim 
4 jaar na mijn eerste werkzaamheden binnen de EVP, is mijn thesis klaar. Ik 
ben je dan ook enorm dankbaar voor je vertrouwen, stortvloed aan (soms 
waanzinnige) ideeën en interessante gesprekken. Ik zal ook zeker nooit het 
schoen-incident in Chicago vergeten of ons etentje daar bij Weber grill! 
Daarnaast heb ik zowel mijn eerste als laatste officiële werkdag gebruik mogen 
maken van jouw kantoor, wat toch wel bijzonder is. Hoewel ik inmiddels de 
academische wereld verlaten heb, weet ik zeker dat alles wat ik hier geleerd 
heb me zeker verder zal helpen in de toekomst. En helemaal klaar ben je in de 
wetenschappelijke wereld natuurlijk nooit, aangezien we zeker nog enkele 
manuscripten gepubliceerd willen krijgen! Nogmaals dank voor alles in de 
afgelopen jaren en we zullen elkaar ongetwijfeld nog vaak genoeg 
tegenkomen. 
 
Hoewel ik geen officiële co-promotor heb gehad tijdens mijn promotie, heb ik 
wel van één iemand in het bijzonder zeer veel steun en vriendschap mogen 
ontvangen, hè opper-paranimf! Beste Timo (of moet ik zeggen TimoPedia) jij 
bent een van de redenen geweest waardoor ik in deze helse wereld ben 
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beland die men ook wel “research” noemt. En ik moet zeggen, ik heb er geen 
moment spijt van gehad. Aangezien we het grootste gedeelte van de afgelopen 
4 jaar op dezelfde kamer hebben doorgebracht, is onze vriendschap alleen 
maar hechter geworden, en de 7-jaar regel hebben we duidelijk gebroken. 
Zoals je ook al in een van je stellingen omschreef: “I never did give anybody 
hell. I just told the truth and they thought it was hell.” Ik weet zeker dat 
genoeg mensen die met ons samen een kamer hebben gedeeld, dit zeker 
beamen. Daarbij hebben we enkele keren samen een congres bezocht, waarbij 
Denemarken wel één van de mooiste congressen, lees: uitstapjes ;-) was. 
Helaas, zullen onze professionele werelden zich vanaf nu enigszins scheiden, 
maar ik weet zeker dat we in de toekomst nog vele dingen samen zullen 
beleven. Ik wens je veel succes met je weg naar Professor Timo, die je 
waarschijnlijk eerst naar het Hoge Noorden zal leiden, maar ik ben ervan 
overtuigd dat de toekomst je toch wel weer een keer naar het Zuiden terug zal 
brengen en anders weet ik je in mijn nieuwe functie ook wel weer te vinden!  
 
Beste Stephan, we kennen elkaar al bijna 30 jaar en hoewel je niet uit het 
wetenschapswereldje komt, heb je het aangedurfd om mij als paranimf te 
ondersteunen, waar ik heel erg blij mee ben. We hebben in de lange tijd die we 
elkaar kennen zeer veel samen meegemaakt, in ieder geval veel te veel om 
zelfs maar in het kort hier neer te schrijven. Wel weet ik zeker dat ik op jou kan 
terugvallen, en dat is iets wat voor mij heel belangrijk is. Binnen de Ealènjers 
vormen we de laatste jaren ook al een mooi team binnen het bestuur, en 
drinken we allebei graag een pilsje. Je beland dankzij mij nu even in een 
wonderbaarlijke wereld, maar met ons carnavalsverleden zijn we natuurlijk 
heel wat gewend! Ik wens jou en Britta een hele mooie toekomst samen toe 
en kijk uit naar de volgende 30 jaar en alles wat die tijd ons zal brengen. 
 
Binnen de EVP zijn er natuurlijk nog veel meer mensen die ik moet, maar 
vooral ook wil bedanken.  
Ow FACS-koning…;-) Beste Erwin, jij was een van de personen binnen 
de afdeling die al wist wie ik was voordat ik ook maar was begonnen. Via alle 
kanalen die er zijn met het Orbis werd er veel informatie uitgewisseld, 
waardoor mijn komst al was aangekondigd. De afgelopen jaren hebben we 
extreem veel uren samen gebrainstormd over alles wat maar met FACS (of wat 
dan ook) te maken had. Hoewel ik denk dat ik je zeker ook wel één of twee 
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dingen heb kunnen leren, heb ik vooral ongelooflijk veel van jou geleerd. 
Uiteindelijk zijn we zelfs nog samen op vakantie geweest met Orbis naar 
Oostenrijk en voor het werk naar Zwitserland, waarbij we tussendoor zelfs nog 
een congres hebben bezocht. Ik weet zeker dat de monocyte-studie nog tot 
een mooie publicatie zal leiden. Voor de toekomst hoop ik dat we nog veel ski-
tripjes kunnen maken, waarbij je wellicht in de toekomst iets minder lang op 
mij hoeft te wachten… Veel geluk gewenst voor de toekomst samen met Linda! 
 
Beste Mat, hartelijk dank voor al je hulp met het ML-1 werk. Je was de 
afgelopen 4 jaar voor mij iemand op wie ik altijd kon rekenen als ik iets wilde 
weten over faag display, maar ook PCR en celkweek behoorden tot jouw 
kennisgebied. We zijn ook nog een paar keer naar Dortmund geweest om 
treintjes te bekijken, want dat is toch een mooie hobby die we delen. Ik hoop 
dat je binnenkort een kamer in huis mag gaan gebruiken om ook je eigen spoor 
weer te kunnen opbouwen. Ik reserveer in ieder geval voor komend jaar het 
dagje Duitsland weer in mijn agenda! 
 
Beste Karen, we hebben ongeveer even lang op de afdeling rondgelopen en 
zijn nu ook bijna tegelijk klaar met onze thesis. Hoewel onze onderzoeken wat 
verder uit elkaar lagen, hebben we heel vaak samen bij de muizen of in het lab 
gewerkt. Ik hoop dat de toekomst jou vol geluk toelacht, maar ik weet zeker 
dat jij goed terecht komt, zowel privé als op het werk. 
 
Lieve Lieve (sorry maar blijft leuk), ondanks dat je later dan een groot gedeelte 
van de andere mensen binnen de groep bent gekomen, denk ik dat je een van 
de personen bent die niet alleen voor top onderzoek zorgt, maar ook voor een 
hele hoop gezelligheid en plezier. Ik heb ook erg genoten van alle keren dat je 
samen met Lucas naar de borrels kwam, jong geleerd is oud gedaan, hè! Voor 
mij was verder het schminken in Aachen wel een hoogtepunt. Heel veel 
respect dat je me liet kliederen! Veel geluk voor de toekomst samen met 
Pieter, Lucas en Marieke. 
 
Lieber Anette, wir haben 4 Jahren zusammen gearbeitet und ich habe immer 
sehr viel Bewunderung gehabt für deine Engagement. Sie waren schnell bei der 
Planung und Durchführung von Experimenten, aber immer mit der höchste 
Qualität. Ich glaube das wir noch viel von dich hören würde, und das du sicher 
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im einer der top Labos der Welt arbeiten solltest. Ich hoffe das wir uns noch 
öfter sehen und vielleicht könnten wir nochmals Schifahren machen, oder am 
wenigsten ein Bier (und Jägermeister) trinken. Viel Glück und bis Bald!  
 
Beste Ine, sinds je naar de patho gekomen bent, heb je een zware tijd gehad, 
geloof ik. Je moest immers een kamer delen met onder andere Timo en mij, en 
wij zijn nu eenmaal nooit rustig hè. Wel heb je met succes deelgenomen aan 
onze cursus, waarvoor nogmaals mijn complimenten. Ik wil je ook danken voor 
alle hulp die je hebt geboden, met het uitvoeren van allerlei experimenten. 
Zelfs al was je dag drie keer volgepland, dan nog vond je altijd ruimte om een 
ander en dus ook mij te helpen. Ik hoop dat je thesis snel volgt en geloof me 
maar als ik zeg dat dit allemaal goed gaat komen. Veel succes met je verdere 
carrière en ik kom graag nog eens BBQ-en. 
 
Dear David, I still do not know which language I should choose when we are 
talking. However, most often we just stuck to English. We have spent a lot of 
time together in the lab but also in our room. And I have to say that it became 
quiet after you left, no more German swearing or loud music coming from your 
ears. Ich möchte Ihnen für die letzten Jahre bedanken und wünschen Ihnen viel 
Glück bei Ihrer nächsten Herausforderung in der Forschung. En voor een 
biertje ben ik altijd wel te bereiken! 
 
Judith, allereerst wil ik je danken voor de uitdaging die je voor me hebt 
neergelegd, om een langer dankwoord te schrijven dan Timo (hoezo Mission 
Impossible?). Ik doe in ieder geval mijn best om in de buurt te komen ;-) We 
hebben sinds je (terug)komst naar de pathologie veel samengewerkt, waarbij 
ik ook veel van je heb geleerd over wetenschap. Je bent nu ongeveer één jaar 
moeder van Sophie en ik heb het gevoel dat het je zeer goed bevalt, ondanks 
de vaak gebroken nachten. Maar ik weet dat een kleintje uiteindelijk toch het 
belangrijkste is, en ook hetgene waarvoor je aan het einde van de dag graag 
naar huis gaat. Succes met je toekomst en ik weet zeker dat we over een paar 
jaar naar jou inauguratie mogen komen. Veel plezier met zowel je 
professionele en persoonlijke leven en de toekomstige uitbreiding van je 
gezinnetje. 
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Onze kamer heeft de laatste jaren ook een behoorlijke buitenlandse invloed 
gehad. Naast de Belgische enclave, was er ook een duidelijk Duitse invloed.  
Thomas, je was de eerste AIO bij Judith en bent onze borrel-specialist. 
Zodra er iets te vieren was zorgde jij ervoor dat dit een geslaagde avond was, 
waarbij er bij voorkeur natuurlijk duits bier aanwezig was. Veel succes met je 
onderzoek hier en in Finland. 
Elke jij was de tweede Duitse invloed in onze kamer en ook jij werkte 
voor Judith. Je weet altijd heel goed wat je wilt en duikt er dan bovenop. Jouw 
inzet en motivatie zijn voor mij een echt voorbeeld. Veel succes met nog alles 
wat de komende jaren brengen. 
 
Floor, jij bent de afgelopen tijd in de kamer mijn buurvrouw geweest. Hoewel 
je veel bezig was met patientendata, statistiek en allemaal van die dingen, heb 
ik bewondering voor je doorzettingsvermogen. Ik denk dat ik allang gillend was 
weggerend. Veel succes in Amsterdam met je opleiding. 
 
Beste Sylvia, je bent de afgelopen jaren degene geweest waar ik met allerlei 
vragen terecht kon, maar vooral op het gebied van vragen omtrent de DEC en 
classificatie van plaques kon ik altijd op jou rekenen. Dank voor al je hulp en 
wijsheden. 
 
Bart, bedankt voor al je gezellige en vooral vaak ook verrassende gesprekken 
die we hebben gehad. Hoewel we vaak dachten dat je een introverte Vlaming 
was, kwamen er vaak heel onverwachte dingen uit je mond. Je positie is niet 
altijd even makkelijk, maar ik weet zeker dat je er voor gaat zorgen dat je 
promotie een groot succes gaat worden. 
 
Hoewel immuno’s en quantificeren nooit mijn favoriete bezigheid zijn geweest 
was dit toch een belangrijk onderdeel van mijn onderzoek. Jack ik wil je dan 
ook heel erg bedanken voor het schrijven en aanpassen van alle quips zodat 
deze ‘lijdensweg’ iets draaglijker werd ;-).  
 
Beste Petra, hoewel je officiële status in onze groep net iets anders was, ben je 
absoluut belangrijk geweest voor de EVP, maar ook voor mij. Als ik weer eens 
een onmogelijke bestelling had, wist ik dat je er alles aan zou doen om te 
regelen dat dit in orde kwam. Daarnaast heb ik ook erg genoten van de 
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uitstapjes, carnaval, maar ook onze wandelingen naar het station als we allebei 
weer eens naar de trein moesten. Veel succes met je nieuwe baan en dank 
voor je hulp en gezelligheid. 
 
Beste Anique, je hebt me leren snijden en immuno’s leren uitvoeren, en 
hoewel het nog altijd geen hobby is, zie ik er wel de meerwaarde van in. 
Hartelijk dank voor al je hulp en de gezellige gesprekken. 
 
Clairy, geregeld stond ik weer eens naast je voor een speciale kleuring, zoals 
een Movat. Dank voor deze mooie kleuringen die zeker hebben bijgedragen 
aan alle kleur in mijn thesis.   
 
Danielle, Ingrid, Audrey, ook jullie hulp is voor mij zeer belangrijk geweest de 
afgelopen jaren. Danielle, als er ook maar iets geregeld moest worden of het 
nu een vlucht naar een congres was of een afspraak met Erik, jij zorgde dat het 
snel en efficiënt geregeld werd. Hoewel er soms enige chaos was met agenda’s 
en afspraken die Erik verschoof, kwam dankzij jou alles uiteindelijk toch weer 
in orde. 
 
Marco, I have to admit that, despite numerous meetings on your research (Bio-
informatics), most of it is still not completely clear to me. Nevertheless, I can 
see the additive value of your analyses in many projects and I would like to 
thank you for your help and also in sharing our frustration we often 
experienced with some projects ;-) 
 
Beste, Marjo, Marion, Emiel, hoewel jullie nog altijd bij MolGen jullie plekje 
hebben zijn jullie ook zeker onderdeel van ons EVP-clubje. Marjo dank voor je 
hulp met onder andere de LysM dieren. Emiel, voor mij ben jij degene die mijn 
macrofaag vragen kon beantwoorden, dank hiervoor. Beste Marion, zowel 
voor mijn studies maar ook als er iets was met muizen, ik kon altijd met mijn 
vragen bij jou terecht. Heel erg bedankt hiervoor het heeft me veel geleerd 
over de pathologie. 
 
Dear Anjana, thank you for your input also when I was applying for a new job 
and all the best in research.  
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Jasper, we hebben kort nog even een kamer gedeeld en hoewel je 3FM nog 
moet leren waarderen weet ik zeker dat jou een mooie toekomst wacht. 
 
Chiara, Pawel, and Sebastièn, I think you are a great asset to our department, 
but unfortunately we did not really have the time to work together. Good luck 
with your projects! 
 
Ook heb ik gedurende de afgelopen vier jaar een aantal studenten mogen 
begeleiden tijdens hun stages. Matthias, Marcel, Ivo, Luuk en Jos, bedankt voor 
jullie harde werk, maar ook gezelligheid tijdens de stages binnen diverse 
projecten en veel succes gewenst met jullie wetenschappelijke carrières.  
 
Daarnaast zijn er ook veel mensen geweest die onze afdeling inmiddels hebben 
verlaten, maar die wel een heel belangrijke bijdrage hebben geleverd aan deze 
thesis op welke manier dan ook.  
Prof. Dr. Lutgens, Beste Esther, vanaf het eerste gesprek dat ik met je voerde 
tijdens mijn sollicitatie was ik onder de indruk van hetgeen je bereikt hebt. Ik 
wil je bedanken voor alle hulp, tips, en (wetenschappelijke) gesprekken. 
 
Beste Linda, jouw vertrek naar Amsterdam was een groot verlies voor onze 
groep, niet alleen qua wetenschap, maar zeker ook voor alle gezelligheid die jij 
met je meebracht. Als muizenmeisje heb ik heel veel van je geleerd over 
muisstudies. Maar je hebt me ook geleerd hoe je moet doorgegeven als er iets 
besteld moet worden ;-) Veel geluk gewenst samen met Lauran en Ella. 
 
Beste Tom, als toekomstige Dr. Dr. (en alle andere titels die nog toegevoegd 
gaan worden), heb ik altijd bewondering gehad voor je eindeloze inzet en 
vooral de onmogelijke uren die jij hebt gewerkt. Dank voor al je hulp bij 
injecties en stamcellen. 
 
Verder wil ik Professor Mat Daemen, Indira, Bea, Veronica, Wouter, Mathijs G., 
Matthijs van G., Susanne, Brenda, Cora, Isabelle en Nadine bedanken voor 
jullie hulp en gezellige momenten gedurende de afgelopen jaren. 
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Uiteraard zijn er binnen de afdeling Pathologie nog veel meer mensen die ik wil 
bedanken voor de afgelopen jaren. Allereerst natuurlijk Professor Dr. Zur 
Hausen. Beste Axel, hartelijk dank voor uw interesse in ons cardiovasculaire 
onderzoek en voor alle mogelijkheden die u mij heeft geboden.  
 
Cor en Elly, hoewel het merendeel van jullie werk niet direct zichtbaar is, weet 
ik zeker dat zonder jullie de afdeling nooit zo goed zou kunnen functioneren. 
Dank voor jullie hulp bij de meest diverse vraagstukken. 
 
Daarnaast wil ik Manon, Veerle, Hanneke, Muriel, Edith, Peter, Kim W, Kim S, 
Kim van S, Ilse en Jürgen van de ‘Epi’s’ bedanken voor hun gezelligheid en 
interessante discussies tijdens de diverse meetings en wetenschapsdagen. 
Joep en Karen, jullie hebben veel tijd doorgebracht onder de EVP-ers toen we 
nog samen in de kleine demo zaten, maar ook tijdens de borrels en carnaval 
waren jullie er altijd bij. Ik wil jullie dan ook bedanken voor alle gesprekken 
over de meest vreemde dingen, van koffie tot blaasmuziek, en hoop ook snel 
op jullie promotie aanwezig te kunnen zijn.  
 
Also Anke, Dorit, Ruth en Shredar thank you all. And I wish you all the best with 
your research in the future.  
 
Buiten de research is er ook nog ‘de kliniek’. Ook alle mensen hier wil ik 
danken, in het bijzonder wil ik Jolanda, Guido, Kathleen, Benoit en Carine 
danken voor hun bijdrage en hulp, of gewoon gezellige gesprekken.  
 
Niet alleen binnen onze afdeling maar ook daarbuiten zijn er veel mensen die 
me hebben gesteund in de afgelopen jaren. Dear Julian, I have always admired 
your great ideas and the way you perform science, but also just the talks and e-
mails. All the best for the future, together with your family. 
 
Verder wil ik vanuit de afdeling Biochemie ook iedereen bedanken met wie ik 
de afgelopen jaren heb samengewerkt. 
Beste Leon, we hebben elkaar ontmoet tijdens de proefdiercursus en 
hierna hebben we nog vaak interessante gesprekken gevoerd en zelfs 
samengewerkt voor studies van zowel Biochemie als Pathologie. Heel erg 
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bedankt voor alle tips en handigheidjes, maar ook je bijdrage aan dit 
proefschrift. 
Verder wil ik iedereen van de groepen Interne Geneeskunde en Immunologie 
bedanken voor alle bijdrages. 
Beste Kristiaan, we hebben vooral in de laatste maanden veel 
samengewerkt. Ik wil je danken voor je directe bijdrages aan verschillende 
hoofdstukken van deze thesis en wens je veel succes met je ongetwijfeld 
succesvolle wetenschappelijke carrière. 
Beste Jozien, ik wil je heel erg bedanken voor alle hulp die je hebt 
geboden bij het FACSen en sorten.  
 
Vanuit de humane monocyten heb ik ook veel samengewerkt met Cardiologie. 
Ik wil dan ook Nynke, Fabienne, Mick en Daniel heel erg bedanken voor jullie 
hulp bij de diverse projecten. 
 
Uiteraard zijn ook de medewerkers van het CPV heel belangrijk geweest om op 
een goede manier onderzoek te kunnen uitvoeren. Ik wil alle medewerkers van 
het CPV dan ook bedanken voor al hun hulp en ondersteuning. In het bijzonder 
wil ik Clarice, Rick en Harry bedanken voor jullie hulp met de muizen, Richard 
voor je hulp als er weer eens iets geregeld moest worden (vaak ook nog op 
korte termijn), en jij er altijd voor zorgde dat alles weer in orde gemaakt werd. 
Tot slot wil ik ook Saskia, Paulien, Marianne, Nadine en Angeli nog bedanken 
voor jullie hulp op verschillende gebieden. 
 
Mijn promotie onderzoek was onderdeel van het CTMM project Circulating 
Cells en ik wil dan ook alle collega’s binnen onze werkgroep hartelijk danken. 
Matthias, ondanks dat je aan de andere kant stond en meer keek naar 
technische en mechanische eigenschappen van cellen, werkte we wel met 
dezelfde cellen. Ellen, vaak hebben we ons afgevraagd wat wij als monocyte-
mensen nu moesten binnen het project, maar ik denk dat we allebei mooie 
resultaten hebben verkregen en ook een goede bijdrage hebben kunnen 
leveren. Daarnaast wil ik Menno, Arthur, Imo, Mark, Joost, Loes, Thijs, Bert, 
Peggy, en alle andere mensen die binnen CTMM hebben gewerkt hartelijk 
danken! 
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Beste Dr. Sikkink en Dr. Van den Akker, ook jullie wil ik hartelijk danken voor de 
samenwerking bij het verzamelen van plaque materiaal, alsook alles wat ik heb 
mogen leren van alles op de OK in Sittard. Hopelijk levert de samenwerking in 
de toekomst nog vele mooie resultaten en publicaties op. 
 
Daarnaast heb ik natuurlijk de afgelopen jaren nog met vele andere mensen 
mogen samenwerken in binnen- en buitenland. 
Professor Halvorsen, dear Bente and dear Tuva thank you for the 
opportunity to work shortly in your lab to assist in some flow cytometry 
experiments. For me this was an extremely interesting and educative 
experience. Good luck with your future research and I am always willing to 
come back for some more assistance!  
 
Verder wil ik ook alle mensen met wie ik binnen Nederland heb samengewerkt 
hartelijk bedanken. Beste Saskia, Ilze, Annemieke en Cobi, heel erg bedankt 
voor alle hulp en input voor het GRK2 stuk. Dit was mijn eerste grote studie en 
mede dankzij jullie is dit een mooie publicatie geworden. 
 
Ook wil ik graag nog een aantal (oud-)studiegenoten bedanken voor al hun 
hulp die ik tijdens mijn studie, maar ook tijdens mijn promotie heb gehad. En 
natuurlijk alle daarbij behorende gezellige middagen en avonden, in het 
bijzonder Dennis, Ivo, Rianne, Ryanne en Siamack bedanken voor alles. 
 
Beste Jennifer, inmiddels ben je samen met Daniel op avontuur gegaan in 
Canada. Hoewel dit betekent dat we de komende tijd niet zoveel gezellige 
etentjes zullen hebben, weet ik zeker dat in het onderzoek een hele mooie 
toekomst op je ligt te wachten. Het voordeel is wel dat ik de komende tijd nog 
kan blijven oefenen om in de toekomst ook eens echt mee te kunnen doen als 
we weer eens het MLW spel ‘SET’ spelen. Ik wens jou en Daniel heel veel geluk 
en succes toe zowel in jullie werk als daarbuiten. 
 
Beste Roger, we hebben vanaf het eerste begin toen we begonnen aan de 
bachelor MLW altijd veel plezier gehad en menig uurtje doorgebracht met 
troeven. Je hebt inmiddels de academische wereld verlaten en bent samen 
met je gezinnetje naar het ‘hoge noorden’ vertrokken om daar aan de slag te 
gaan. Gelukkig ben je nog vaak in Limburg te vinden en weten wij ook de weg 
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naar Nootdorp inmiddels te vinden. Veel geluk gewenst samen met Nathalie 
en Mads en wellicht brengt de toekomst je wel weer terug naar het Limburgse 
Land. 
 
Uiteindelijk is het toch nog een flinke dankwoord geworden en hoop ik 
iedereen te hebben bedankt, door de lange lijst van namen sluit ik niet uit dat 
ik toch nog iemand ben vergeten te bedanken. Daarom wil ik nogmaals 
iedereen hartelijk danken voor alle hulp, input, gesprekken, gezelligheid en 
alles meer gedurende de afgelopen jaren. Hierbij wil ik ook al mijn ooms, 
tantes, neven en nichten, maar ook iedereen binnen de verenigingen waarin ik 
actief ben (geweest), bedanken voor alles en hopelijk begrijpen jullie nu een 
beetje wat ik tijdens mijn promotie nu echt heb gedaan. 
 
Buiten het werk heb ik ook veel steun mogen ontvangen van mijn 
schoonfamilie, Erna, Ben en Ludia, Pascal en Chantal, en Jessica en Rob 
allemaal heel erg bedankt voor jullie steun, interesse en lekkere etentjes. 
 
Beste Oma Lenie, ik wil u hierbij ook hartelijk danken voor al uw steun, maar 
ook interesse in alles waar ik de afgelopen jaren mee bezig ben geweest. Ik 
hoop dat we de komende jaren nog veel leuke en mooie momenten moge 
beleven met de hele familie. 
 
Beste Michel en Rianne, ook jullie wil ik bedanken voor jullie ondersteuning. 
De afgelopen jaren is er veel veranderd en jullie hebben nu ook jullie eigen 
plekje gevonden in Awt-Gelaen bij pap en mam om de hoek. Ik hoop dat we de 
komende jaren nog vaak samen kunnen genieten van al het goede dat op ons 
afkomt. Veel succes en geluk toegewenst!  
 
Beste Thomas en Mandy, uiteraard wil ik ook jullie bedanken. Momenteel zijn 
jullie hard aan het zoeken naar een mooi plekje hier in het zuiden van het land, 
om zo al het gereis tussen Limburg en Holland wat te kunnen beperken. Ik 
weer zeker dat jullie hier ook snel in zullen slagen! Dank voor het plezier dat 
jullie me de afgelopen jaren geboden hebben. Ook voor jullie veel succes en 
geluk toegewenst. 
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Lieve Pap en Mam, de afgelopen 30 jaar hebben jullie altijd voor mij klaar 
gestaan. Tijdens alle hoogte- maar ook dieptepunten wist ik dat jullie er voor 
mij waren om vreugde en verdriet te delen. Alles wat ik, maar ook Michel en 
Thomas bereikt hebben, is voor een groot gedeelte aan jullie te danken. 
Hoewel woorden waarschijnlijk niet kunnen dekken hoeveel jullie voor mij 
betekend hebben, wil ik jullie heel erg bedanken voor alles wat jullie voor mij 
hebben gedaan  en de wijsheid, vertrouwen en liefde die jullie mij hebben 
gegeven.  
 
Tot slot natuurlijk wil ik natuurlijk mijn lieve vrouw Stefanie en zoon Finn 
bedanken voor de liefde en het geluk die jullie mij bieden. Lieve schat, dankzij 
al jouw steun en hulp heb ik de afgelopen jaren kunnen werken aan dit boekje. 
Hoewel ik vaak lange dagen maakte of af en toe weg was op congres, zorgde jij 
ervoor dat alles goed verliep. Afgelopen jaren is er veel veranderd, we zijn 
getrouwd en onze zoon Finn is geboren. Wat de toekomst nog zal  brengen 
weet niemand, maar dat we dit samen gaan beleven weet ik zeker. Ik hou heel 
veel van jullie allebei. 
 
 
 
 
 
 
Jeroen 
 
 
 
Als je de richting van de wind niet kunt veranderen, 
verander dan de stand van je zeilen 
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